


29th International Epilepsy Congress

28th August - 1st September 2011

FINAL PROGRAMME



29th International Epilepsy Congress



ROME 2011



INTERNATIONAL
LEAGUE
AGAINST
EPILEPSY



28th August - 1st September



Zebinix is indicated as adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.



95% whale

*Small change
Big difference*

Zebinix® is under license from Bial

Prescribing information
can be found overleaf

Date of preparation: June 2011
ZEB-UK 2202

Zebinix is not currently commercialised in Italy

Once-daily
Zebinix®
eslicarbazepine acetate

Evolved to add quality to life



CONTENTS

Welcome Messages and Committee	1
IBE Jubilee	3
General Congress Information	6
Congress Centre Floor Plan	13
Awards	15
Scientific Programme Information	17
Full Week Timetable	19
Scientific Programme	
Sunday 28 th August	21
Monday 29 th August	25
Tuesday 30 th August	35
Wednesday 31 st August	47
Thursday 1 st September	61
Posters	67
Poster Sessions	
Monday 29 th August	71
Tuesday 30 th August	99
Wednesday 31 st August	125
List of Speakers	151
Exhibitors List and Exhibition Floor Plan	157



Zebinix is indicated as adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.

Zebinix® (eslicarbazepine acetate)

Please refer to the SPC before prescribing. **Presentation:** Tablets containing 800 mg eslicarbazepine acetate. **Indication:** Adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation. **Dose and administration:** May be taken with or without food. Starting dose is 400 mg once daily, increased to 800 mg once daily after one or two weeks. Dose may be increased to 1200 mg once daily. Withdraw gradually to minimise the potential of increased seizure frequency. **Elderly patients:** Caution. **Children and adolescents <18 years of age:** Not recommended. **Patients with renal impairment:** Adjust dose according to creatinine clearance (CL_{CR}). Not recommended in severe impairment. **Patients with hepatic impairment:** No dose adjustment in mild to moderate impairment. Not recommended in severe impairment. **Contraindications:** Hypersensitivity to the active substance, other carboxamide derivatives (e.g. carbamazepine, oxcarbazepine) or any excipients. Known second or third degree AV block. **Pregnancy:** No data on the use of Zebinix in pregnant women. Carefully re-evaluate treatment if women become pregnant or plan to become pregnant, and use minimum effective doses. Interacts with oral contraceptives. Use an alternative method of contraception during treatment and up to the end of the current menstrual cycle after treatment has been stopped. **Lactation:** Excretion in human breast milk is unknown. Breastfeeding should be discontinued during treatment. **Warnings and precautions:** May cause some CNS reactions such as dizziness and somnolence. Do not use with oxcarbazepine. Rash has been reported. Discontinue if signs or symptoms of hypersensitivity develop. Screen for allele HLA-B*1502 in individuals of Han Chinese and Thai origin as this has been shown to be strongly associated with the risk of developing Stevens-Johnson syndrome (SJS) when treated with carbamazepine. Examine serum sodium levels in patients with pre-existing renal disease or who are treated with medicinal products which may lead to hyponatraemia or if clinical signs of hyponatraemia occur. Discontinue if clinically relevant hyponatraemia develops. Do not use in primary generalised seizures. Prolongations in PR interval have been observed. Caution in patients with medical conditions or when taking concomitant medicinal products associated with PR prolongation. Monitor for signs of suicidal ideation and behaviours. **Drug interactions:** Has an inducing effect on the metabolism of medicinal products mainly eliminated by CYP3A4 or UDP-glucuronyl transferases, therefore the dose of these products may need to be increased when used concomitantly with Zebinix. May take 2 to 3 weeks to reach the new level of enzyme activity when initiating, discontinuing

or changing dose, therefore take time delay into account when using with other medicines that require dose adjustment. Interactions can arise when co-administering high doses with medicinal products that are mainly metabolised by CYP2C19. Carbamazepine: Zebinix dose may need to be increased if used concomitantly with carbamazepine. Concomitant treatment with carbamazepine increased the risk of the diplopia, abnormal coordination and dizziness. An increase in other adverse reactions cannot be excluded. Phenytoin: An increase of Zebinix dose and a decrease of phenytoin dose may be required. Lamotrigine and topiramate: No dose adjustments are required. Valproate and levetiracetam: Concomitant administration appeared not to affect the exposure to eslicarbazepine but has not been verified by conventional interaction studies. Oral contraceptives: Interacts with the oral contraceptive. Simvastatin: An increase of the simvastatin dose may be required when used concomitantly with Zebinix. Warfarin: Can decrease exposure to S-warfarin. No effects on R-warfarin or coagulation. Monitoring of INR should be performed in the first weeks after initiation or ending concomitant treatment. Digoxin: no effect. MAOIs: an interaction between eslicarbazepine acetate and MAOIs is theoretically possible. **Side effects:** Adverse reactions were usually mild to moderate in intensity and occurred predominantly during the first weeks of treatment with Zebinix. Refer to SPC for all side effects. Very common effects ($\geq 1/10$): dizziness, somnolence. Common effects ($\geq 1/100$, $< 1/10$): Headache, abnormal coordination, disturbance in attention, tremor, diplopia, vision blurred, vertigo, nausea, vomiting, diarrhoea, rash, fatigue, gait disturbance. Serious side effects: hypersensitivity, hyponatraemia, dehydration, grand mal convulsion, ocular hyperaemia, palpitations, bradycardia, hypertension, hypotension, epistaxis, liver disorder, drug toxicity, poisoning. Some rare adverse reactions such as bone marrow depression, anaphylactic reactions, severe cutaneous reactions (e.g. Stevens-Johnson Syndrome), systemic lupus erythematosus or serious cardiac arrhythmias did not occur during clinical studies. However, they have been reported with oxcarbazepine and their occurrence during treatment with Zebinix cannot be excluded. **Legal category:** POM. **Basic UK NHS cost:** Zebinix 800 mg: pack of 30 £154.20. **Marketing authorisation numbers:** EU/1/09/514/012-020. **Marketing authorisation holder:** Bial-Portela & C^a, S.A. À Av. da Siderurgia Nacional 4745-457 S. Mamede do Coronado – Portugal. **Further information from:** Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Herts, AL10 9SN, UK. **Date of preparation:** December 2010

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk
Adverse events should also be reported to Eisai Ltd on 0208 600 1400/0845 676 1400 or lmedinfo@eisai.net

Once-daily
Zebinix®
eslicarbazepine acetate
Evolved to add quality to life



ACKNOWLEDGEMENTS

The Scientific Advisory and Organising Committee (SAOC) would like to thank the following people for their contribution towards the congress programme.

Teaching Programme Coordinators

Giuliano Avanzini (Italy), Janet Mifsud (Malta), Chong-Tin Tan (Malaysia), Walter Van Emde Boas (Netherlands)

Abstract Review Committee

A. Arzimanoglou (France), S. Baulac (France), E. Beghi (Italy), D. Bergen (United States), M. Bialer (Israel), I. Blümcke (Germany), A. Bogacz Fressola (Uruguay), G. Capovilla (Italy), F. Cendes (Brazil), M. Roberta Cilio (Italy), H. de Boer (Netherlands), O. Delalande (France), N. Delanty (Ireland), J. Duncan (United Kingdom), A. Farrell (Ireland), S. Francione (Italy), J. French (United States), Lucia Fusco (Italy), A. Gambardella (Italy), S. Gentile (Italy), V. Gross-Tsur (Israel), D. Hesdorffer (United States), P. Jayakar (United States), J. Jerney (Hungary), A. Kanner (United States), M. Koutroumanidis (United Kingdom), P. Kwan (Hong Kong), S. Lai (Taiwan), W. Liao (China), S.H. Lim (Singapore), M. Mantegazza (France), GW Mathern (United States), M. Mula (Italy), T. O'Brien (Australia), Ç. Özkara (Turkey), P. Plouin (France), H. Potschka (Germany), T. Ravizza (Italy), G. Rubboli (Italy), L. Sander (United Kingdom), S. Schachter (United States), B. Schmidt (Germany), M. Secco (Canada), M. Simonato (Italy), S. Sisodiya (United Kingdom), M. Smith (Canada), P. Tinuper (Italy), R. Tuchman (United States), P. Van Bogaert (Belgium), W. Van Emde Boas (Netherlands)

Poster Tours Selection Committee

Chair: Marco de Curtis (Italy)

Members: A. Berg (United States), I. Blümcke (Germany), MR. Cilio (Italy), T. Covanis (Greece), R. Guerrini (Italy), P. Tinuper (Italy), P. Kwan (Hong Kong), J. Mifsud (Malta), M. Mula (Italy), D. Nordli (United States), Ç. Özkara (Turkey), G. Rubboli (Italy), I. Scheffer (Australia)





WELCOME FROM THE COMMITTEE

Dear Friends and Colleagues,

On behalf of the Scientific Advisory and Organising Committee (SAOC), it gives us great pleasure to welcome you to the **29th International Epilepsy Congress (IEC)** in the ancient city of Rome.

Continuing on from the 2009 celebration in Budapest marking the ILAE Centenary, the 29th IEC will honour and celebrate the 50th anniversary of the International Bureau for Epilepsy and the Jubilee Year of its foundation. To mark this historic event, the Scientific Advisory and Organising Committee has constructed a programme of great promise. Topics will explore and integrate the scientific and social aspects of the issues faced by physicians, caregivers, persons with epilepsy and by all others involved in the field of epilepsy. These topics include: 'When do we consider epilepsy cured?'; 'Impaired consciousness in epilepsy'; 'Epilepsy during puberty – the wonder years'; 'Older, slowing down and seizing up – epilepsy strikes again'; 'Predicting the unpredictable: the adverse effects of treatments'; 'Challenges in developing a new approach for classification in epilepsy' and 'Avoiding epilepsy deaths'; which will be addressed in the Presidential Symposium. In addition, special activities have been organized to celebrate the Jubilee Year of IBE, such as a photo competition, a book of greetings, details of the history of IBE and other special Jubilee events.

Whilst we will ensure that the programme appeals to each and every one of us for whom the understanding and management of epilepsy plays such an important role, we do hope that the Congress will also represent an opportunity for you to explore this remarkable city at a time when Italy also celebrates its local history with the 150th anniversary of national unification.

We hope that you will enjoy your time in Rome and celebrate this momentous occasion.

With warm regards,

Scientific Advisory and Organising Committee



SOLOMON L. MOSHÉ
(UNITED STATES)
Co-Chair



MIKE GLYNN
(IRELAND)
Co-Chair



EMILIO PERUCCA
(ITALY)
Congress Director



FEDERICO VIGEVANO
(ITALY)
Scientific Programme Director



JANET MIFSUD
(MALTA)
Member



GIOVANNI BATTISTA PESCE
(ITALY)
Member



WELCOME MESSAGE FROM THE MAYOR OF ROME

The contribution to the progress and development of medicine has always been and will increasingly be a priority in the programmes promoted by the City of Rome. Hosting the International Epilepsy Congress is therefore an honour and a great opportunity, as we are aware that from the works of this Congress and from your discussion and sharing, new important knowledge will undoubtedly arise in the field of diagnosis and treatment of epilepsy.

All Romans, either from direct experience or just for having admired at the Vatican Museum “the Transfiguration” - Raffaello’s painting where a young man with epilepsy is portrayed - are in some way interested in this disease and would like to know more about its treatment.

I have learnt that 2011 is the 50th anniversary of the International Bureau for Epilepsy and that this society was established in Rome in 1961. I wish that today, as 50 years ago, Rome will be the theatre of important events related to the fight against epilepsy.

Let me wish you, on behalf of all Romans, the warmest welcome to this City: I hope that Rome, with its art, its history and its overall beauty, will be an adequate host for this Congress, and give you the strength to continue in your important and difficult mission. I wish you very fruitful work.

Giovanni Alemanno

Mayor of Rome





IBE JUBILEE



International Bureau for Epilepsy

1961 - 2011

50 years focussed on epilepsy

Jubilee Photography Exhibition

In May 2010, IBE launched an exciting photography competition as one of the first activities to celebrate its Golden Jubilee. Titled 'Epilepsy Without Words' the competition invited photographers young and old, amateur and professional, to produce an image that they felt captured the feeling of epilepsy. The competition, supported by UCB Pharma, had two categories, camera photographs and mobile phone photographs, and with a total prize fund of US\$7,000. By the closing date in May 2011, more than 300 dramatic, emotional and compelling images had been submitted, presenting the judging panel with a very difficult task.

The top 60 photographs have been mounted to create a wonderful exhibition in the Rome Marriott Park Hotel foyer, where details of the winning photographs will also be available. The winning photograph in the camera category has been produced as a postcard and is included in each delegate bag. You can also obtain a postcard of the 2nd and 3rd prize winning photographs from the camera category by visiting the IBE exhibition area in the Exhibition Hall.

All 300 photographs can be viewed in a special gallery on the IBE website: www.ibe-epilepsy.org/jubilee/jubilee-photo-competition.

Judging Panel: Denise Chapman (Australia), Shunglon Lai (Taiwan), Susanne Lund (Sweden), Peter Murphy (Ireland), Simon Shorvon (United Kingdom), Tatsuya Tanaka (Japan), Sam Wiebe (Canada).

History of IBE

Since its foundation in 1961, IBE has travelled a long and interesting road and has experienced dramatic growth both in terms of membership and of programmes of activity. Now is a good time to reflect on IBE's journey to date and to review difficulties met as well as successes enjoyed. Cataloguing 50 years of activities is no easy task and IBE is grateful to Hanneke de Boer who undertook this arduous task. Almost 12 months were spent in gathering information on IBE's early beginnings and its progression to a global presence with representation in 92 countries world-wide. A colourful condensed history of IBE's first 50 years is the result of Mrs. de Boer's hard work and IBE is delighted to include a copy in each delegate bag for everyone to enjoy.

The history will also be available on IBE's website in the coming weeks and, in time, it is planned to have a full and detailed history prepared.

International Epilepsy News

IBE has been producing a regular magazine for almost 50 years, right from the day that George Burden sat behind a typewriter in 1963 and wrote the first one-page newsletter. In the intervening years the newsletter has undergone several changes of style and layout, thanks to the diligent editors who have been responsible for its development in the intervening 48 years.

International Epilepsy News, or IE News as it is more often called, is one of IBE's most important windows to the world and is circulated in more than 120 countries each quarter. To mark IBE's fiftieth anniversary, a revised layout was introduced earlier this year by the current editor Carlos Acevedo. The second magazine using the new design has been prepared in time for the congress. Contents will range from the announcement of congress award winners to news of the latest initiatives to receive support funding under IBE's very successful Promising Strategies Program. The latest issue will be provided to each congress delegate and will also be available at the IBE counter in the Exhibition Hall.



Milestones Walkway

Down through the years since 1961, IBE has reached several important milestones in its busy history. Rome 2011 provides the opportunity to celebrate these through a colourful Milestones Walkway which threads its way from the Congress Registration Desk to the IBE counter in the Exhibition Area. Designed to allow the passerby to grab a quick glimpse of a significant date or period in IBE's busy history, delegates will be able to recognise those moments in the Bureau's past that have helped in the establishment of IBE and which opened the doors to future development. We hope you like it.


IBE Members Poster Display

From small beginnings, IBE now has 122 members in 92 countries around the world. These range from very large national foundations with significant branch networks, large membership numbers and extensive funding, to small voluntary organisations in

developing nations that face a daily struggle to survive. Irrespective of size, location or financial capacity, each IBE member follows the same objective – to help improve the lives of people with epilepsy and those who care for them.

Showcasing its diverse membership, the IBE Members Poster display at the 29th International Epilepsy Congress, is the largest such poster display ever mounted by the Bureau. With a specially commissioned poster for each one of IBE's members, delegates can find out about the efforts made, difficulties faced and successes of each one of this huge global network.

The posters have been grouped and colour coded by region – Africa, Eastern Mediterranean, Europe, Latin America, North America, South East Asia and Western Pacific - to help you locate any poster you particularly want to see. But we are confident that you will want to view them all!



EPILEPSY WITHOUT WORDS

**Capture the feeling of
epilepsy with a click!**

**PHOTOGRAPHY
COMPETITION**
runs from 15 May 2010 - 1 May 2011

Visit www.ibe-epilepsy.org or email
ibedublin@eircom.net for more details



International Bureau for Epilepsy



9th ASIAN & OCEANIAN EPILEPSY CONGRESS MANILA 2012

22nd – 25th March 2012



INTERNATIONAL
LEAGUE
AGAINST
EPILEPSY **ILAE**
ESTABLISHED 1926



7th LATIN AMERICAN CONGRESS ON EPILEPSY QUITO 2012

14th – 17th November 2012



INTERNATIONAL
LEAGUE
AGAINST
EPILEPSY **ILAE**
ESTABLISHED 1926



GENERAL CONGRESS INFORMATION

Congress centre

Rome Marriott Park Hotel,
Via Colonnello Tommaso Masala, 54
Rome, 00148 Italy
Tel: +39-06-658821
Fax: +39-06-65882750

Registration

The Registration Area is located in the main lobby of the Rome Marriott Park Hotel.

Congress bags should be collected on-site in the Registration Area upon exchange of a voucher.

Please note that name badges must be worn at all times.

Speakers Room

The Speakers Room is located on the lower level of the Rome Marriott Park Hotel beside the business meeting rooms.

Opening times for the Speakers Room are listed on the Facilities Timetable. Equipment to review and amend presentations will be available to all speakers and technical assistance will also be provided in this room. Please note that all speakers should submit their final PowerPoint presentations to the speakers room no less than 3 hours in advance of their session. Speakers at early morning sessions are required to submit their material no later than 17:00 on the evening before their session is scheduled.

Language

The official language of the Congress is English; please note that translation facilities will not be provided.

Certificates of Attendance

Certificates of Attendance (including CME details) can be collected from the Registration Area from Tuesday onwards.





GENERAL CONGRESS INFORMATION

Facilities Timetable

	Sunday	Monday	Tuesday	Wednesday	Thursday
Registration	08:00 - 19:00	07:00 - 18:00	07:00 - 18:00	07:00 - 17:30	07:00 - 13:30
Exhibition	-	09:00 - 17:00	09:00 - 17:00	09:00 - 17:00	09:00 - 12:00
Coffee Breaks	-	11:00 - 11:30	11:00 - 11:30	11:00 - 11:30	11:00 - 11:30
	-	16:00 - 16:30	15:30 - 16:00	16:00 - 16:30	-
Poster Display	-	09:00 - 18:00	09:00 - 18:00	09:00 - 18:00	-
Poster Tours	-	13:00 - 14:30	13:00 - 14:00	13:00 - 14:30	-
Lunches	-	13:00 - 14:30	13:00 - 14:00	13:00 - 14:30	-
Internet Centre	09:00 - 18:00	09:00 - 18:00	09:00 - 18:00	09:00 - 18:00	09:00 - 13:00
Speakers Room	08:00 - 19:00	07:00 - 18:00	07:00 - 18:00	07:00 - 17:30	07:00 - 12:00

Exhibition

The Exhibition Area is situated in the Tiziano Foyer adjacent to the hotel lobby. Exhibition opening times are listed on the Facilities Timetable. Exhibitor badges (pre-registered exhibitors only) will be available for collection at the Registration Area.

Lunches and coffee breaks

Lunches and coffee breaks will be served in the Exhibition Area. Lunches will also be served in the Michelangelo Foyer (beside the Poster Area).

Congress Secretariat

Members of the Congress Secretariat can be contacted at anytime at the Registration Area. For queries arising after the congress, please contact:

29th International Epilepsy Congress
 ILAE / IBE Congress Secretariat
 7 Priory Hall
 Stillorgan
 Dublin 18
 Ireland
 Tel +353 1 2056720
 Fax +353 1 2056156
 Email : info@epilepsycongress.org

CME Accreditation

The 29th International Epilepsy Congress is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Please visit www.uems.net for further information.

The 29th IEC is designated for up to **22 hours** of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, please see the details on the [AMA website](http://www.ama-assn.org), www.ama-assn.org, for further details.

The statement of accreditation will be incorporated into the certificates of attendance issued to fully registered delegates during the congress. Please contact the Congress Secretariat in the Registration Area if you require further information.



TRANSPORT

SHUTTLE BUS SERVICE TO & FROM THE CONGRESS VENUE

The congress venue, the Rome Marriott Park Hotel, is located 11km from the international airport, Leonardo da Vinci / Fiumicino Airport, and 14km from Rome city centre.

Shuttle buses will operate during the Congress between the venue and the city centre. Tickets should be purchased in advance and can be bought at the designated transport desk at the congress venue.

Drop off & collection point at the venue:

Main entrance of the Rome Marriott Park Hotel.

Drop off & collection point in the city:

Piazza dei Tribunali (beside Ponte Umberto I).

Closest metro station: Lepanto

Journey time: approximately 40 - 50 minutes (depending on traffic).

Ticket prices:

8 EUR return journey

5 EUR single journey

Booking: Shuttles must be booked in advance at the transport desk at the congress venue.

Note: For the first bus at 06:30 on Monday 29th August, delegates can purchase tickets on the bus.

Shuttle timetable (both to and from the city):

Sunday	Monday	Tuesday	Wednesday	Thursday
08:00	06:30, 08:00	06:30, 08:00	06:30, 08:00	06:30, 08:00
09:00, 10:00	09:00, 10:00	09:00, 10:00	09:00, 10:00	09:00, 10:00
11:00, 12:00	11:00, 12:00	11:00, 12:00	11:00, 12:00	11:00, 12:00
13:00	13:00, 13:30	13:00, 13:30	13:00, 13:30	13:00
14:00	14:00, 14:30	14:00, 14:30	14:00, 14:30	
15:00	15:00, 15:30	15:00, 15:30	15:00, 15:30	
16:00	16:00, 16:30	16:00, 16:30	16:00, 16:30	
17:00	17:00, 17:30	17:00, 17:30	17:00, 17:30	
18:00	18:00, 18:30	18:00, 18:30	18:00, 18:30	
19:00, 20:00	19:00, 20:00	19:00, 20:00	19:00, 20:00	
21:00, 22:00	21:00, 22:00	21:00, 22:00	21:00, 22:00	
23:00, 00:00*	23:00, 00:00*	23:00, 00:00*	23:00, 00:00*	
	01:00*	01:00*	01:00*	

* Shuttle buses after midnight cost 9EUR for single journey and 12EUR for return journey.

Note: Depending on demand, additional shuttle buses will be added. Please check at the transport desk.



PUBLIC TRANSPORT TO & FROM VENUE

The venue can be reached by public transport to Muratella train station, and then by a complimentary shuttle bus to the congress venue (5 minutes bus journey approximately).

Routes:

- a. Metro line B to Piramide, then train from Ostiense station (just beside Piramide) to Muratella Station
- or
- b. Tram line 8 to Trastevere station, then train to Muratella station.

Note: See section below on local transport in Rome for information on tickets and timetables.

Free shuttle buses between venue and Muratella train station:

Timetable: Every 30-40 minutes.

LOCAL TRANSPORT IN ROME

Public transport

Rome has an integrated public transport system; the same ticket may be used on all metros, buses and trams in the urban area.

Ticket price: 1 EUR single journey (valid for 75 minutes including 1 metro trip) / 4 EUR one-day ticket.

Purchasing a ticket: Tickets can be purchased at larger stations, from newsstands, 'tabacchi', or vending machines (the drivers do not sell tickets). Tickets can be bought at the congress venue, the Rome Marriott Park Hotel, in the tobacco store in the main lobby.

Train tickets can be purchased at train stations from either a self-service machine or from a ticket window.

Validating a ticket: All tickets for transportation must be validated before the start of the journey, using the validation machines located at the entry gates of the metro stations, within the entrance area of all rail stations and at the rear of buses and trams.

Metro:

Metro lines: The Roman metro has two lines, A (red) and B (blue), which cross at Termini Central Station. The A line crosses the city from North to South and the B line crosses the city from East to West.

Timetable: Metros run approximately every 7-10 minutes, from 05.30 to 23.30 every day (until 00.30 on Saturdays).

Bus:

Bus routes: There are buses to almost everywhere in greater Rome. The ATAC local buses serve the city centre and most nearby suburbs.

Bus stations: The main bus stations are: Anagnina, Lepanto, Ponte Mammolo, Termini, Laurentina, Magliana, Santa Rubra, Tiburtina; bus timetables are displayed at these stops.

Timetable: Buses run from 05.30 until midnight daily.

Trams:

Tram routes: There are 6 tram routes in Rome, serving nearly all parts of the city.

Timetable: Trams run approximately every six minutes (12 minutes on Sunday).

Taxis

When taking a taxi in Rome, it is important to look for the official metered white or yellow taxis. There are taxi ranks in many locations throughout the centre. Please note that it is very difficult to hail a taxi driving down the streets, particularly at night. Make sure your taxi is metered; insist on the metered fare, rather than an arranged price.

AIRPORT SHUTTLE BUSES

Hotel shuttle buses operate between the airport (Leonardo da Vinci / Fiumicino) and the Rome Marriott Park Hotel.

Congress delegates can avail of this service at a reduced cost.

Airport shuttle timetable:

From the Airport: Every 30 minutes from 07.30 to 12.00 and from 15.00 to 20.30.

From the Rome Marriott Park Hotel: Every 30 minutes from 07.00 to 12.00 and from 15.00 to 20.00.

Drop off & collection point at the airport:

Outside terminal 3, near stops 19 and 20. The shuttle bus is marked with the "Marriott" logo.

Journey time: approximately 25 minutes (depending on traffic).

Ticket price: 5 EUR single journey.

Booking: No advance reservations accepted.



GENERAL CONGRESS INFORMATION

On-site information

Smoking policy	The Congress has a strict no smoking policy.
Cloakroom (coats & luggage)	The cloakroom is located in the Exhibition Area beside Hall 4.
Wheelchair accessibility	All parts of Marriott Rome Park Hotel are wheelchair accessible.
Message Board	The Message Board is situated in the Registration Area. Delegates are advised to check it regularly.
Speakers Room	The Speakers Room is located on the lower level of the Rome Marriott Park Hotel beside the business meeting rooms.
Internet Centre	The Internet Centre is located in the Poster Area (Botticelli Ballroom).

Liability and insurance

The International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) and their agents do not accept any liability whatsoever for death, personal injury, accidents, theft, loss or damage to persons, property or belongings of participants or accompanying persons, either before, during or following the congress, tours or their stay in Rome. It is therefore recommended that participants arrange their own personal health, accident and travel insurance.

IBE General Assembly

The IBE General Assembly will take place on **Wednesday 31st August, 12:00 - 16:00**, in Bramante 6 & 7. All representatives of IBE member associations are invited to attend. Lunch will be provided.

ILAE General Assembly

The ILAE General Assembly will take place on **Wednesday 31st August, 14:00 – 16:00**, in Hall 5. Each Chapter has been invited to send two representatives.





SPONSORS

The 29th International Epilepsy Congress acknowledges the support of the following companies

Platinum Sponsor



Eisai Europe Ltd.

Gold Sponsor



THE EPILEPSY COMPANY™

UCB Pharma S.A.

Silver Sponsor



GlaxoSmithKline

SOCIAL EVENTS

Opening Ceremony and Welcome Reception

The Opening Ceremony will take place on Sunday 28th August at 19:30 in Hall 1 of the Rome Marriott Park Hotel. The Ceremony will open with welcomes from representatives of IBE and ILAE as well as the congress committee. This will be followed by the Awards Ceremony, which will consist of the Ambassador for Epilepsy Award, the Social Accomplishment Award, the Lifetime Achievement Award, the Michael Prize and the Morris-Coole Epilepsia Prize.

All delegates are invited to join a Welcome Reception which will be held beside the outdoor pool of the Rome Marriott Park Hotel.

Sponsors



Cyberonics S.A. / N.V.



Electrical Geodesics, Inc.



Medtronic



Novartis



Pfizer Inc.

Special Event Concert

The Special Event Concert will take place on Tuesday 30th August from 21:00 until late.

The special event concert will take place as part of the Jubilee celebrations commemorating the 50th anniversary of the foundation of the International Bureau for Epilepsy. It will be held in the Auditorium Conciliazione, on Via della Conciliazione which leads to St. Peter's Square. The Auditorium Conciliazione was the venue for the epilepsy congress in 1961, when the IBE was founded.



The recently renovated Sala Grande will play host to the world-renowned Carabinieri Band for the special event concert of the 29th IEC. A buffet will be served in the elegant Foyer of the Auditorium Conciliazione.

The venue is in the centre of Rome, near St. Peter's Square, and well within walking distance of city-centre hotels, so delegates staying in the city centre can easily stroll to the concert. There will be shuttle buses from the congress venue to the Auditorium Conciliazione after the day's programme has ended and return shuttles back to the congress venue after the buffet.

Supported by **Cyberonics**

La Banda dei Carabinieri

The Band was founded in 1820 when the Royal Carabinieri Corps assembled a group of buglers for the first time. This was then transformed into a fanfare in 1862 and by 1920 had further developed into a full Band contingent of the Carabinieri Force. The Band became famous for its quality of style and has had many prestigious tours abroad in Europe, North and South America, the Middle East and Japan. The Carabinieri Band, with 103 musicians, each one expert in a particular instrument, interpret the most famous compositions with a rich repertoire from traditional military marches to modern and classical music.



Tickets

All tickets have already been reserved for this event. Please check with the Social Events desk during the congress as more tickets may become available.

TOURS

A range of full and half-day excursions are available daily throughout the congress and can be booked at the Accommodation & Tours desk which is located on the right-hand side of the Exhibition Area.

ROME PRACTICAL INFORMATION

Business hours

In general, most offices will operate between the hours of 09:00 and 16:30, Monday to Friday, although business hours do vary from one industry to another. Most Rome banks open from 08:30 to 13:30 and 14:45 to 15:45 Monday to Friday. Shops are open on Monday from 15:30 to 19:30 (some shops may be open in the morning) and Tuesday to Saturday from 09:30 / 10:00 to 13:00 and 15:30 to 19:00 / 19:30 (some shops do not close for the afternoon break).

ATM

There is an ATM located in the lobby of the Rome Marriott Park Hotel.

Currency

The currency in Italy is the Euro.

Electricity

The voltage in Italy is 220V (50Hz). The plug outlets require unique three-pin Italian plugs (three round pins in a row). Many hotels are equipped with the two-pin continental European type plug outlets.

Communications



International dialing code: +39
Area code for Rome: 06

Time difference


Rome is in the Central European Time Zone (Greenwich Mean Time + 1 hour / U.S. Eastern Standard Time + 6 hours).



CONGRESS CENTRE FLOOR PLAN



- REGISTRATION AREA
- SESSION ROOMS
- POSTER AREA & INTERNET CENTRE
- SPEAKERS ROOM
- BUSINESS MEETING ROOMS
- EXHIBITION AREA
- SCIENTIFIC EXHIBIT & HOSPITALITY SUITES
- LUNCH & COFFEE BREAKS
- CAFE BAR
- SHOP (PUBLIC TRANSPORT TICKETS)
- CLOAKROOM





AWARDS

Lifetime Achievement Award

The Lifetime Achievement Award in Epilepsy is given jointly by IBE and ILAE. The Award is given to an individual to recognise and honour his or her exceptional and outstanding personal contribution over a long period of time to activities that advance the cause of epilepsy. The Award reflects international peer recognition. It consists of two commemorative and inscribed silver candlesticks, a financial prize of US\$5,000 and a scroll. The name of each recipient is added to the Lifetime Achievement Award winners' Hall of Fame maintained by IBE and ILAE. This award is the highest honour of IBE and ILAE.

The recipient of the Lifetime Achievement Award is: **Jerome Engel Jr.** (United States)

Jerome Engel, Jr., MD, PhD, is Director of the Seizure Disorder Center, the Jonathan Sinay Distinguished Professor of Neurology, Neurobiology, and Psychiatry and Biobehavioral Sciences, and a member of the Brain Research Institute at UCLA. Dr. Engel is Past President of the American Clinical Neurophysiology Society, the American Epilepsy Society, and the International League against Epilepsy, and is a past co-chair of the Global Campaign Against Epilepsy.

Social Accomplishment Award

The Social Accomplishment Award in Epilepsy is given jointly by IBE and ILAE every two years. It is given to an individual to recognise his or her outstanding personal contribution to activities that have resulted in a significant advance in the social well-being and / or quality of life of people with epilepsy.

The Award reflects international peer recognition. It consists of an engraved glass trophy and a certificate. The name of each recipient is added to the Award winners' Hall of Fame maintained by IBE and ILAE.

The recipient of the Social Accomplishment Award is: **Pravina Shah** (India)

Dr. Pravina Shah was Professor and Head of Neurology at the King Edward Memorial Hospital in Mumbai India for 19 years. She is the immediate Past President of the Indian Epilepsy Association and currently consults at Fortis Hospitals. She has worked tirelessly to dispel myths and taboos about epilepsy, engaging with the media and reaching out to opinion makers in the government.

Ambassador for Epilepsy Awards

The Ambassador for Epilepsy Award is given jointly by IBE and ILAE and not more than 12 Awards will be given at any one time. The Award recognises outstanding personal contributions to activities that advance the cause of epilepsy. The Award reflects international peer recognition and it is given for the lifetime of the recipient. The following recipients will be presented with an Ambassador's pin during the Opening Ceremony of the 29th International Epilepsy Congress.

The recipients of the Ambassador for Epilepsy Award are:

Susan Axelrod (United States)
Hasan Aziz (Pakistan)
Lionel Carmant (Canada)
Jaime Fandiño-Franky (Colombia)
Andres Kanner (United States)
Weiping Liao (China)
Wolfgang Löscher (Germany)
Eli M. Mizrahi (United States)
Rosemary Panelli (Australia)
Asla Pitkänen (Finland)
Steven Schachter (United States)
Walter Van Emde Boas (Netherlands)

This brings to 287 the total number of Ambassadors for Epilepsy created since the award was first introduced at the suggestion of IBE in 1968.



The Michael Prize

The Michael Prize was originally set up in 1963 to stimulate epilepsy research in Germany; it is now one of the most highly regarded international awards for the best contribution to scientific and clinical research promoting further development in epileptology. The prize is awarded biennially and specially designed to attract younger scientists normally not older than 45 years; the prize fund is €20,000.

The recipient of the 2011 Michael Prize is:
Eleonora Aronica (Netherlands)

The award will be presented during the Opening Ceremony on Sunday 28th August. The winning paper will be presented during the Prize Symposium on **Monday 29th August between 16:30 and 17:30** in Hall 1.

The Morris-Coole Epilepsia Prize

The Morris-Coole Epilepsia prize, awarded by ILAE, was inaugurated 5 years ago. This annual prize is awarded to a young researcher who was first author of a top quality research paper published in *Epilepsia* in the previous calendar year. The goal of the prize is to stimulate excellence in epilepsy research and to encourage young investigators (in both clinical and basic research fields) to carry out high-quality studies. The Prize consists of \$5,000 and a specially designed insignia pin. This year the prize has been awarded to **Dr. Laura Jansen** (USA) for her paper entitled 'Impaired maturation of cortical GABA(A) receptor expression in paediatric epilepsy' *Epilepsia* 2010, 51:1456-67. Her findings will be presented during the Prize Symposium on **Monday 29th August between 16:30 and 17:30** in Hall 1.





SCIENTIFIC PROGRAMME INFORMATION

Presidential Symposium

Avoiding epilepsy deaths

Over the last few years several studies have demonstrated that people with epilepsy have a shorter life span with 2-3 fold increase in mortality including the 24 fold increase in SUDEP. It has recently been reported that 1 in 100 people with epilepsy per year may suffer from SUDEP, especially those suffering from frequent convulsive seizures. In this symposium we will assemble information from the perspective of care-takers, epidemiologists, basic scientists, and even consider intervention procedures to prevent unnecessary epilepsy deaths. The session will be followed by post-presidential symposia that will further elaborate on the topic. This Presidential Symposium will seek to highlight the need for a twin pronged approach to SUDEP: finding ways to prevent unnecessary epilepsy deaths and using research to find the cause and cure for SUDEP.

Post-Presidential symposia

Expanding on the topics developed during the Presidential Symposium, two post-presidential symposia entitled '**Epilepsy Destroys Lives**' part 1 and part 2 will take place on Monday 29th August from 11:30 to 13:00 and on Wednesday 31st August from 11:30 to 13:00 respectively. These symposia will feature as an important element of the scientific programme and promise to highlight major developments in the medical and social field of epilepsy from around the world.

Prize Symposium

The Prize Symposium will take place on **Monday 29th August from 16:30 to 17:30** in Hall 1.

TEACHING PROGRAMME

Coordinators: Giuliano Avanzini (Italy), Janet Mifsud (Malta), Chong-Tin Tan (Malaysia), Walter Van Emde Boas (Netherlands)

Workshops

On Sunday, an exciting range of interactive workshops will take place including the Claudio Munari Workshop 2011, an IBE session entitled '**Setting future direction for IBE: the next 50 years**', a Neurobiology workshop entitled

'**Metabolic mechanisms of epileptogenesis**' and a '**Report on WONOEP**'.

'How To' Series

A series of 'how to' teaching sessions with the theme '**Starting an epilepsy surgery programme**' will take place from Monday to Thursday from 07:30 to 09:00. The series will explore this theme by focusing on patient selection in epilepsy surgery, psychiatric and psychosocial aspects of epilepsy surgery and paediatric epilepsy surgery.

Case-Oriented Learning Series

There will be four case-oriented learning sessions from Monday to Thursday from 07:30 to 09:00 entitled 'Is it epilepsy or not? Interpretation of epileptiform seizure discharges', 'Is it focal or generalised epilepsy?', 'How EEG and polygraphy can help', 'Epilepsy and sleep: what are we treating and with what effect?' and 'Epilepsy, sleep and learning: what and how to treat'.

Video Sessions

Four video sessions will take place from Monday to Thursday from 07:30 to 09:00. They will focus on 'Non epileptic attacks in the paediatric age', 'Emotional brain and seizure semiology', 'Automatic behaviours in epilepsy and sleep' and 'Neonatal seizures and epilepsies'.

ABSTRACTS

The SAOC would like to thank all of those who submitted an abstract for review for the 29th International Epilepsy Congress. Over 870 abstracts were received in 14 categories.

Abstracts from the 29th IEC are available on the the interactive session planner which can be found on the Congress website. Delegates have the opportunity to access abstracts online in the Internet Centre (Botticelli Ballroom), which is located on the ground floor level beside Hall 2.

The SAOC would also like to thank all of those who participated in the abstract review.



Abstract Review Committee

A. Arzimanoglou (France), S. Baulac (France), E. Beghi (Italy), D. Bergen (United States), M. Bialer (Israel), I. Blümcke (Germany), A. Bogacz Fressola (Uruguay), G. Capovilla (Italy), F. Cendes (Brazil), M. Roberta Cilio (Italy), H. de Boer (Netherlands), O. Delalande (France), N. Delanty (Ireland), J. Duncan (United Kingdom), A. Farrell (Ireland), S. Francione (Italy), J. French (United States), Lucia Fusco (Italy), A. Gambardella (Italy), S. Gentile (Italy), V. Gross-Tsur (Israel), D. Hesdorffer (United States), P. Jayakar (United States), J. Jerney (Hungary), A. Kanner (United States), M. Koutroumanidis (United Kingdom), P. Kwan (Hong Kong), S. Lai (Taiwan), W. Liao (China), S.H. Lim (Singapore), M. Mantegazza (France), GW Mathern (United States), M. Mula (Italy), T. O'Brien (Australia), Ç. Özkara (Turkey), P. Plouin (France), H. Potschka (Germany), T. Ravizza (Italy), G. Rubboli (Italy), L. Sander (United Kingdom), S. Schachter (United States), B. Schmidt (Germany), M. Secco (Canada), M. Simonato (Italy), S. Sisodiya (United Kingdom), M. Smith (Canada), P. Tinuper (Italy), R. Tuchman (United States), P. Van Bogaert (Belgium), W. Van Emde Boas (Netherlands)

Platform Sessions

55 abstracts were selected for platform presentation. Platform sessions will take place on Monday - Wednesday between 14:30 – 16:00.

Posters

Poster presenters are kindly asked to set up their posters between 08:00 and 09:00 on their assigned day. Posters must be removed between 18:00 and 19:00. Please note that the 29th IEC does not take responsibility for unclaimed posters. The Poster Area (Botticelli Room) is located on the ground floor level beside Hall 2.

Poster Tours (for more see page 67)

Guided poster tours, led by experts in the field, are being organised during the congress. Presenters are asked to be available at their poster on their assigned day (13:00 - 14:30 on Monday and Wednesday and 13:00 - 14:00 on Tuesday). Each presenter will have 3-5 minutes to present his/her research and answer questions.

Poster Tours Selection Committee

Chair: Marco de Curtis (Italy)

Members:

A. Berg (United States), I. Blümcke (Germany), MR. Cilio (Italy), T. Covanis (Greece), R. Guerrini (Italy), P. Tinuper (Italy), P. Kwan (Hong Kong), J. Mifsud (Malta), M. Mula (Italy), D. Nordli (United States), Ç. Özkara (Turkey), G. Rubboli (Italy), I. Scheffer (Australia)

Travel Bursaries

In order to further encourage young investigators to participate in the 29th International Epilepsy Congress, 30 travel bursaries have been awarded to assist with registration, travel and accommodation expenses. The below travel bursaries were awarded in equal measure to IBE and ILAE applicants.

Travel Bursary Awardees

First Name	Last Name	Country
Ingvor	Aiha	Sweden
Action	Amos	Malawi
Natalia	Avaliani	Sweden
René	Bøgh-Larsen	Denmark
Abderrahmane	Chahidi	Morocco
Antonietta	Coppola	Italy
Lyubomira	Dereleva	United Kingdom
Trestan Rey	Ebare	Philippines
Zvanaka Monica	Gomo	Zimbabwe
Nicola	Hamil	United Kingdom
Na	He	China
K. Malcolm	Jeyaraj	India
Taurai	Kadzviti	Zimbabwe
Symon Muchiri	Kariuki	Kenya
Nato	Kotaria	Georgia
Robert	Lamberts	Netherlands
Mbuso	Mahlalela	Swaziland
Laura	Mirandola	Italy
Marcia Elisabete	Morita	Brazil
Betty	Nsachilwa	Zambia
Mauricio	Olave Aguirre	Colombia
Geke	Overvliet	Netherlands
Gabriela	Pesantez	Ecuador
Gun - May	Prest	Finland
Hemav	Rajbhandari	Nepal
Emmanuel	Sanya	Nigeria
Sita Jayalakshmi	Sattaluri	India
Katja	Seppinen	Finland
Karen	Skjei	United States
Parameswaran	Vaikom Ramachandran	India



FULL WEEK TIMETABLE

	Sunday 28th August	Monday 29th August	Tuesday 30th August
07:30-07:45			
07:45-08:00			
08:00-08:15			
08:15-08:30			
08:30-08:45			
08:45-09:00			
09:00-09:15			
09:15-09:30			
09:30-09:45			
09:45-10:00			
10:00-10:15			
10:15-10:30			
10:30-10:45			
10:45-11:00			
11:00-11:15			
11:15-11:30			
11:30-11:45			
11:45-12:00			
12:00-12:15			
12:15-12:30			
12:30-12:45			
12:45-13:00			
13:00-13:15			
13:15-13:30			
13:30-13:45			
13:45-14:00			
14:00-14:15			
14:15-14:30			
14:30-14:45			
14:45-15:00			
15:00-15:15			
15:15-15:30			
15:30-15:45			
15:45-16:00			
16:00-16:15			
16:15-16:30			
16:30-16:45			
16:45-17:00			
17:00-17:15			
17:15-17:30			
17:30-17:45			
17:45-18:00			
18:00-18:15			
18:15-18:30			
18:30-18:45			
18:45-19:00			
19:00-19:15			
19:15-19:30			
19:30-19:45			
19:45-20:00			
20:00-20:15			
20:15-20:30			
20:30-20:45			
20:45-21:00			
21:00-21:15			
21:15-21:30			

	Sunday 28th August	Monday 29th August	Tuesday 30th August
07:30-09:00		Teaching & Video Sessions 07:30 - 09:00	Teaching & Video Sessions 07:30 - 09:00
08:00-09:00			Elekta Breakfast Symposium 08:00 - 09:00
09:00-11:00		Presidential Symposium 09:00 - 11:00	Plenary Session When do we consider epilepsy cured? 09:00 - 11:00
09:00-11:00			Plenary Session Impaired consciousness in epilepsy: mechanisms and clinical significance 09:00 - 11:00
11:00-11:30		Coffee Break 11:00 - 11:30	Coffee Break 11:00 - 11:30
11:30-13:00		Post Presidential Symposium 11:30 - 13:00	Parallel Sessions 11:30 - 13:00
11:30-13:00		Parallel Sessions 11:30 - 13:00	
13:00-14:00		Lunch & Posters 13:00 - 14:30	Lunch & Posters 13:00 - 14:00
14:00-15:00			Platform Session 4 14:00 - 15:45
14:00-15:00			Platform Session 5 - 6 14:00 - 15:30
15:30-17:00	Cyberonics Satellite Symposium 15:30 - 17:00		Coffee Break 15:30 - 16:00
15:30-17:00	Medtronic Inc. Satellite Symposium 15:30 - 17:00		Eisai Europe Ltd Satellite Symposium 16:00 - 17:30
18:00-19:30		UCB Pharma Satellite Symposium 18:00 - 19:30	GlaxoSmithKline Satellite Symposium 18:00 - 19:30
19:30-20:30	Opening Ceremony 19:30 - 20:30		
20:30-21:30	Welcome Reception 20:30 - 21:30		Special Event Concert 21:00 - Late



FULL WEEK TIMETABLE

		Wednesday 31st August		Thursday 1st September		
Setup		EGI Breakfast Symposium 07:30 - 09:00	Teaching & Video Sessions 07:30 - 09:00	Teaching & Video Sessions 07:30 - 09:00		07:30-07:45
						07:45-08:00
Posters all day - Poster Tours 13:00 - 14:30		Plenary Session Predicting the unpredictable: the adverse effects of treatments 09:00 - 11:00	Plenary Session Epilepsy during puberty - the wonder years 09:00 - 11:00	Plenary Session Challenges in developing a new approach for classification in epilepsy 09:00 - 11:00	Plenary Session Older, slowing down and seizing up - epilepsy strikes again 09:00 - 11:00	08:00-08:15
						08:15-08:30
						08:30-08:45
						08:45-09:00
						09:00-09:15
						09:15-09:30
						09:30-09:45
						09:45-10:00
						10:00-10:15
						10:15-10:30
						10:30-10:45
						10:45-11:00
		Coffee Break	11:00 - 11:30	Coffee Break	11:00 - 11:30	11:00-11:15
						11:15-11:30
						11:30-11:45
		Post Presidential Symposium 11:30 - 13:00	Parallel Sessions 11:30 - 13:00	Parallel Sessions 11:30 - 13:00	Teaching Sessions 11:30 - 13:00	11:45-12:00
						12:00-12:15
						12:15-12:30
						12:30-12:45
						12:45-13:00
		Lunch & Posters 13:00 - 14:30			13:00-13:15	
					13:15-13:30	
					13:30-13:45	
					13:45-14:00	
					14:00-14:15	
					14:15-14:30	
					14:30-14:45	
					14:45-15:00	
					15:00-15:15	
					15:15-15:30	
					15:30-15:45	
					15:45-16:00	
					16:00-16:15	
					16:15-16:30	
					16:30-16:45	
					16:45-17:00	
					17:00-17:15	
					17:15-17:30	
					17:30-17:45	
					17:45-18:00	
					18:00-18:15	
					18:15-18:30	
					18:30-18:45	
					18:45-19:00	
					19:00-19:15	
					19:15-19:30	
					19:30-19:45	
					19:45-20:00	
					20:00-20:15	
					20:15-20:30	
					20:30-20:45	
					20:45-21:00	
					21:00-21:15	
					21:15-21:30	



SUNDAY 28TH AUGUST

SUNDAY 28TH AUGUST

	HALL 1	HALL 2	HALL 5	HALL 6	
09:00-09:15					09:00-09:15
09:15-09:30					09:15-09:30
09:30-09:45					09:30-09:45
09:45-10:00					09:45-10:00
10:00-10:15					10:00-10:15
10:15-10:30					10:15-10:30
10:30-10:45					10:30-10:45
10:45-11:00					10:45-11:00
11:00-11:15					11:00-11:15
11:15-11:30					11:15-11:30
11:30-11:45					11:30-11:45
11:45-12:00					11:45-12:00
12:00-12:15					12:00-12:15
12:15-12:30	Claudio Munari Workshop Part 1 Indications, clinical features and non-invasive diagnosis	IBE Workshop Setting future direction for IBE: the next 50 years		Neurobiology Workshop Metabolic mechanisms of epileptogenesis	12:15-12:30
12:30-12:45					12:30-12:45
12:45-13:00					12:45-13:00
13:00-13:15					13:00-13:15
13:15-13:30					13:15-13:30
13:30-13:45					13:30-13:45
13:45-14:00					13:45-14:00
14:00-14:15	Claudio Munari Workshop Part 2 Invasive diagnosis, surgery and outcome			Neurobiology Workshop Report on WONOE	14:00-14:15
14:15-14:30					14:15-14:30
14:30-14:45					14:30-14:45
14:45-15:00					14:45-15:00
15:00-15:15					15:00-15:15
15:15-15:30					15:15-15:30
15:30-15:45		Cyberonics Satellite Symposium	Medtronic Inc. Satellite Symposium		15:30-15:45
15:45-16:00					15:45-16:00
16:00-16:15					16:00-16:15
16:15-16:30					16:15-16:30
16:30-16:45					16:30-16:45
16:45-17:00					16:45-17:00
17:00-17:15					17:00-17:15
17:15-17:30					17:15-17:30
17:30-17:45	Merritt-Putnam Symposium				17:30-17:45
17:45-18:00					17:45-18:00
18:00-18:15					18:00-18:15
18:15-18:30					18:15-18:30
18:30-18:45					18:30-18:45
18:45-19:00					18:45-19:00
19:00-19:15					19:00-19:15
19:15-19:30					19:15-19:30
19:30-19:45					19:30-19:45
19:45-20:00					19:45-20:00
20:00-20:15	Opening Ceremony				20:00-20:15
20:15-20:30					20:15-20:30
20:30-20:45					20:30-20:45
20:45-21:00	Welcome Reception				20:45-21:00
21:00-21:15					21:00-21:15
21:15-21:30					21:15-21:30



SUNDAY 28TH AUGUST

12:15-13:30

CLAUDIO MUNARI WORKSHOP 2011

Hall 1

Epilepsy surgery in paediatric age:

Indications, diagnosis and results at the beginning of the 3rd Millennium

Part 1: Indications, clinical features and non-invasive diagnosis

Chair: Philippe Kahane, France

Indications considering clinical features and psychomotor development

Bernardo Dalla Bernardina, Italy

Electro-clinical features as defined by video-EEG recordings

Hans Holthausen, Germany

Electro-clinically based neuroimaging studies

Lucia Fusco, Italy

14:00-15:15

CLAUDIO MUNARI WORKSHOP 2011

Hall 1

Part 2: Invasive diagnosis, surgery and outcome

Chairs: Stefano Francione, Italy & Patrick Chauvel, France

Subdural recordings and stimulations

Hans Luders, United States

Stereo-EEG recordings and stimulations

Philippe Kahane, France

From lesionectomy to hemispherotomy: always a tailored choice

Giorgio Lo Russo, Italy

Surgical outcome: an overview

Ingrid Tuxhorn, United States

SUNDAY 28TH AUGUST



12:30-15:00

IBE WORKSHOP

Hall 2

Setting future direction for IBE: the next 50 years

Chair: Hanneke de Boer, Netherlands

Constitutional amendment: changing times, changing needs

Johan Falk Pedersen, Norway

Advocating for change: tips from an insider

Gay Mitchell, Ireland

Legislation: working with policy makers

Alexandra Finucane, United States

Changing communications and networks: developing e-communities

Peter Murphy, Ireland

Funding crisis: new opportunities in fundraising

Robert Cole, Australia

12:30-13:45

NEUROBIOLOGY WORKSHOP

Hall 6

Metabolic mechanisms of epileptogenesis

Chairs: Astrid Nehlig, France & Edward Bertram, United States

MRI of structural, functional and metabolic markers of epileptogenesis in animals

Olli Gröhn, Finland

The ketogenic diet and epilepsy

Jong Rho, United States

Targeting metabolic mechanism for novel epilepsy treatments

Manisha Patel, United States

13:45-15:00

NEUROBIOLOGY WORKSHOP

Hall 6

Report on WONOE

Chair: Jeffrey Noebels, United States



15:30-17:00	CYBERONICS SATELLITE SYMPOSIUM Neurostimulation for epilepsy: veni, vidi, vici? <i>Chairs: Paul Boon, Belgium & Paolo Tinuper, Italy</i> Neurostimulation today <i>Paolo Tinuper, Italy & Paul Boon, Belgium</i> Neurostimulation tomorrow: myth or reality? Impact of seizure detection capability <i>Andreas Schulze-Bonhage, Germany</i> The head/heart connection: a path to automated seizure detection, warning and treatment <i>Ivan Osorio, United States</i> Closing the loop: a revolution in epilepsy care? <i>Paul Boon, Belgium</i>	Hall 2
15:30-17:00	MEDTRONIC INC. SATELLITE SYMPOSIUM Novel technology to treat refractory epilepsy <i>Chair: Arthur Cukiert, Brazil</i> DBS for epilepsy; SANTE long term results <i>Katrin Lambrecht, United States</i> Rationale and clinical considerations for DBS in epilepsy <i>Arthur Cukiert, Brazil</i> DBS mechanism of action and new technology development <i>Paul Stypulkowski, United States</i> Evaluation of DBS for epilepsy in a primate model <i>Stefan Chabardes, France</i>	Hall 5
17:30-19:00	MERRITT-PUTNAM SYMPOSIUM <i>(sponsored by Pfizer, Inc.)</i> The state of genetics in epilepsy <i>Chair: Giuliano Avanzini, Italy</i> Are genetic rodent models helping our understanding of the mechanisms of epilepsy and the development of better treatments? <i>Antoine Depaulis, France</i> To what extent do genes influence response to AEDs? <i>Holger Lerche, Germany</i> A critical examination of the current state of epilepsy genetic studies <i>David Greenberg, United States</i>	Hall 1
19:30-20:30	OPENING CEREMONY	Hall 1
20:30-21:30	WELCOME RECEPTION	Reception Area



MONDAY 29TH AUGUST

MONDAY 29TH AUGUST

	Poster Area	HALL 1	HALL 2	HALL 3		
07:30-08:00			Case Oriented Series Is it epilepsy or not? Interpretation of epileptiform seizure discharges	Video Session Non epileptic attacks in the paediatric age		
08:00-08:30	Set up					
08:30-09:00						
09:00-09:30	Posters all day - Poster Tours 13:00 - 14:30	Presidential Symposium Avoiding epilepsy deaths				
09:30-10:00						
10:00-10:30						
10:30-11:00						
11:00-11:30		Coffee Break 11:00 - 11:30				
11:30-12:00		Post Presidential Symposium Epilepsy destroys lives part 1	Parallel Session A new international classification system for focal cortical dysplasias	Parallel Session Genetic partial epilepsies: the clinical, genetic and therapeutic spectrum		
12:00-12:30						
12:30-13:00						
13:00-13:30		Lunch & Posters 13:00 - 14:30				
13:30-14:00						
14:00-14:30						
14:30-14:30		Platform Session 1 Pediatric epilepsy: triggers, language and spasms	Platform Session 2 Death, injuries and epilepsy			
15:00-15:30						
15:30-16:00						
16:00-16:30	Coffee Break 16:00 - 16:30					
16:30-17:00		Prize Symposium				
17:00-17:30						
17:30-18:00						
18:00-18:30		UCB Pharma Satellite Symposium				
18:30-19:00						
19:00-19:30						



MONDAY 29TH AUGUST

HALL 4	HALL 5	HALL 6		
"How To" Series Patient selection and non-invasive evaluation: perspective for starting a programme		Teaching Session Neuromodulation in the treatment of epilepsy	07:30-08:00	
			08:00-08:30	
				08:30-09:00
				09:00-09:30
				09:30-10:00
				10:00-10:30
				10:30-11:00
Coffee Break 11:00 - 11:30			11:00-11:30	
Parallel Session Controversies in psychiatric aspects of epilepsy		Parallel Session Epilepsy in the visual arts and in literature	Parallel Session Compliance in epilepsy: what are the issues?	11:30-12:00
				12:00-12:30
	12:30-13:00			
Lunch & Posters 13:00 - 14:30			13:00-13:30	
			13:30-14:00	
			14:00-14:30	
Platform Session 3 Translational studies	Invited Platform Session Epilepsy care after a major natural disaster		14:30-14:30	
			15:00-15:30	
			15:30-16:00	
Coffee Break 16:00 - 16:30			16:00-16:30	
			16:30-17:00	
			17:00-17:30	
			17:30-18:00	
			18:00-18:30	
			18:30-19:00	
			19:00-19:30	

MONDAY 29TH AUGUST



MONDAY 29TH AUGUST

- 07:30-09:00** **CASE ORIENTED LEARNING SERIES** **Hall 2**
**Diagnosis and management of epilepsy and sleep:
Is it epilepsy or not? Interpretation of epileptiform seizure discharges**
Chair: Prasanna Jayakar, United States
- Speakers:*
Paolo Tinuper, Italy
Perrine Plouin, France
Prasanna Jayakar, United States
- 07:30-09:00** **VIDEO SESSION** (*Organised in conjunction with the Italian League against Epilepsy*)
Clinical semiology of epileptic and related conditions: **Hall 3**
Non epileptic attacks in the paediatric age
Chairs: Giuseppe Capovilla, Italy & Natalio Fejerman, Argentina
- Speakers:*
Roberto Caraballo, Argentina
Sameer M Zuberi, United Kingdom
Giuseppe Capovilla, Italy
- 07:30-09:00** **“HOW TO” SERIES** **Hall 4**
**Starting an epilepsy surgery programme:
Patient selection and non-invasive evaluation: perspective for starting
a programme**
Chair: Walter Van Emde Boas, Netherlands
- Speakers:*
Hermann Stefan, Germany
Manuel Campos, Chile
Walter van Emde Boas, Netherlands
- 07:30-09:00** **TEACHING SESSION** **Hall 6**
Neuromodulation in the treatment of epilepsy
Chair: Bernhard Steinhoff, Germany
- Speakers:*
Gonzalo Alarcon, United Kingdom
Kristl Vonck, Belgium
Bernhard Steinhoff, Germany



09:00-11:00

PRESIDENTIAL SYMPOSIUM

Hall 1

Avoiding epilepsy deaths

Chairs: Mike Glynn, Ireland & Solomon L Moshé, USA

Am I going to die with my disease? A carer's perspective

Susan Axelrod, USA

Epilepsy kills

Ley Sander, United Kingdom

Treatment failures and epilepsy-related deaths

Shlomo Shinnar, United States

The brain, the heart, and epilepsy: the scientific fight against SUDEP

Jeffrey Noebels, United States

Is it preventable? Lessons from the United Kingdom

John Paul Leach, United Kingdom

11:30-13:00

POST PRESIDENTIAL SYMPOSIUM

Hall 1

Epilepsy destroys lives part 1

Chairs: Helen Cross, United Kingdom & Sichuo Li, China

How can I help as a leader in my profession to win the war on epilepsy?

Wilfred Kipkemboi Bungei, Kenya

Can one live well with epilepsy?

Helen Cross, United Kingdom

Catastrophic epilepsies strike all ages: how do we get rid of the catastrophe?

Terence O'Brien, Australia

Enlisting the governments in the war against epilepsy

Esper Cavalheiro, Brazil

MONDAY 29TH AUGUST



11:30-13:00

PARALLEL SESSION

Hall 2

A new international classification system for focal cortical dysplasias

Chairs: Roberto Spreafico, Italy & Ingmar Blümcke, Germany

Molecular and cellular pathomechanisms of cortical development

Renzo Guerrini, Italy

Neuroradiological findings classifying focal cortical dysplasias

A James Barkovich, United States

Neurophysiological and clinical findings classifying focal cortical dysplasia

Roberto Spreafico, Italy

Neuropathological findings classifying focal cortical dysplasias

Ingmar Blümcke, Germany

11:30-13:00

PARALLEL SESSION

Hall 3

Genetic focal epilepsies: the clinical, genetic and therapeutic spectrum

Chairs: Roberto Michelucci, Italy & Yushi Inoue, Japan

Focal epilepsies and genetic channelopathies

Weiping Liao, China

Basic mechanisms of focal epilepsy with mutations in LGI1

Stephanie Baulac, France

Focal epilepsies due to mutations of genes that do not code for ion channels

Roberto Michelucci, Italy

The possibility of surgical treatment of focal epilepsy associated with genetic abnormalities

Yushi Inoue, Japan



11:30-13:00

PARALLEL SESSION

Hall 4

Controversies in psychiatric aspects of epilepsy

Chairs: Andres Kanner, United States & Marco Mula, Italy

The global burden of epilepsy: impact of psychiatric comorbidities

Lilia Núñez Orozco, Mexico

Should antidepressant drugs be tested as antiepileptic agents?

Andres Kanner, United States

Are psychiatric disorders of epilepsy different from primary psychiatric disorders?

Marco Mula, Italy

Should all surgical candidates undergo a presurgical psychiatric evaluation?

P Satish Chandra, India

11:30-13:00

PARALLEL SESSION

Hall 5

Epilepsy in the visual arts and in literature

Chair: Peter Wolf, Denmark

Insights into epilepsy from contemporary artists

Steven Schachter, United States

Stimulation and enhancement of creativity from epilepsy

Jim Chambliss, Australia

Epilepsy in literature

Peter Wolf, Denmark

11:30-13:00

PARALLEL SESSION

Hall 6

Compliance in epilepsy: what are the issues?

Chair: Donna Bergen, United States

How common is non compliance in epilepsy?

Marco Tulio Medina, Honduras

Why am I not taking my medication? A patient's perspective

Ashok Pillai, India

Health and cost implications of poor compliance in epilepsy

Donna Bergen, United States



14:30–16:00

PLATFORM SESSION 1

Hall 2

Paediatric epilepsy: triggers, language and spasms

Chairs: Alexis Arzimanoglou, France & Angelina Kakooza, Uganda

001

Seizure triggers in children with SCN1A-related epilepsy

*Sanchez-Carpintero R, Urestarrazu E, Perea DA, Aznarez N, Narbona-Garcia J
Spain*

002

Relation between vaccination and occurrence of seizures in SCN1A mutation positive patients: the first Italian multi-centric study

*Petrelli C, Passamonti C, Baldassari C, Verrotti A, Capovilla G, Viri M, Coppola G, Vignoli A, Zamponi N
Italy*

003

Functional connectivity of language activation in childhood focal epilepsy

*Sepeta L, Zimmaro LA, Duke ES, Berl MM, VanMeter J, Vaidya CJ, Yerys B, Gaillard WD
United States*

004

The association between frequency of nocturnal epilepsy and language disturbance in children

*Overvliet GM, Besseling R, Vles J, Hofman P, Debeij-van Hall M, Backes W, Aldenkamp A
Netherlands*

005

Lateralising signs in infantile spasms: differences in video and EEG analysis

*Dressler A, Klaus M-T, Muehlechner A, Moerzinger M, Pahs G, Benninger F, Feucht M
Austria*

006

Relationship between initial EEG characteristics and seizure outcomes in the children of infantile spasms with normal MRI finding

*Yeon GM, Kim YM, Nam SO, Lee Y-J
Korea, Republic of*



14:30–16:00

PLATFORM SESSION 2

Hall 3

Death, injuries and epilepsy*Chair: TBA*

- 007** **Postictal decerebrate rigidity: clinical evidence of the involvement of cerebral electrical shutdown combined with respiratory distress as a possible mechanism of SUDEP**
Cenusa M, Mothersill IW, Grunwald T, Krämer G
Switzerland
- 008** **Cause-specific mortality among patients with epilepsy: results of a 40-year cohort study**
Granbichler CA, Oberaigner W, Kuchukhidze G, Unterberger I, Ndayisaba J-P, Bauer G, Trinka E^{1,2}
Austria
- 009** **Circadian seizure patterns in SUDEP: patients with nocturnal seizures are at highest risk**
Lamberts RJ¹, Laffan A², Thijs RD¹, Sander JW^{1,3}, Langan Y²
¹Netherlands, ²Ireland, ³United Kingdom
- 010** **Effect of interictal epileptic activities on heart rate variability in unilateral temporal lobe epilepsy**
Kinoshita M, Demura Y, Matsumoto R, Ikeda A
Japan
- 011** **The frequency and associated risk factors of seizure-related injury, near-drowning and vehicular crashes in a community sample of patients with epilepsy**
D'Souza WJ¹, Tan M¹, Ficker D², O'Brien T¹, Cook M¹
¹Australia, ²United States
- 012** **Reduced heart rate variability is associated with ictal hypoxemia**
Bateman LM, Wong V, Pathak SR, Seyal M
United States



14:30–16:00

PLATFORM SESSION 3

Hall 4

Translational studies

Chairs: Filiz Onat, Turkey & Michele Simonato, Italy

- 013 Hippocampal CA3 transcriptome signature and dentate gyrus MRI features correlate with initial precipitating injury in refractory temporal lobe epilepsy**
Bando SY, Alegro MC, Amaro Jr E, Silva AV, Castro LHM, Wen H-T, Lima LA, Brentani H, Moreira-Filho CA
Brazil
- 014 Altered expression of Cl⁻ transporters in tumour-related epilepsies**
Palma E¹, Conti L¹, Roseti C¹, Lauro C¹, Cipriani R¹, de Groot M², Aronica E2, Limatola C1
¹Italy, ²Netherlands
- 015 Persistence of sensory information integration during absence seizures: evidence from in vivo intracellular investigation in a genetic model**
Chipaux M, Charpier S
France
- 016 Involvement of the mTOR signaling pathway in hippocampal granule cell dispersion and gliosis in a mouse model of mesio-temporal lobe epilepsy**
Nitta N¹, Nozaki K¹, Depaulis A²
¹Japan, ²France
- 017 Lentiviral-mediated over-expression of the potassium channel Kv1.1 as a treatment for focal neocortical epilepsy**
Wykes RC, Heeroma JH, Kullmann DM, Walker MC, Schorge S
United Kingdom
- 018 Functional characterization of human induced pluripotent stem (iPS) cells grafted in hyperexcitable organotypic culture**
Avaliani N¹, Sorensen AT¹, Koch P², Brustle O², Kokaia M¹
¹Sweden, ²Germany

**14:30–16:00****INVITED PLATFORM SESSION****Hall 5****Epilepsy care after a major natural disaster***Chairs: Sunao Kaneko, Japan & Sam Wiebe, Canada*

Epilepsy care after the earthquake in Haiti

Lionel Carmant, Canada

Epilepsy care after the earthquake in Chile

Carlos Acevedo, Chile

Epilepsy patients in and around the tsunami-devastated area in Japan in 2011

Nobukazu Nakasato, Japan

Epilepsy and natural disasters in Pakistan: earthquake in 2005 and floods in 2010

*Hasan Aziz, Pakistan***16:30-17:30****PRIZE SYMPOSIUM****Hall 1***Chair: Timothy Pedley, United States*Winner of the 2011 Morris-Coole Epilepsia Prize - *Laura Jansen, United States*
Impaired maturation of cortical GABAergic inhibition in paediatric epilepsyWinner of the 2011 Michael Prize - *Eleonora Aronica, Netherlands*

The Michael Lecture: Focal lesions in human epilepsy: a molecular and neuropathological perspective

18:00-19:30**UCB PHARMA SATELLITE SYMPOSIUM****Hall 1****Tailoring treatment to the individual patient with epilepsy: a new era for optimising control***Chair: Philippe Ryvlin, France*

Ancient drugs in 2011: first becomes last? - selecting an optimal therapeutic choice

Patrick Kwan, Hong Kong

Treating to achieve control: optimising therapy from a clinician's point of view

Konrad Werhahn, Germany

Emerging insights from an online epilepsy community – what can we learn from patients?

Jamie Heywood, United States



TUESDAY 30TH AUGUST

	Poster Area	HALL 1	HALL 2	HALL 3
07:30-08:00				Video Session Emotional brain and seizure semiology
08:00-08:30	Set up		Elekta Breakfast Symposium	
08:30-09:00				
09:00-09:30	Posters all day - Poster Tours 13:00 - 14:00	Plenary Session When do we consider epilepsy cured?	Plenary Session Impaired consciousness in epilepsy: mechanisms and clinical significance	
09:30-10:00				
10:00-10:30				
10:30-11:00		Coffee Break 11:00 - 11:30		
11:00-11:30				
11:30-12:00		Parallel Session Sudden unexpected death in epilepsy: SUDEP	Parallel Session Epileptic encephalopathies: a progressive disorder in non progressive diseases	Parallel Session Novel strategies for repairing the epileptic brain
12:00-12:30				
12:30-13:00		Lunch & Posters 13:00 - 14:00		
13:00-13:30				
13:30-14:00				
14:00-14:30			Platform Session 4 Pharmacotherapy	Platform Session 5 Global outreach
14:30-14:30				
15:00-15:30				
15:30-16:00			Coffee Break 15:30 - 16:00	
16:00-16:30			Eisai Europe Ltd Satellite Symposium	
16:30-17:00				
17:00-17:30				
17:30-18:00				
18:00-18:30		GlaxoSmithKline Satellite Symposium		
18:30-19:00				
19:00-19:30				
19:30-20:00				
20:00-20:30				
20:30-21:00				
21:00-21:30	Special Event Concert			

TUESDAY 30TH AUGUST



TUESDAY 30TH AUGUST

HALL 4	HALL 5	HALL 6	
Teaching Session Epilepsy genetics at the clinic - 2011	"How To" Series Which patients can have surgery without invasive evaluation, which cannot?	Case Oriented Series Is it focal or generalised epilepsy? How EEG and polygraphy can help	07:30-08:00
			08:00-08:30
			08:30-09:00
			09:00-09:30
			09:30-10:00
			10:00-10:30
			10:30-11:00
			Coffee Break 11:00 - 11:30
Parallel Session Status epilepticus: London Colloquium report	Parallel Session "An investment in knowledge pays the best interest" (Benjamin Franklin)	Parallel Session Epilepsy: alternative, spiritual and traditional therapy	11:30-12:00
			12:00-12:30
			12:30-13:00
Lunch & Posters 13:00 - 14:00			13:00-13:30
			13:30-14:00
Platform Session 6 Neurodiagnostics			14:00-14:30
			14:30-14:30
			15:00-15:30
Coffee Break 15:30 - 16:00			15:30-16:00
			16:00-16:30
			16:30-17:00
			17:00-17:30
			17:30-18:00
			18:00-18:30
			18:30-19:00
			19:00-19:30
			19:30-20:00
			20:00-20:30
			20:30-21:00
Special Event Concert			21:00-21:30

TUESDAY 30TH AUGUST



TUESDAY 30TH AUGUST

07:30-09:00 **VIDEO SESSION** (*Organised in conjunction with the Italian League against Epilepsy*)
Clinical semiology of epileptic and related conditions: **Hall 3**

Emotional brain and seizure semiology

Chair: Eugen Trinka, Austria

Speakers:

Elena Gardella, Italy

Antonio Gil-Nagel, Spain

Eugen Trinka, Austria

07:30-09:00 **TEACHING SESSION** **Hall 4**
Epilepsy Genetics at the Clinic - 2011

Chair: Sam Berkovic, Australia

Epilepsy genetics for the adult epileptologist

Sam Berkovic, Australia

Infantile epileptic encephalopathies - genetics and the impact of the new terminology for classification

Ingrid Scheffer, Australia

GLUT1: a surprisingly important player in epilepsy with treatment implications

Peter De Jonghe, Belgium

07:30-09:00 **"HOW TO" SERIES** **Hall 5**
Starting an epilepsy surgery programme:
Which patients can have surgery without invasive evaluation, which cannot?

Chair: Giorgio Lo Russo, Italy

Speakers:

Philippe Kahane, France

Çigdem Özkara, Turkey

Giorgio Lo Russo, Italy

07:30-09:00 **CASE ORIENTED LEARNING SERIES** **Hall 6**
Diagnosis and management of epilepsy and sleep:
Is it focal or generalised epilepsy? How EEG and polygraphy can help

Chair: Edward Bertram, United States

Speakers:

Guido Rubboli, Italy

Shih Hui Lim, Singapore

Edward Bertram, United States



08:00-09:00

ELEKTA BREAKFAST SYMPOSIUM

Hall 2

Clinical application of Magnetoencephalography (MEG) for refractory epilepsy: advances in functional mapping and localization of the epileptogenic zone

Chair: Richard Burgess, United States

Magnetoencephalography: theory and non-invasive functional mapping
Xavier De Tiège, Belgium

Use of MEG for preoperative evaluation of epilepsy patients: indications, workflow, analysis, and value
Richard Burgess, United States

09:00-11:00

PLENARY SESSION

Hall 1

When do we consider epilepsy cured?

Chairs: Ettore Beghi, Italy & Gary Mathern, United States

How should we define a “cure” for epilepsy?
Gary Mathern, United States

Remission and long-term prognosis of epilepsy syndromes: current cohort and epidemiological evidence
Ettore Beghi, Italy

Long-term prognosis in epilepsy patients: does surgery “cure” epilepsy?
Taisuke Otsuki, Japan

Can epileptogenesis be “cured” by prevention? Evidence from animal studies
Asla Pitkänen, Finland

How does epilepsy “cure” impact a person’s social life?
Mary-Lou Smith, Canada

09:00-11:00

PLENARY SESSION

Hall 2

Impaired consciousness in epilepsy: mechanisms and clinical significance

Chairs: Fabienne Picard, Switzerland & Hal Blumenfeld, United States

Functional anatomy of disorder of consciousness
Steven Laureys, Belgium

Neuroimaging, the default mode network and unconsciousness in generalized epilepsy
Jean Gotman, Canada

Electrophysiology of impaired consciousness in focal epilepsy
Fabrice Bartolomei, France

From basic mechanisms to impaired driving in epileptic unconsciousness
Hal Blumenfeld, United States



11:30-13:00

PARALLEL SESSION

Hall 1

Sudden Unexpected Death in Epilepsy: SUDEP

Chairs: Ley Sander, Netherlands & Masako Watanabe, Japan

Incidence and predisposing factors

Torbjörn Tomson, Sweden

Basic Mechanisms of SUDEP: can we predict and prevent?

Alicia Goldman, United States

The MORTEMUS experience

Philippe Ryvlin, France

Facing the facts

Jane Hanna, United Kingdom

11:30-13:00

PARALLEL SESSION

Hall 2

Epileptic encephalopathies: a progressive disorder in non progressive diseases

Chairs: Giuseppe Capovilla, Italy & Federico Vigevano, Italy

Introduction to the topic

Giuseppe Capovilla, Italy

Modeling infantile spasms to discover treatments and cures

Aristea Galanopoulou, United States

Pathophysiology of psychomotor regression in epileptic encephalopathies:

FDG-PET and EEG-fMRI data

Patrick Van Bogaert, Belgium

Does treatment make a difference?

Federico Vigevano, Italy



11:30-13:00

PARALLEL SESSION

Hall 3

Novel strategies for repairing the epileptic brain: viral vectors, stem cells, anti-inflammatory agents and optogenetics

Chairs: Annamaria Vezzani, Italy & H Steve White, United States

Viral vector-based gene therapy for epilepsy
Michele Simonato, Italy

Stem cell-based therapy for epilepsy
Scott Baraban, United States

Anti-inflammatory treatment of epilepsy
Teresa Ravizza, Italy

Optogenetic control of epileptiform activity
Merab Kokaia, Sweden

11:30-13:00

PARALLEL SESSION

Hall 4

Status Epilepticus: London Colloquium Report

Chairs: Simon Shorvon, United Kingdom & Eugen Trinka, Austria

Current concepts and basic mechanisms of status epilepticus
Daniel Lowenstein, United States

Treatment of status epilepticus: an update
Reetta Kälviäinen, Finland

Treatment of status epilepticus in resource-restricted environments
Nadir Bharucha, India

How can protocols be designed for different populations and ages?
Eugen Trinka, Austria



11:30-13:00

PARALLEL SESSION

Hall 5

“An investment in knowledge pays the best interest” (Benjamin Franklin)

Chair: Mike Glynn, Ireland

Promising Strategies Programme: why, who and how

Mike Glynn, Ireland

All about Juanito: epilepsy in animation

Tomás Mesa, Chile

Empowerment through training bears a fruitful harvest

Anthony Zimba, Zambia

Artistic licence: crafting a future in China

Ding Ding, China

11:30-13:00

PARALLEL SESSION

Hall 6

Epilepsy: alternative, spiritual and traditional therapies

Chair: Alicia Bogacz, Uruguay & Jerome Engel Jr., United States

Traditional remedies in Asia

Shunglon Lai, Taiwan

Traditional remedies in Latin America

Alicia Bogacz, Uruguay

Traditional remedies in Africa

Mpoe Johanna Keikelame, South Africa

Is there a role for contemplative practices in the treatment of epilepsy?

Jerome Engel Jr., United States



14:00-15:45

PLATFORM SESSION 4

Hall 2

Pharmacotherapy*Chair: Michel Baulac, France*

- 019** **Patterns of treatment response in newly diagnosed epilepsy**
Brodie M¹, Barry SJ¹, Bamagous G¹, Norrie J¹, Kwan P²
¹United Kingdom, ²Hong Kong
- 020** **Use of peramppanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial-onset seizures: results of a global phase III study**
French J¹, Elger C², Goldberg-Stern H³, Thomson A⁴, Krauss GL¹, Labiner D¹, Squillacote D¹, Yang H¹, Kumar D¹, Laurenza A¹
¹United States, ²Germany, ³Israel, ⁴Argentina
- 021** **An evaluation of efficacy and safety of adjunctive eslicarbazepine acetate in three double-blind clinical studies on patients with partial-onset seizures unsatisfactorily treated with carbamazepine**
Halasz P¹, Ben-Menachem E², Gil-Nagel A³, Gabbai AA⁴, Almeida L⁵, Moreira J⁵, Soares-da-Silva P⁵,
¹Hungary, ²Sweden, ³Spain, ⁴Brazil, ⁵Portugal
- 022** **Successful use of Fenfluramine as add-on treatment in Dravet syndrome**
Ceulemans B, Boel M, Leyssens K, Van Rossem C, Neels P, Jorens PG, Lagae L³
 Belgium
- 023** **Long-term safety and efficacy of oral everolimus in the treatment of patients with subependymal giant cell astrocytomas in tuberous sclerosis complex: results from an open-label, extension phase of a prospective, phase I-II study**
Krueger DA, Care MM, Holland-Bouley K, Agricola K, Tudor C, Mangeshkar P, Wilson K, Weber-Byars A, Sahnoud T, Franz DN
 United States
- 024** **Prenatal exposure to antiepileptic drugs: cognitive functioning at six years of age**
Bromley RL, Shallcross R, Gummery A, Mawer G, Clayton-Smith J, Briggs M, Cheyne C, García-Fiñana M, Baker G, Liverpool and Manchester Neurodevelopment Group
 United Kingdom
- 869** **Comparison of zonisamide and carbamazepine monotherapy in adults with newly diagnosed partial epilepsy: preliminary results of a phase III, randomised, double-blind, non-inferiority trial**
Baulac M
 France



14:00–15:30

PLATFORM SESSION 5

Hall 3

Global outreach

Chairs: Shunglon Lai, Taiwan & Marco Tulio Medina, Honduras

025

The prevalence of epilepsy, treatment gap and education levels of people living with epilepsy in Malawi

Amos A¹, Wapling L²

¹Malawi, ²United Kingdom

026

An anthropological study on epilepsy among Guaraní communities in Bolivia

Bruno E¹, Bartoloni A¹, Sofia V¹, Rafael F², Magnelli D¹, Ortiz E³, Padilla S³,

Quattrocchi G¹, Bartalesi F¹, Segundo H³, Zappia M¹, Preux PM², Nicoletti A¹

¹Italy, ²France, ³Bolivia

027

Epilepsy awareness amongst students: an observation in metropolitan city of Delhi, India

Bala K, Khurana S, Sharma V, Singh R

India

028

The risk factors for epilepsy treatment gap and non-adherence to anti-epileptic drugs in Kilifi, Kenya

Mbuba CK¹, Ngugi AK¹, Muchohi SN¹, Edwards T², Odermatt P³, Carter JA²,

Newton CR¹

¹Kenya, ²United Kingdom, ³Switzerland

029

Factors influencing the development of the perceived stigma in people with newly diagnosed epilepsy: the one year prospective study

Lee S-A, No S-K, Kim O-J, Kwon J-H, Park H-K, Ryu JY, Jo K-D, Lee S-M, Kim W-J,

Kwon O-Y

Korea, Republic of

030

Women with epilepsy: how knowledgeable are they about issues related to pregnancy in epilepsy?

Jette N, Metcalfe A, Roberts J, Abdulla F, Hanson A, Federico P, Wiebe S

Canada



14:00–15:30

PLATFORM SESSION 6**Hall 4****Neurodiagnostics***Chairs: Guido Rubboli, Italy & Jean Gotman, Canada*

- 031** **Integrative analysis of PET, ECoG and DTI data in order to assess the spatial relationship between multi-modality data sets in children with epilepsy**
Muzik O, Pai D, Juhasz C, Hua J
United States
- 032** **Simple visual assessment of intracerebrally recorded high frequency oscillations versus their automated detection**
Brazdil M, Pail M, Halamek J, Daniel P, Kuba R, Tyrlikova I, Chrastina J, Jurak P
Czech Republic
- 033** **What is the ideal time to perform postoperative electroencephalogram following anterior temporal lobectomy?**
Rathore C, Radhakrishnan K
India
- 034** **Pre and post-operative interictal EEG discharges as predictors of seizure control after surgery in mesial temporal lobe epilepsy associated with hippocampal sclerosis**
Barbosa PH, Morita ME, Lizcano A, Yasuda CL, Cendes F
Brazil
- 035** **High density simultaneous EEG-fMRI in focal epilepsy: ESI-fMRI for improved characterisation of interictal events**
Vogrin SJ¹, Lau S², D'Souza W¹, Kuhlmann L², Hauelsen J², Cook MJ¹
¹Australia, ²Germany
- 036** **Seizure-association fibers in patients with chronic focal seizures: in vivo neural connectivity study and tensor imaging study**
Chuang M-F, Hsin YL
China



16:00-17:30

EISAI EUROPE LTD. SATELLITE SYMPOSIUM

Hall 1

Optimising care for epilepsy patients: looking beyond AED efficacy

Chair: Joyce Cramer, United States

Understanding our patients: do we need to improve communication?

Frank Gilliam, United States

Matching drugs to patients with newly diagnosed and refractory epilepsy

Martin Brodie, United Kingdom & Antonio Gil-Nagel, Spain

Epilepsy patient care: a multi-disciplinary approach

Sophie Dupont, France and Melesina Goodwin, United Kingdom

18:00-19:30

GLAXOSMITHKLINE SATELLITE SYMPOSIUM

Hall 1

Add-on therapy for focal epilepsy: working towards a rational choice

Chair: Ettore Beghi, Italy

How can preclinical studies inform the choice of add-on therapy?

Graeme Sills, United Kingdom

Does mechanism of action matter in clinical practice?

Philippe Ryvlin, France

Emerging targets and mechanisms in add-on therapy

Holger Lerche, Germany





WEDNESDAY 31ST AUGUST

	Poster Area	HALL 1	HALL 2	HALL 3
07:30-08:00			"How To" Series Psychiatric and psychosocial aspects of epilepsy surgery	Video Session Automatic behaviours in epilepsy and sleep
08:00-08:30	Set up			
08:30-09:00				
09:00-09:30	Posters all day - Poster Tours 13:00 - 14:30	Plenary Session Predicting the unpredictable: the adverse effects of treatments	Plenary Session Epilepsy during puberty - the wonder years	
09:30-10:00				
10:00-10:30				
10:30-11:00				
11:00-11:30		Coffee Break 11:00 - 11:30		
11:30-12:00		Post Presidential Symposium Epilepsy destroys lives part 2	Parallel Session Neurodevelopmental comorbidities in children	Parallel Session Antiepileptic drug discovery and development
12:00-12:30				
12:30-13:00				
13:00-13:30		Lunch & Posters 13:00 - 14:30		
13:30-14:00				
14:00-14:30				
14:30-14:30			Platform Session 7 Genes and mutations	Platform Session 8 Surgery: who are the best candidates, beyond resections and outcomes
15:00-15:30				
15:30-16:00				
16:00-16:30	Coffee Break 16:00 - 16:30			
16:30-17:00			Biocodex Satellite Symposium	
17:00-17:30				
17:30-18:00				
18:00-18:30				
18:30-19:00				
19:00-19:30				

WEDNESDAY 31ST AUGUST



WEDNESDAY 31ST AUGUST

HALL 4	HALL 5	HALL 6	BRAMANTE 6 & 7	
Case Oriented Series Epilepsy and sleep: what are we treating and with what effect?	EGI Breakfast Symposium	Teaching Session Synergising and advocacy		07:30-08:00
				08:00-08:30
				08:30-09:00
				09:00-09:30
				09:30-10:00
				10:00-10:30
				10:30-11:00
Coffee Break			11:00 - 11:30	11:00-11:30
Parallel Session Brain tumours and epilepsy: a mechanistic perspective	Parallel Session Bridging basic and clinical epileptology in Africa	Parallel Session Functional genomic of epilepsy: how EPICURE advanced our knowledge		11:30-12:00
			IBE General Assembly	12:00-12:30
				12:30-13:00
				13:00-13:30
				13:30-14:00
Lunch & Posters			13:00 - 14:30	14:00-14:30
Platform Session 9 Epilepsy syndromes	ILAE General Assembly		14:30-14:30	
		15:00-15:30		
		15:30-16:00		
		16:00-16:30		
Coffee Break			16:00 - 16:30	16:30-17:00
Novartis Satellite Symposium				17:00-17:30
				17:30-18:00
				18:00-18:30
				18:30-19:00
				19:00-19:30

WEDNESDAY 31ST AUGUST



WEDNESDAY 31ST AUGUST

- 07:30-09:00** **“HOW TO” SERIES** **Hall 2**
**Starting an epilepsy surgery programme:
Psychiatric and psychosocial aspects of epilepsy surgery: pre and
post-surgical**
Chair: Chong-Tin Tan, Malaysia
- Speakers:*
Andres Kanner, United States
P Satish Chandra, India
Chong-Tin Tan, Malaysia
- 07:30-09:00** **VIDEO SESSION** (*Organised in conjunction with the Italian League against Epilepsy*)
Clinical semiology of epileptic and related conditions: **Hall 3**
Automatic behaviours in epilepsy and sleep
Chair: Athanasios Covanis, Greece
- Speakers:*
Carlo Alberto Tassinari, Italy
Claudio Bassetti, Switzerland
Athanasios Covanis, Greece
- 07:30-09:00** **CASE ORIENTED LEARNING SERIES** **Hall 4**
**Diagnosis and management of epilepsy and sleep:
Epilepsy and sleep: what are we treating and with what effect?**
Chair: Lino Nobili, Italy
- Speakers:*
Al de Weerd, Netherlands
Anna Kelemen, Hungary
Lino Nobili, Italy
- 07:30-09:00** **ELECTRICAL GEODESICS, INC. (EGI) BREAKFAST SYMPOSIUM** **Hall 5**
Advanced EEG... the clinical contribution
Chair: Paolo Manganotti, Italy
- Applying Electrical Source Imaging (ESI) in pre-surgical planning
Margitta Seeck, Switzerland
- Comparison of source localization results from dense array EEG, IC electrodes,
depth electrodes and traditional EEG
Takamichi Yamamoto, Japan
- The role of dense array EEG in the presurgical evaluation
Mark Holmes, United States

**07:30-09:00****TEACHING SESSION****Hall 6****Synergising and advocacy: bringing IBE and ILAE together at a national and regional level***Chair: Janet Mifsud, Malta*

Why synergise and advocate?

Janet Mifsud, Malta

Introducing Canadian youth to careers in epilepsy through the 'Brain Matters' programme

Mary Secco, Canada

Building bridges between the two epilepsy organisations in India: a rewarding journey

*Vinod Saxena, India***09:00-11:00****PLENARY SESSION****Hall 1****Predicting the unpredictable: the adverse effects of treatments***Chairs: Heidrun Potschka, Germany & Patrick Kwan, Hong Kong*

Adverse effects of AEDs: impact on quality of life and drug choice

Frank Gilliam, United States

Predicting AED adverse effects: it's all in the drug?

Heidrun Potschka, Germany

Predicting AED idiosyncratic reactions: it's all in the genes?

Patrick Kwan, Hong Kong

Predicting adverse AED interactions

*Meir Bialer, Israel***09:00-11:00****PLENARY SESSION****Hall 2****Epilepsy during puberty - the wonder years***Chairs: Eduardo Barragán, Mexico & Dana Craiu, Romania*

Why and what etiologies

Karen Ballaban Gil, United States

How is basic science influencing our understanding of epilepsy concepts and terminology in epilepsies of adolescence?

Astrid Nehlig, France

Therapeutic choices in epilepsy during puberty. What and why?

Dana Craiu, Romania

Social issues in the wonder years

Eduardo Barragán, Mexico



11:30-13:00

POST PRESIDENTIAL SYMPOSIUM

Hall 1

Epilepsy destroys lives part 2

Chairs: Tarun Dua, WHO Switzerland & Dale Hesdorffer (United States)

The Chinese experience

Sichuo Li, China

The Brazilian experience

Li Li Min, Brazil

The European initiative

Michel Baulac, France

The North American initiative and the Institute of Medicine (IOM) report

Frances Jensen, United States

11:30-13:00

PARALLEL SESSION

Hall 2

Neurodevelopmental comorbidities in children

Chairs: Perrine Plouin, France & Renzo Guerrini, Italy

Autism and epilepsy: reality or fashion?

Roberto Tuchman, United States

ADHD and learning disorders: are they important in patients with epilepsy?

Alexis Arzimanoglou, France

Psychiatric medication in children with epilepsy: is it safe to use?

Varda Gross-Tsur, Israel



11:30-13:00

PARALLEL SESSION

Hall 3

Antiepileptic drug discovery and development: what are the challenges in the current environment?

Chairs: Wolfgang Löscher, Germany & Meir Bialer, Israel

Animal seizures and epilepsy models – what do they really tell us about clinical efficacy?

H Steve White, United States

From understanding the pathophysiology of refractory focal onset epilepsy to development of more effective therapies

Wolfgang Löscher, Germany

Investigational AEDs in the pipeline: will they make a difference for the patient with refractory epilepsy?

Bernd Schmidt, Germany

New challenges in demonstrating clinical efficacy in refractory epilepsies

Jacqueline French, United States

11:30-13:00

PARALLEL SESSION

Hall 4

Brain tumours and epilepsy: a mechanistic perspective

Chairs: Rüdiger Köhling, Germany & Eleonora Aronica, Netherlands

Pathophysiological and peritumoral changes underlying tumour-related epilepsy

Harald Sontheimer, United States

Mechanisms of tumour-associated ictogenesis

Rüdiger Köhling, Germany

Insights from neuropathological studies in humans

Eleonora Aronica, Netherlands

Rational seizure control in brain cancer

Charles J Vecht, Netherlands



11:30-13:00	PARALLEL SESSION Bridging basic and clinical epileptology in Africa <i>Chairs: Pierre Marie Preux, France & Anthony Zimba, Zambia</i> Managing epilepsy in Africa: problems and future perspectives <i>Albert Akpalu, Ghana</i> Epilepsy in malaria and other infections <i>Charles Newton, Kenya</i> Anti-convulsant African plants <i>Elisabeth Ngo Bum, Cameroon</i> Animal models of epilepsy and the potential of African investigators <i>Marina Bentivoglio, Italy</i>	Hall 5
11:30-13:00	PARALLEL SESSION Functional genomics of epilepsy: how EPICURE advanced our knowledge <i>Chairs: Janet Mifsud, Malta & Giuliano Avanzini, Italy</i> The power of an integrated approach involving geneticists, neurophysiologists and clinicians <i>Giuliano Avanzini, Italy</i> Strategies for identification of epilepsy genes: results and perspectives <i>Thomas Sander, Germany</i> Functional study of epilepsy genes <i>Massimo Mantegazza, Italy</i> Modelling genetically determined abnormalities of the cerebral cortex <i>Alfonso Represa, France</i>	Hall 6
12:00-16:00	IBE GENERAL ASSEMBLY	Bramante 6 & 7
14:00-16:00	ILAE GENERAL ASSEMBLY	Hall 5



14:30–16:00

PLATFORM SESSION 7

Hall 2

Genes and mutations*Chairs: Sam Berkovic, Australia & Amedeo Bianchi, Italy*

037

Whole exome sequencing implicates SLC25A22 as a gene for MMPEI

Poduri A¹, Heinzen EL¹, Salih MA², Chitsazzadeh V¹, Hill RS¹, Elhosary PC¹, Barry BJ¹, Partlow JN¹, Ge D¹, Shianna KV¹, Bashiri FA², Zeidan RM², Elmalik SA², Kabiraj MMU², Stödberg T³, Scheffer IE⁴, Barkovich AJ¹, Goldstein D¹, Walsh CA¹
¹United States, ²Saudi Arabia, ³Sweden, ⁴Australia

038

Cerebral microdysgenesis in refractory epilepsy patients with SCN1A mutations

Skjei K, Harding B, Marsh E
 United States

039

KCNQ2 mutations are a cause of neonatal epileptic encephalopathies with a clinical and radiological phenotype

Weckhuysen S^{1,2}, Mandelstam S³, Suls A¹, Audenaert D¹, Deconinck T¹, Claes L¹, Deprez L¹, Smets K¹, Hristova D⁴, Yordanova I⁴, Jordanova A¹, Ceulemans B¹, Jansen A¹, Hasaerts D¹, Roelens F¹, Lagae L¹, Yendle S³, Stanley T⁵, Heron S³, Mulley J³, Berkovic S³, Scheffer I³, De Jonghe P¹
¹Belgium, ²Netherlands, ³Australia, ⁴Bulgaria, ⁵New Zealand

040

Epileptic and non epileptic features in patients with early onset epileptic encephalopathy and STXBP1 mutations

Milh M, Villeneuve N, Mondher C, Kaminska A, Larroche C, Gitiaux C, Borges-Correa Cacciagli P, Mignon-Ravix C, Cuberos H, Chabrol B, Villard L
 France

041

Expansion of the phenotype associated with PCDH19-mutations

Hjalgrim H¹, Dibbens LM², Scheffer IE², Olofsson K¹, Nikanorova M¹, Jepsen B¹, Møller RS¹
¹Denmark, ²Australia

042

Association of Interleukin-6 polymorphism with susceptibility to febrile seizures

Choi J, Kim K-J, Hwang Y-S
 Korea, Republic of



14:30–16:00

PLATFORM SESSION 8

Hall 3

Surgery: who are the best candidates, beyond resections and outcomes

Chairs: Tatsuya Tanaka, Japan & Bernard Steinhoff, Germany

043

Temporal lobe epilepsy surgery in the sixth decade and beyond

*Pillay N, Avendano R, Partlo L, Hader W, Wiebe S
Canada*

044

Which frequency comes first in intracranial EEG ictal onset: high or low?

*Chung JM¹, Tsuchiya N², Maoz U¹, Tuduscic O¹, Mamelak AN¹, Eliashiv D¹
¹United States, ²Japan*

045

[18F]GE-179 PET demonstrates increased NMDA receptor availability in patients with refractory epilepsy and frequent interictal epileptiform discharges (IEDs)

*McGinnity CJ¹, Hammers A², Riaño Barros DA¹, Gousias IS¹, Luthra SK¹, Jones PA¹, Trigg W¹, Brooks DJ¹, Koepp MJ¹, Duncan JS¹
¹United Kingdom, ²France*

046

Neural networks underlying seizures from the motor system: quantification and classification from intracerebral recordings

*Bonini E, McGonigal A, Gavaret M, Regis J, Wendling F, Chauvel P, Bartolomei F
France*

047

Alterative treatment of intractable epilepsy with focal brain cooling

*Fujii M, Inoue T, HE Y, Imoto H, Tanaka N, Oku T, Maruta Y, Koizumi H, Nomura S, Owada Y, Saito T, Yamakawa T, Tokiwa T, Yamakawa T, Suzuki M, Consortium of Advanced Epilepsy Treatment (CADET)
Japan*

048

Prevalence of psychiatric disorders before and after corticoamygdalohippocampectomy: study of 115 patients with refractory temporal lobe epilepsy and mesial temporal sclerosis

*Mazetto L, Lobato FG, Marinho MM, Caboclo LOS, Yacubian EMT, Centeno RS, De Araujo Filho GM
Brazil*



14:30–16:00

PLATFORM SESSION 9**Hall 4****Epilepsy syndromes***Chairs: Holger Lerche, Germany & Edouard Hirsch, France*

- 049** **Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted county, Minnesota from 1980-2004: a population-based study**
Wirrell EC, Grossardt B, Wong-Kissel L, Nickels KC
United States
- 050** **Natural history and long-term evolution in families with autosomal dominant cortical tremor, myoclonus, and epilepsy**
Coppola A, Santulli L, Del Gaudio L, Minetti C, Striano S, Zara F, Striano P
Italy
- 051** **Stormy onset epilepsy in girls with de novo protocadherin 19 mutations**
Specchio N, Terracciano A, Marini C, Mei D, Trivisano M, Sicca F, Fusco L, Granata T, Freri E, Cusmai R, Darra F, Dalla Bernardina B, Guerrini R, Bertini E, Vigeveno F
Italy
- 052** **Prospective analysis of familial mesial temporal lobe epilepsy**
Morita ME, Yasuda CL, Betting LEG, Costa ALF, Kobayashi E, Lopes-Cendes I, Cendes F
Brazil
- 053** **Malformations of cortical development and epilepsy: clinical, electrophysiological, radiological profile and predictors of remission**
Sattaluri SJ, Krishna M, Panigrahi M, Ram Mohan V, Varma R
India
- 054** **Detailed video-EEG characterization and clinical aspects in 25 children with neonatal onset epileptic encephalopathy and suppression burst pattern**
Eisermann M, Kaminska A, Plouin P, Dulac O, Nabbout R
France



16:30-18:00

BIOCODEX SATELLITE SYMPOSIUM

Hall 3

Dravet syndrome: addressing the needs of patients and families

Chairs: Charlotte Dravet, France & Renzo Guerrini, Italy

Diagnosis and long-term course

Ingrid Scheffer, Australia

Helping families cope with the devastation of Dravet syndrome

Peter Camfield, Canada

Stiripentol: an example of antiepileptic drug development in childhood epilepsies

Rima Nabbout, France

16:30-18:00

NOVARTIS SATELLITE SYMPOSIUM

Hall 4

Advancing the treatment of neuropathologies through targeting of the mTOR pathway

Chair: Aristeia Galanopoulou, United States

Infantile spasms and epilepsy associated with tuberous sclerosis complex

Paolo Curatolo, Italy

The role of mTOR in TSC – evidence and clinical implications

Sergiusz Jóźwiak, Poland

The mTOR pathway: future perspectives in neuroscience

Aristeia Galanopoulou, United States



Life with epilepsy can be much more
than just a gap between seizures

Add VIMPAT® with confidence when monotherapy is not enough

- ◆ Improved seizure control, regardless of current or prior AED therapy ¹
- ◆ Demonstrated long-term efficacy ²
- ◆ Easy to use – with a low potential for PK drug-drug interactions ³
- ◆ A novel mode of action ^{3-5*}

Licensed for adjunctive therapy in epilepsy patients
with partial-onset seizures ≥16 years old.

*The precise mechanism by which VIMPAT® (lacosamide) exerts
its anti-epileptic effect in humans remains to be fully elucidated.


VIMPAT[®]
lacosamide



Confidence, when monotherapy is not enough

EU ABBREVIATED PRESCRIBING INFORMATION: Name of the medicinal product: VIMPAT[®] (lacosamide). **Pharmaceutical form:** Film-coated tablets containing 50mg, 100mg, 150 mg, or 200mg lacosamide, syrup containing 15 mg/ml lacosamide, and solution for infusion containing 10 mg/ml lacosamide. **Therapeutic indications:** VIMPAT[®] is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. VIMPAT[®] solution for infusion is an alternative for patients when oral administration is temporarily not feasible. **Posology and method of administration:** VIMPAT[®] must be taken twice a day. The recommended starting dose is 50 mg twice a day which should be increased to an initial therapeutic dose of 100 mg twice a day after one week. Depending on response and tolerability, the maintenance dose can be further increased by 50 mg twice a day every week, to a maximum recommended daily dose of 400 mg (200 mg twice a day). VIMPAT[®] may be taken with or without food. If VIMPAT[®] has to be discontinued, it is recommended this be done gradually (e.g. taper the daily dose by 200 mg/week). A maximum dose of 250 mg/day is recommended for patients with severe renal impairment ($CL_{CR} \leq 30$ ml/min) and in patients with endstage renal disease. For patients requiring haemodialysis a supplement of up to 50% of the divided daily dose directly after the end of haemodialysis is recommended. **Contraindications:** Hypersensitivity to the active substance or any of the excipients; known second- or third-degree atrioventricular (AV) block. **Special warnings and precautions for use:** Treatment with VIMPAT[®] has been associated with dizziness which could increase the occurrence of accidental injury or falls. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicine. Prolongations in PR interval with VIMPAT[®] have been observed in clinical studies. VIMPAT[®] should be used with caution in patients with known conduction problems or severe cardiac disease such as a history of myocardial infarction or heart failure. Caution should especially be exerted when treating elderly patients as they may be at an increased risk of cardiac disorders or when VIMPAT[®] is used in combination with products known to be associated with PR prolongation. Second degree or higher AV block has been reported in post-marketing experience. In the placebo-controlled trials of lacosamide in epilepsy patients, atrial fibrillation or flutter were not reported; however both have been reported in open-label epilepsy trials and in post-marketing experience. Patients should be made aware of the symptoms of second-degree or higher AV block [e.g. slow or irregular pulse, feeling of lightheaded and fainting] and of the symptoms of atrial fibrillation and flutter [e.g. palpitations, rapid or irregular pulse, shortness of breath]. Patients should be counselled to seek medical advice should any of these symptoms occur. Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents in several indications. A meta-analysis of randomised placebo controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for VIMPAT[®]. Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients [and caregivers of patients] should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge. VIMPAT[®] syrup contains sodium methylhydroxybenzoate (E219), which may cause allergic reactions (possibly delayed). It contains 3.7 g sorbitol (E420) per dose (200 mg lacosamide), corresponding to a calorific value of 9.7 kcal. Patients with rare hereditary problems of fructose intolerance should not take this medicine. The syrup contains aspartame (E951), a source of phenylalanine, which may be harmful for people with phenylketonuria. VIMPAT[®] syrup and solution for infusion contain sodium. To be taken into consideration for patients on a controlled sodium diet. **Effects on ability to drive and use machines:** VIMPAT[®] may have minor to moderate influence on the ability to drive and use machines. VIMPAT[®] treatment has been associated with dizziness or blurred vision. Accordingly, patients should be advised not to drive a car or to operate other potentially hazardous machinery until they are familiar with the effects of VIMPAT[®] on their ability to perform such activities. **Interaction with other medicinal products and other forms of interaction:** VIMPAT[®] should be used with caution in patients treated with medicinal products known to be associated with PR prolongation (e.g. carbamazepine, lamotrigine, pregabalin) and in patients treated with class I antiarrhythmic drugs. However, subgroup analysis did not identify an increased magnitude of PR prolongation in patients with concomitant administration of carbamazepine or lamotrigine in clinical trials. Lacosamide does not inhibit or induce CYP2C19 and CYP3A4 to a clinically relevant extent. Lacosamide did not affect the AUC of midazolam but Cmax of midazolam was slightly increased (30%). Lacosamide did not affect the pharmacokinetics of omeprazole. Omeprazole did not give rise to a clinically significant change in lacosamide exposure. Thus moderate inhibitors of CYP2C19 are unlikely to affect systemic lacosamide exposure to a clinically relevant extent. Caution is recommended in concomitant treatment with strong inhibitors of CYP2C9 (e.g. fluconazole) and CYP3A4 (e.g. itraconazole, ciclosporin, ritonavir, clarithromycin), which may lead to increased systemic exposure of lacosamide. Such interactions have not been established *in vivo* but are possible based on *in vitro* data. Strong enzyme inducers such as rifampicin or St John's wort (Hypericum perforatum) may moderately reduce the systemic exposure of VIMPAT[®]. Therefore, starting or ending treatment with these enzyme inducers should be done with caution. **With antiepileptic drugs:** In interaction trials lacosamide did not significantly affect the plasma concentrations of carbamazepine and valproic acid. Lacosamide plasma concentrations were not affected by carbamazepine and by valproic acid. A population PK analysis estimated that concomitant treatment with other anti-epileptic drugs known to be enzyme inducers (carbamazepine, phenytoin, phenobarbital, in various doses) decreased the overall systemic exposure of lacosamide by 25%. **With oral contraceptives:** In an interaction trial there was no clinically relevant interaction between lacosamide and the oral contraceptives ethinylestradiol and levonorgestrel. Progesterone concentrations were not affected when the medicinal products were co-administered. **With other medicinal products and substances:** Interaction trials showed that lacosamide had no effect on the pharmacokinetics of digoxin. There was no clinically relevant interaction between lacosamide and metformin. No data on the interaction of lacosamide with alcohol are available. Lacosamide has a low protein binding of less than 15%. Therefore, clinically relevant interactions with other drugs through competition for protein binding sites are considered unlikely. **Pregnancy:** There are no adequate data from the use of VIMPAT[®] in pregnant women. The potential risk for humans is unknown. VIMPAT[®] should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus). If women decide to become pregnant, the use of this product should be carefully re-evaluated. **Breastfeeding:** It is unknown whether VIMPAT[®] is excreted in human breast milk. For precautionary measures, breast-feeding should be discontinued during treatment with VIMPAT[®]. **Undesirable effects:** The most common adverse reactions ($\geq 10\%$) were dizziness, headache, diplopia, and nausea. They were usually mild to moderate in intensity. Some were dose-related and could be alleviated by reducing the dose. Incidence and severity of CNS and gastrointestinal (GI) adverse reactions usually decreased over time. Other common adverse reactions ($\geq 1\%$ - $<10\%$) are depression, confusional state, insomnia, balance disorder, coordination abnormal, memory impairment, cognitive disorder, somnolence, tremor, nystagmus, hypoesthesia, dysarthria, disturbance in attention, vision blurred, vertigo, tinnitus, vomiting, constipation, flatulence, dyspepsia, dry mouth, pruritus, rash, muscle spasms, gait disturbance, asthenia, fatigue, irritability, injection site pain or discomfort (specific to solution for infusion), irritation (specific to solution for infusion), fall, and skin laceration. The use of VIMPAT[®] is associated with dose-related increase in the PR interval. Adverse reactions associated with PR interval prolongation [e.g. atrioventricular block, syncope, bradycardia] may occur. **Laboratory abnormalities:** Abnormalities in liver function tests have been observed in controlled trials with lacosamide in adult patients with partial-onset seizures who were taking 1 to 3 concomitant anti-epileptic drugs. Elevations of ALT to $\geq 3 \times ULN$ occurred in 0.7% (7/935) of Vimpat patients and 0% (0/356) of placebo patients. **Multorgan Hypersensitivity Reactions:** Multorgan hypersensitivity reactions have been reported in patients treated with some antiepileptic agents. These reactions are variable in expression but typically present with fever and rash and can be associated with involvement of different organ systems. Potential cases have been reported rarely with lacosamide and if multorgan hypersensitivity reaction is suspected, lacosamide should be discontinued. Refer to the *Summary of Product Characteristics* for other adverse reactions. **Overdose:** There is limited clinical experience with VIMPAT[®] overdose in humans. Clinical symptoms (dizziness and nausea) following doses of 1200 mg/day were mainly related to the central nervous system and the gastrointestinal system and resolved with dose adjustments. The highest reported overdose in the clinical development program for VIMPAT[®] was 12 g taken in conjunction with toxic doses of multiple other antiepileptic drugs. The subject was initially comatose and then fully recovered without permanent sequelae. There is no specific antidote for overdose with VIMPAT[®]. Treatment of VIMPAT[®] overdose should include general supportive measures and may include haemodialysis if necessary. **Date of revision:** 06 May 2011. Refer to the *full prescribing information* in your country before prescribing. **Marketing authorisation holder:** UCB Pharma, S.A. Allée de la Recherche 60 B-1070 Bruxelles Belgium. **Marketing authorisation number(s):** EU/1/008/470/001-017. **Date of first authorisation:** 29 August 2008. **Legal classification:** Medicinal product subject to medical prescription. **GSRC ICM-SCT-009601-042011.** © 2010 – 2011 UCB Pharma, S.A. All rights reserved. **Date of preparation:** 06 May 2011. **References:** 1. Chung S et al. *CNS Drugs* 2010; **24** (12): 1041-1054. 2. Cross, S.A et al. *Drugs* 2009; **69** (4): 449-459. 3. VIMPAT[®] Summary of Product Characteristics, 06 May 2011. 4. Beyreuther BK et al. *CNS Drug Rev* 2007; **13** (1): 21-42. 5. Errington AC et al. *Mol Pharmacol* 2008; **73**: 157-169.

Please be advised that whilst all VIMPAT[®] film coated tablets are now being manufactured with a new coating that does not contain soya-lectin, there may still be existing supply of the previous film coated tablet formulation in some markets. The lectin containing film-coated tablets are contra-indicated in patients with hypersensitivity to peanuts or soya.

A copy of the VIMPAT[®] Summary of Product Characteristics is available at the UCB booth.



Confidence, when monotherapy is not enough



THURSDAY 1ST SEPTEMBER

	HALL 3	HALL 4	HALL 5	HALL 6	
07:30-08:00	"How To" Series Children are not small adults: starting paediatric epilepsy surgery	Video Session Neonatal seizures and epilepsies	Teaching Session Updating epileptogenic mechanisms	Case Oriented Series Epilepsy, sleep and learning: what and how to treat	07:30-08:00
08:00-08:30					08:00-08:30
08:30-09:00					08:30-09:00
09:00-09:30	Plenary Session Challenges in developing a new approach for classification in epilepsy	Plenary Session Older, slowing down and seizing up - epilepsy strikes again			09:00-09:30
09:30-10:00					09:30-10:00
10:00-10:30					10:00-10:30
10:30-11:00					10:30-11:00
11:00-11:30	Coffee Break 11:00 - 11:30				11:00-11:30
11:30-12:00	Teaching Session Multimodal imaging in epilepsy: EEG and beyond	Teaching Session Neuroimmunological aspects of epilepsy	Parallel Session Advances in dynamic characterization of ictogenesis: the San Servolo experience	Teaching Session AED kinetics across the ages	11:30-12:00
12:00-12:30					12:00-12:30
12:30-13:00					12:30-13:00



THURSDAY 1ST SEPTEMBER

- 07:30-09:00** **“HOW TO” SERIES** **Hall 3**
Starting an epilepsy surgery programme:
Children are not small adults: starting paediatric epilepsy surgery
Chair: Helen Cross, United Kingdom
- Speakers:*
Gary Mathern, United States
Olivier Delalande, France
Helen Cross, United Kingdom
- 07:30-09:00** **VIDEO SESSION** (*Organised in conjunction with the Italian League against Epilepsy*)
Clinical semiology of epileptic and related conditions: **Hall 4**
Neonatal seizures and epilepsies
Chair: Perrine Plouin, France
- Speakers:*
Maria Roberta Cilio, Italy
Akihisa Okumura, Japan
Perrine Plouin, France
- 07:30-09:00** **TEACHING SESSION** **Hall 5**
Updating epileptogenic mechanisms
Chair: Terence O'Brien, Australia
- Speakers:*
Jaideep Kapur, United States
Asla Pitkänen, Finland
Terence O'Brien, Australia
- 07:30-09:00** **CASE ORIENTED LEARNING SERIES** **Hall 6**
Diagnosis and management of epilepsy and sleep:
Epilepsy, sleep and learning: what and how to treat
Chair: Lieven Lagae, Belgium
- Speakers:*
Michalis Koutroumanides, United Kingdom
Lieven Lagae, Belgium
Dana Craiu, Romania



09:00-11:00

PLENARY SESSION

Hall 3

Challenges in developing a new approach for classification in epilepsy

Chairs: Anne Berg, United States & Giuseppe Capovilla, Italy

Introduction to the new ILAE classification of the epilepsies: why is it time for change?

Ingrid Scheffer, Australia

Impact of genetics on classification of the epilepsies

Sam Berkovic, Australia

Impact of neuroimaging on the classification of the epilepsies

John Duncan, United Kingdom

How does the classification system impact on basic research and animal models?

Marco De Curtis, Italy

Tailoring the new classification for diagnosis and global outreach

Sam Wiebe, Canada

The new organization: pros

Edouard Hirsch, France

The new organization: cons

Sanjay Sisodiya, United Kingdom

Round table: the pros and cons of the new ILAE seizure classification system:

Anne Berg (United States), Sam Berkovic (Australia), Giuseppe Capovilla (Italy), Marco De Curtis (Italy), John Duncan (United Kingdom), Edouard Hirsch (France), Ingrid Scheffer (Australia), Sanjay Sisodiya (United Kingdom), Sam Wiebe (Canada)



09:00-11:00

PLENARY SESSION

Hall 4

Older, slowing down and seizing up - epilepsy strikes again

Chairs: Carlos Acevedo, Chile & Simon Shorvon, United Kingdom

Why do old people have seizures?

Simon Shorvon, United Kingdom

What is it about aging which predisposes to epilepsy?

Alon Friedmann, Israel

To treat or not to treat?

Günter Krämer, Switzerland

Quality of life and the elderly

Carlos Acevedo, Chile

11:30-13:00

TEACHING SESSION

Hall 3

Multimodal imaging in epilepsy: EEG and beyond

Chair: John Duncan, United Kingdom

Structural MRI + tractography

Fernando Cendes, Brazil

EEG-fMRI and high frequency EEG

Jean Gotman, Canada

3-D reconstructions of MRI data, including functional MRI and isotope-imaging

John Duncan, United Kingdom

11:30-13:00

TEACHING SESSION

Hall 4

Neuroimmunological aspects of epilepsy

Chair: Christian Bien, Germany

Speakers:

Angela Vincent, United Kingdom

Annamaria Vezzani, Italy

Christian Bien, Germany



11:30-13:00

PARALLEL SESSION

Hall 5

**Advances in dynamic characterization of ictogenesis:
the San Servolo Experience**

Chair: Marco de Curtis, Italy

Introduction

Giuliano Avanzini, Italy

Neuroimaging of absence epilepsy

Tyanhua Yang, China

Fingerprints of brain activation in epileptic syndromes and encephalopathies

Michael Siniatchkin, Germany

EEG-fMRI: a new insight into focal seizure dynamics

Louise Tyvaert, France

11:30-13:00

TEACHING SESSION

Hall 6

AED kinetics across the ages

Chair: John Pellock, United States

Speakers:

Svein Johannessen, Norway

Torbjörn Tomson, Sweden

John Pellock, United States





POSTERS

The Poster Area (Botticelli Room) is located on ground floor level beside Hall 2.

Posters will be set up from Monday 29th August - Wednesday 31st August between 08:00 and 09:00 and will be on display between 09:00 and 18:00. Poster dismantling will take place between 18:00 and 19:00 from Monday 29th August - Wednesday 31st August.

POSTER TOURS

The timetable below illustrates which topics are on each day:

MONDAY 29TH AUGUST

13:00-14:30

Poster Area (Botticelli Room)

Tour Guide(s)	Poster Session	Poster #
Reetta Kälviäinen	Adult epileptology I	p055 - p064
Gonzalo Alarcon	Adult epileptology II	p065 - p080
Shih Hui Lim	Adult epileptology III	p081 - p090
Paolo Tinuper	Adult epileptology IV	p091 - p103
Donna Bergen	Adult epileptology V	p104 - p116
Jaideep Kapur	Basic sciences I	p117 - p127
Alon Friedman / Uwe Heinemann	Basic sciences II	p128 - p137
Jong Rho / Astrid Nehlig / Terence O'Brien	Basic sciences III	p138 - p148
Edward Bertram / Michele Simonato	Basic sciences IV	p149 - p160
Heidrun Potschka / Aristeia Galanopoulou	Basic sciences V	p161 - p171
Alfonso Represa / Marco de Curtis / Rüdiger Köhling	Basic sciences VI	p172 - p184
Simon Harvey	Paediatric epileptology I	p186 - p193
Gonzalo Alarcon	Paediatric epileptology II	p194 - p201
Patrick Van Bogaert	Paediatric epileptology III	p202 - p209
Judit Jerney	Paediatric epileptology IV	p210 - p220
Alexis Arzimanoglou	Paediatric epileptology V	p221 - p232
Roberto Michelucci	Clinical neurophysiology I	p233 - p244
Guido Rubboli / Michael Siniatchkin	Clinical neurophysiology II	p245 - p256
Prasanna Jayakar	Clinical neurophysiology III	p257 - p269
Rima Nababout / Renzo Guerrini	Genetics I	p270 - p281
Stephanie Baulac / Sameer M Zuberi	Genetics II	p282 - p291
Shinichi Hirose	Genetics III	p292 - p303
Alicia Goldman	Genetics IV	p304 - p314
Barbara Koppel / Marco Mula	Neuropsychology / psychiatry I	p315 - p324
Mary Secco	Neuropsychology / psychiatry II	p325 - p337

The Scientific Advisory and Organising Committee has chosen to organise guided poster tours (led by experts in the field), giving a chance to all researchers to present their work during the Congress. Therefore, presenters will be available at their poster on their assigned day (13:00 - 14:30 on Monday 29th August and Wednesday 31st August and 13:00 - 14:00 on Tuesday 30th August). Each presenter shall be given 3- 5 minutes to illustrate their poster and answer questions.

The full poster abstracts are viewable online under "posters" in the interactive session planner which can be found on the Congress website.



TUESDAY 30TH AUGUST

13:00-14:00

Poster Area (Botticelli Room)

Tour Guide(s)	Poster Session	Poster #
John Paul Leach	Drug therapy I	p338 - p348
Jacqueline French	Drug therapy II	p349 - p360
Shunglon Lai	Drug therapy III	p361 - p372
Bernd Schmidt	Drug therapy IV	p373 - p384
Perrine Plouin	Paediatric epileptology VI	p385 - p394
Jo Whilmhurst	Paediatric epileptology VII	p395 - p405
Ingrid Tuxhorn	Paediatric epileptology VIII	p406 - p414
Karen Ballaban Gil	Paediatric epileptology IX	p415 - p420
Ley Sander	Epidemiology I	p421 - p430
Ding Ding	Epidemiology II	p431 - p438
Ettore Beghi	Epidemiology III	p439 - p448
Torbjörn Tomson	Adult epileptology VI	p449 - p461
Maria Paola Canevini	Adult epileptology VII	p462 - p474
Holger Lerche	Adult epileptology VIII	p475 - p486
Carlo Alberto Tassinari	Adult epileptology IX	p487 - p498
Andreas Schultze Bonhage	Adult epileptology X	p499 - p511
Norman Delanty / Alicia Bogacz	Alternative therapies I	p512 - p521
Steven Schachter	Alternative therapies II	p522 - p528
John Duncan	Neuroimaging I	p529 - p539
Fernando Cendes	Neuroimaging II	p540 - p550
Fergus Rugg-Gunn	Neuroimaging III	p551 - p559
TBA	Neuroimaging IV	p560 - p568
Hal Blumenfeld	Neuroimaging V	p569 - p577
Bill Gaillard	Neuroimaging VI	p578 - p587



WEDNESDAY 31ST AUGUST

13:00-14:30

Poster Area (Botticelli Room)

Tour Guide(s)	Poster Session	Poster #
Çigdem Özkara / Olivier Delalande	Epilepsy surgery I	p588 - p598
Mario Alonso	Epilepsy surgery II	p599 - p611
Eleonora Aronica	Epilepsy surgery III	p612 - p625
Philippe Kahane / Stefano Francione	Epilepsy surgery IV	p626 - p637
Gary Mathern	Epilepsy surgery V	p638 - p646
Jerome Engel Jr. / Lino Nobili	Epilepsy surgery VI	p647 - p659
Jean Gotman / Patrick Kwan	Epilepsy surgery VII	p660 - p669
Kai Eriksson	Paediatric epileptology X	p670 - p681
Paolo Curatolo	Paediatric epileptology XI	p682 - p692
Hans Holtausen	Paediatric epileptology XII	p693 - p705
Michalis Koutroumanidis	Paediatric epileptology XIII	p706 - p718
Tiziana Granata	Paediatric epileptology XIV	p719 - p729
Ingmar Blümcke	Neuropathology	p730 - p737
Marco Mula	Neuropsychology / psychiatry III	p738 - p750
Simona Cappelletti	Neuropsychology / psychiatry IV	p751 - p764
Andres Kanner	Neuropsychology / psychiatry V	p765 - p774
TBA	Social issues / nursing I	p775 - p780
Hanneke de Boer	Social issues / nursing II	p781 - p789
Carlos Acevedo	Social issues / nursing III	p790 - p798
Philippe Ryvlin	Drug therapy V	p799 - p809
Jack Pellock	Drug therapy VI	p810 - p821
Gunter Kramer	Drug therapy VII	p822 - p833
Byung-In Lee	Drug therapy VIII	p834 - p845
Eugen Trinka	Drug therapy IX	p846 - p858
Herman Stefan	Late submissions	p860 - p874

Working together

As a world leading pharmaceutical company we research, develop, manufacture and sell innovative medicines and vaccines. We take the social and ethical responsibility that comes with our activities very seriously and this includes our commitment to community health and education programmes around the world.

Last year our global community investment was valued at £380 million, which is equivalent to over 5% of our pre-tax profit.

This included medicines valued at £27 million for humanitarian needs including the victims of the Asian tsunami, the Guatemalan and Pakistan earthquakes, and the hurricane in New Orleans. This is in addition to our global programmes to fight malaria, support communities affected by HIV/AIDS and eliminate the disfiguring tropical disease lymphatic filariasis.

It's all part of one single-minded aim. To help people

Do more, feel better, live longer



GlaxoSmithKline

www.gsk.com





MONDAY 29TH AUGUST 2011

13:00-14:30 Poster Session: Adult epileptology I

Poster Area (Botticelli Room)

p055 What really matters to people with epilepsy in 2011? A pan-European patient survey

Cramer JA¹, Dupont S², Goodwin M³, Trinka E⁴ (1United States, 2France, 3United Kingdom, 4Austria)

p056 Sudden unexpected death in epilepsy (SUDEP) safety checklist: a way of quantifying and describing a patient's risk of SUDEP using a practical clinical checklist on a single sheet

Cox DA, Shankar R (United Kingdom)

p057 Clinical profiles, prognosis, and management outcomes of patients with status epilepticus (SE) and predictive factors for refractory convulsive SE: a 7-year retrospective study

Fernandez MLL, Fabiana NL, Pasco PMD, Casanova-Gutierrez J (Philippines)

p058 The management of refractory status epilepticus in adults in the UK: the call for a standardised care protocol

Patel M, Bagary M, Mccorry D (United Kingdom)

p059 Nonconvulsive status epilepticus (NCSE) and non convulsive seizures (NCS) in critical care units: determination of related factors

Aguirre Sepulveda AA, Villanueva Benguria XJ, Rivera Torres E (Chile)

p060 Cost of epilepsy care among adult Nigerians managed in a university hospital

Sanya EO, Adekeye K, Wahab KW, Ajayi K, Ademiluyi BA (Nigeria)

p061 Tobacco habit in nocturnal frontal lobe epilepsy (NFLE)

Naldi J, Bisulli F, Vignatelli L, Licchetta L, Pittau F, Stipa C, Mostacci B, Leta C, Broli M, Provini F, Montagna P, Tinuper P (Italy)

p062 Capturing the patient's experience of epilepsy: a review of patient interview data, literature, and expert opinion to identify aspects of seizure severity

Borghs S¹, Tomaszewski E², Halling K³ (1Belgium, 2United States, 3Sweden)

p063 Nonconvulsive status epilepticus: value of a Benzodiazepine trial for predicting outcomes

Krumholz A, Hopp J, Sanchez A (United States)

p064 Vitamin-D status in an out-clinic patient population of a tertiary referral epilepsy-center

Augustijn P, van Iterson L (Netherlands)


13:00-14:30 Poster Session: Adult epileptology II
Poster Area (Botticelli Room)

- p065 Do calcified lesions require longer duration of treatment?**
Narayana RV, Pati R (India)
- p066 Epilepsy patients responding to a ketogenic diet: mutations in SLC2A, coding for the glucose transporter type 1 (GLUT1)?**
Becker F¹, Weckhuysen S², Suls A², Schubert J¹, Grueninger S¹, DeJonghe P², Cross H³, Madeleyen R¹, Korn-Merker E¹, Lerche H¹, Yvonne W¹ (1Germany, 2Belgium, 3United Kingdom)
- p067 The effect of vitamin B supplementation on homocysteine in patients with epilepsy treated with carbamazepin or valproic acid**
Bochynska A, Lipczynska-Lojkowska W, Gugala-Iwaniuk M, Lechowicz W, Restel M, Graban A, Lipska B, Ryglewicz D (Poland)
- p068 The evolution of visual field loss in individuals who continue vigabatrin therapy over a ten-year period**
Clayton LM, Sander JW, Acheson J, Sisodiya SM (United Kingdom)
- p069 Teratogenic effect of antiepileptic drugs on epilepsy patients**
Bozdemir H, Aslan K, Demir T (Turkey)
- p070 Self-knowledge of medical history and quality of life of the patients with seizures before non-invasive video- EEG examination in adults in University Hospital Ostrava, Czech republic-3 months prospective study**
Slonkova J, Sedlakova M, Kolibacova M, Soldanova Z, Storkanova M (Czech Republic)

- p071 Complications of management of newly diagnosed epilepsy in elderly in clinical practice**
Ballesteros Plaza L, De La Morena Vicente MA, Pérez Martínez DA, Anaya Caravaca B, Martín García H, Vidal Díaz B (Spain)
- p072 Pluronic P85 enhances the delivery of phenytoin to the brain versus verapamil in vivo study**
Chen S, Zhou L, Zhou J, Chen Z (China)
- p073 Preventive effects of calcium channel blocker on the development of delirium tremens in alcohol withdrawal seizure patients**
Park H-K, Jeung D-S, Yang K-I, Choi Y-I, Seo I-K (Korea, Republic of)
- p074 Reducing risks: have the changing anti-epileptic drug prescribing habits, in pregnancy, resulted in an improvement in pregnancy outcomes between 1995 and 2010**
Kinney MO¹, Morrow JI¹, Bannon F¹, Irwin B¹, Hunt S¹, Russell A¹, Smithson W¹, Parsons L¹, Robertson I¹, Morrison PJ¹, Liggan B², Delanty N², Craig J¹ (1United Kingdom, 2Ireland)
- p075 Short term predictive factors outcome in patient with withdrawal of antiepileptic drugs**
Cucureanu D, Cucureanu A (Romania)
- p076 Cognitive and behavioral adverse effects of topiramate used as add-on treatment of refractory epilepsy in patients with mild to moderate mental retardation: prospective study**
Milivojevic D, Stevanic N (Serbia)



p077 Lacosamide: long-term safety in partial-onset seizures
LeRoy RE, Krauss G, Fountain NB, Dilley D, D'Cruz O, Doty P (United States)

p078 Long-term safety and efficacy of the RNS system for adjunctive treatment of medically intractable partial onset seizures in adults
Jobst BC (United States)

p079 Valproate dose is an independent risk factor for autism spectrum disorder: evidence from prospective assessments in the Australian Brain, Cognition and Antiepileptic Drugs study
Wood AG^{1,2}, Nadebaum C², Anderson VA², Reutens DC², Barton S², O'Brien T², Vajda FV² (¹United Kingdom, ²Australia)

p080 Association between carbamazepine-induced severe cutaneous adverse and HLA-B*1502 allele in Han people of China
Zhou JQ, Wang Q, Chen SD, Chen LQ, Pan JL, Zhou LM (China)


13:00-14:30 Poster Session: Adult epileptology III
Poster Area (Botticelli Room)

p081 Paroxysmal movement disorder and epileptic seizures associated with anti-VGKC antibody encephalitis
Coppens S, Legros B (Belgium)

p082 Proposal to study the immune-mediated epilepsies in adults
Pimentel J, Canas N, Almeida V, Peleção R, Alves I, Sales F (Portugal)

p083 Limbic encephalitis associated with 4 auto-antibodies (Anti VGKC, AMPA, GAD, IA2)
Mosbah A, Aubert S, Didelot A, De Brochgrave V, Bartolomei F (France)

p084 Partial epileptic seizures in stroke patients
Atic S, Atic D (Serbia)

p085 Limbic encephalitis with antibodies to voltage gated potassium channel complex: phenotyping the subforms with LGI1 and CASPR-2 antibodies
Malter MP, Schoene-Bake J-C, Wandinger K-P, Stoecker W, Elger CE, Bien CG (Germany)

p086 Clinical spectrum of posterior reversible encephalopathy syndrome
Chen Y-M, Wu Q-S (China)

p087 Epilepsy in coeliac disease: not just a matter of calcifications
Licchetta L, Bisulli F, Naldi I, Stipa C, Volta U, Matà S, Tinuper P (Italy)

p088 Early post-stroke epileptic seizures
Mijo S, Zekja I, Grabova S, Kapisyzi M, Xhaxho S, Kruja J (Albania)

p089 Epilepsy and multiple sclerosis: the initial presentation, course and causality
Sokic DV, Drulovic J, Ristic AJ, Jankovic SM, Bascarevic V, Skrielj F (Serbia)

p090 Partial epilepsy and brain tumors
Govori Berisha V (Albania)



13:00-14:30 Poster Session: Adult epileptology IV

Poster Area (Botticelli Room)

p091 **Epilepsies in the elderly: etiology, seizures and co-morbidities**
Stefan H, Kerling F, Brandt C, Füratsch N, Schmitz B, Wandschneider B, Kretz R, Runge U, Geithner J, Karakizikis H, Rosenow F, Pfäfflin M, May T (Germany)

p092 **A computerised algorithm for communicating treatment progress and offering choice to patients and carers across eight major domains in the epilepsy management of the learning disabled population**
Shankar B, Cox D (United Kingdom)

p093 **Study on clinical and EEG features in patients with temporal lobe epilepsy**
Tudorica V, Zaharia C, Pircscoveanu D (Romania)

p094 **Diagnostic challenges of de novo epilepsy in elderly. A two year prospective study**
Vaudano AE, Scaldefferri N, Di Clemente L, Santroni G, De Luca L, Ferraccioli M, Di Bonaventura C, Giallonardo AT, Gregori B (Italy)

p095 **Predictors of five-year remission in focal epilepsy of unknown cause**
Gasparini S, Beghi E, Labate A, Mumoli L, Leonardi CG, Cianci V, Latella MA, Ferlazzo E, Gambardella A, Aguglia U (Italy)

p096 **The prognosis of focal epilepsies in adult patients followed at two Italian epilepsy centers: the efficacy of "new" antiepileptic drugs**
Gilioli J, Franceschetti S, Canafoglia L, Casazza M, Chiesa V, Gardella E, La Briola F, Panzica F, Vignoli A, Visani E, Canevini MP, Binelli S (Italy)

p097 **Gelastic seizures without hypothalamic hamartomata**
O'Connor G, Chaila E, Mullins G, Delanty N (Ireland)

p098 **Anti-LGI1 antibodies in a patient with short tonic seizures combined with speech arrest and anxiety**
Dorn J, Mothersill I, Krämer G (Switzerland)

p099 **Insomnia in epilepsy patients. Clinical and Polysomnographic characteristics**
Koziorynska E, Rodriguez AJ (United States)

p100 **Application of new ILAE axis classification to classify patients: a study from tertiary care epilepsy clinic in south india**
Challamalla SB, Jaya Laxmi S, Surya Prabha T, Kaul S, Alladi S (India)

p101 **Nocturnal frontal lobe epilepsy and parasomnias differential diagnosis: a prospective study of 48 patients**
Broli M, Bisulli F, Di Vito L, Leta C, Licchetta L, Mostacci B, Naldi I, Pittau F, Stipa C, Tinuper P (Italy)

p102 **Clinical and neurophysiological analysis of adults patients with epileptic seizures only during sleep**
Pereira de Silva NF, Rodriguez SA, Janota FR, Rosito N, Kochen SS (Argentina)

p103 **Rural epilepsy clinic: reachout program**
Shah P, D'Souza C, Wagle SP (India)


13:00-14:30 Poster Session: Adult epileptology V
Poster Area (Botticelli Room)

p104 Sleepiness during day and sleep disturbances in a population of epileptic patients: a case-control study
Zummo L, Gammino M, Lo Bue A, Urso L, Terruso V, Marrone O, Daniele O (Italy)

p105 How far do patients travel for prolonged ambulatory electroencephalography and does it help?
Mohamed A, Bosero J, Bradbury R, O'Connell A (Australia)

p106 Tonic eye deviation due to hyperglycemia induced focal seizures: case report
Tseng Y, Lin H (Taiwan, Republic of China)

p107 Alteration of global workspace (GW) during loss of consciousness: a study of parietal seizures
Lambert J, Wendling F, Arthuis M, Chauvel P, Bartolomei F (France)

p108 An observational longitudinal study on late seizures in neurosurgical patients
Bartolini E, Lenzi B, Vannozzi R, Parenti G, Murri L, Iudice A (Italy)

p109 Localizer and lateralizing value of unilateral facial motor manifestation (UFMM) in focal epilepsy, using video electroencephalography and/or direct cortical stimulation
Paoli N, Campora N, Besocke G, Aberastury M, Galan M, García M, Agosta G, Rey R, Ferraro S, Silva W (Argentina)

p110 The effect of the modified Atkins diet for adults with intractable epilepsy
Zare M, Okhovat AA, Najafi MR, Mahvary G, Esmaeel Zada A (Iran, Islamic Republic of)

p111 Application of proposed consensus definition of drug resistant epilepsy in clinical practice
De La Morena Vicente MA, Viudez Jiménez I, Ballesteros Plaza L, Perez Martínez DA, Vidal Díaz B, Martín García H (Spain)

p112 State of autonomic nervous system (ANS) in mesial temporal epilepsy patients
Karlov V¹, Gleizer M² (1Russian Federation, 2Israel)

p113 Preliminary observations on an ambulatory intracranial EEG (iEEG) epilepsy management system
Cook M¹, D'Souza W¹, Murphy M¹, Litewka L¹, O'Brien T¹, Yerra R¹, Morokoff A¹, Hosking S¹, Germaine D¹, Berkovic S¹, Lightfoot P¹, Fabinyi G¹, Boling W¹, Archer J¹, Himes D², Ruedebusch V², Sheffield D² (1Australia, 2United States)

p114 Detection of epileptic seizures by pattern recognition from wireless accelerometer data
Stigwall J, Hildeman A, Wipenmyr J, Wipenmyr J, Pettersson T, Malmgren K, Rydenhag B (Sweden)

p115 Cognitive modulation of epileptiform EEG discharges in patients with juvenile myoclonic epilepsy
Beniczky S¹, Guaranha MS², Conradsen I¹, Singh MB³, Rutar V⁴, Lorber B⁴, Braga P⁵, Bogacz Fressola A⁵, Yacubian EMT², Wolf P¹ (1Denmark, 2Brazil, 3India, 4Slovenia, 5Uruguay)

p116 Inhibitory effect of olfactory stimuli in refractory mesial temporal lobe epilepsy patients: a pilot study
Lunardi MS¹, Lin K¹, Claudino LS¹, Walz R¹, Wolf P² (1Brazil, 2Denmark)



13:00-14:30 Poster Session: Basic sciences I

Poster Area (Botticelli Room)

- p117 Intense olfactory stimulation blocks seizures in an experimental model of epilepsy**
Berti P, Cortes de Oliveira JA, Del Vecchio F, Pereira MGAG, Marroni SS, Garcia-Cairasco N (Brazil)
- p118 The antiepileptic drugs carbamazepine, phenytoin and lamotrigine display no selectivity versus NaV1.1 and NaV1.2 channels**
Valérie L, Cervello P, Lanneau C, Biton B, Avenet P (France)
- p119 Adenosine receptors A1 and A2a modulate the occurrence of fast ripples in the dentate gyrus and hippocampal CA3 area**
Ortiz E, Gutierrez R (Mexico)
- p120 Optogenetic inhibition of epileptic activity**
Mantoan L, Wykes R, Schorge S, Walker MC, Kullmann DM (United Kingdom)
- p121 P-glycoprotein regulation in isolated human brain capillaries**
Salvamoser J, Avenary J, Fischborn S, Peraud A, Rémi J, Noachter S, Fricker G, Potschka H (Germany)
- p122 A common GABAergic signaling defect in human epileptic lesions**
Huberfeld G¹, Menendez de la Prida L², Le Van Quyen M¹, Capelle L¹, Clemenceau S¹, Pallud J¹, Baulac M¹, Miles R¹ (¹France, ²Spain)

- p123 Role of GABA-B receptors in termination of cortical seizures in immature rats**
Mares P (Czech Republic)
- p124 Alterations in Shaker-related K+ channel expression contribute to epileptogenesis and chronic epilepsy**
Hamil NE, Walker MC (United Kingdom)
- p125 Effects of vagus nerve stimulation on kindling epileptogenesis and blood-brain barrier integrity in rats with cortical dysplasia**
Gurses C, Karabacak E, Orhan N, Arican N, Ahishali B, Kemikler G, Elmas I, Cevik A, Kucuk M, Kaya M (Turkey)
- p126 The role of ETB receptors in development of ET-1 induced seizures in immature rats**
Tsenov G, Otahál J, Kubová H (Czech Republic)
- p127 Expression of the calcium-sensing receptor and the metabotropic glutamate receptor 1 in hippocampus of patients with temporal lobe epilepsy**
Hespanholo Nascimento P, Teocchi MA, Pinto da Luz de Oliveira E, Tedeschi H, Latuf Filho P, Vassallo J, de Souza Queiroz L, Freire Rodrigues de Souza Li L (Brazil)


13:00-14:30 Poster Session: Basic sciences II
Poster Area (Botticelli Room)

- p128 In vivo imaging of glia activation in adult rats as a biomarker of epileptogenesis using quantitative magnetic resonance spectroscopy (MRS)**
Ravizza T, Frasca A, Micotti E, Filibian M, Vezzani A (Italy)
- p129 Role of mitochondrial function in seizure induced neuronal cell death**
Kovac S^{1,2}, Domijan A-M³, Walker MC¹, Abramov AY¹
(¹United Kingdom, ²Germany, ³Croatia)
- p130 Lack of astrocyte potassium channel Kir4.1 in patients with mesial temporal lobe epilepsy**
Heuser K¹, Eid T², Lauritzen F¹, Gjerstad L¹, Taubøll E¹, Spencer DD², Ottersen OP¹, Nagelhus EA¹, de Lanerolle NC²
(¹Norway, ²United States)
- p131 Increased expression of tumor necrosis factor-alpha in the rat hippocampus after acute homocysteine administration**
Kim K (Korea, Republic of)
- p132 Astroglial loss and edema formation in the rat piriform cortex and hippocampus following pilocarpine-induced status epilepticus**
Song HK, Choi HC (Korea, Republic of)
- p133 Inhibitory effects of minozac on proinflammatory cytokines and chemokine improve hippocampal neuronal injury and epileptic behavior in pilocarpine induced mice model**
Tang H, Du P, Li X, Li G, Liu J, Lin H, Ma Y, Fan W, Wang X, Zhu C, Hu W (China)
- p134 Microglia in epilepsy are activated in a region specific manner: a morphologic analysis in the epileptic rat hippocampus**
Papageorgiou IE, Fetani AF, Kann O, Heinemann U (Germany)
- p136 Increase of albumin in the rat hippocampus enhances interictal spiking but not ictal events during acute seizures**
Frigerio F, Frasca A, Parrella S, Noè FM, Vezzani A, Ravizza T (Italy)
- p137 Analysis of hippocampal cell proliferation and neuronal progenitor cells in a model of virus encephalitis associated epilepsy**
von Rüden E-L, Avemary J, Zellinger C, Algermissen D, Bock P, Beineke A, Baumgärtner W, Stein VM, Tipold A, Potschka H (Germany)



13:00-14:30 Poster Session: Basic sciences III

Poster Area (Botticelli Room)

p138 Abnormal maturation of non-dysmorphic neurons in focal cortical dysplasia: immunohistochemical considerations

Itoh M, Hanai S, Saito T, Nakagawa E, Otsuki T, Goto Y, Sasaki M (Japan)

p139 New model of refractory convulsive status epilepticus induced with orphenadrine in rats

Rejda K, Nieoczym D, Czuczwar M, Kiś J, Wlaź P, Turski WA (Poland)

p140 Febrile seizure as a long-term pre-conditioning context which may regulate epileptogenesis in doublecortin KO mice

Hamelin S, Khalaf R, Chabrol T, Francis F, Depaulis A (France)

p141 Inhibitory effects of focal brain cooling for motor cortical seizures in cats and nonhuman primates

Inoue T, He Y, Fujii M, Fujioka H, Tokiwa T, Kida H, Imoto H, Maruta Y, Nomura S, Yamakawa T, Suzuki M (Japan)

p142 Assessment of the role of polyunsaturated fatty acids in the underlying mechanisms of the ketogenic diet

Curatolo N, Lecoince C, Benoist J-F, Lebon S, Gressens P, Auvin S (France)

p143 A kindling model of temporal lobe epilepsy in rhesus macaque induced by coriaria lactone

Liu Y, Yang T, Hong Z, Li H, Zhou D (China)

p144 Myo-inositol and kainic acid induced cell loss in rat hippocampus

Kotaria N, Bikashvili T, Zhvania M, Japaridze N (Georgia)

p145 Hippocampal neurogenesis increases after seizures in mice treated with beta-hydroxybutyrate

Kim DW, Kim JM (Korea, Republic of)

p146 Behavioral, EEG and neuropathological features of an epilepsy focal model induced by continuous low intensity electrical perorant path stimulation in Wistar rats

Broggini ACS, Scandiuzzi RC, Romcy-Pereira RN, Leite JP (Brazil)

p147 Screening of key proteins involved in refractory epilepsy using the kindling temporal lobe epilepsy model of rhesus induced by Coriaria Lactone

Hong Z, Yang T-H, Li H-X, Zhou D (China)

p148 Effect of seizures during brain development on prepulse inhibition of the acoustic startle reflex in a rat model of schizophrenia

Labbate GP, Silva RCB, Silva AV (Brazil)


13:00-14:30 Poster Session: Basic sciences IV
Poster Area (Botticelli Room)

p149 Local application of valproate enhances survival in the novel tetanus toxin / cobalt chloride rat model of neocortical epilepsy
Altenmüller DM, Hebel JM, Rassner M, Freiman T, Feuerstein TJ, Zentner J (Germany)

p150 Effect of 7-nitroindazole a neuronal nitric oxide synthase inhibitor on cortical epileptic seizures in rats
Otahal J, Brozickova C, Jindrova M, Kubova H (Czech Republic)

p151 Effect of tempol on brain superoxide anion production and neuronal injury associated with seizures in immature rats
Folbergrova J, Otahal J, Druga R (Czech Republic)

p152 The effects of androsterone on calbindin-D28k expression by interneurons in the hippocampi of a pilocarpine-induced seizure model
Kim W-J, Lee S-Y, Lee B-I (Korea, Republic of)

p153 Status-like activity induced by some drugs in animals with genetical absence epilepsy
Gabova AV¹, Kuznetsova GD¹, Perescis MFJ², Zinyaeva RF¹, van Rijn C² (1Russian Federation, 2Netherlands)

p154 Development and characterization of new prodrugs of bumetanide in combination with the monooxygenase inhibitor piperonyl butoxide for anti-epileptogenesis
Töllner K¹, Brandt C¹, Töpfer M¹, Brunhofer G², Erker T², Feit PW¹, Löscher W¹ (1Germany, 2Austria)

p155 Effects of Ro-25-6981, a selective antagonist of NMDA receptors containing NR2B subunit on cortical phenomena in developing rats
Szczurowska EK, Mareš P (Czech Republic)

p156 Electroencephalographic and behavioural effects of intracerebroventricular injection of grayanotoxin in adult wistar rats
Halac HM, Temiz G, Kuru P, Torun M, Iskender E, Karamahmutoglu T, Gulcebi Idrizoglu M, Onat F (Turkey)

p157 Sesamol protects kainic acid induced status epilepticus in rats: evidence for an antioxidant, anti-apoptotic, and neuroprotective intervention
Golechha M, Bhatia J, Chaudhry U, Saluja D, Golechha K, Arya DS (India)

p158 The effect of intracerebroventricular nimodipine injections on kindling induced locomotor activity changes in wistar rats
Sakalli HE, Topkara B, Jafarova M, Akin D, Yananli HR, Berkman KM (Turkey)

p159 Effects of topiramate on the apoptosis of hippocampus of electrical kindled rats and epilepsy
Chen X, Bao G, Li Y, Wang Z, Zhang X (China)

p160 Effects of infantile acute repeated hyperglycemia on neuronal density of hippocampus and severity of pentylenetetrazol induced epileptiform convulsions in Wistar rats
Moghimi A, Moghadami M, Jalal R, Behnam Rasouli M, Mahdavi Shahri N (Iran, Islamic Republic of)



13:00-14:30 Poster Session: Basic sciences V

Poster Area (Botticelli Room)

p161 Disruption of long-term memory by high mobility group box 1 protein: a possible mechanism underlying memory impairments associated with temporal lobe epilepsy
Mazarati A^{1,2}, Maroso M², Iori V², Carli M², Vezzani A²
(¹United States, ²Italy)

p162 Experimental study on the effects of EPO, C-EPO on the protein expression of Jak2/ STAT5 and PI3K/ akt in hippocampus of epilepsy rats induced by kainic acid
Lin W, Wang Z, Wu SS, Jiang H, Ma B, Ji L (China)

p163 Experimental study on the neuroprotection role of EPO, C-EPO on hippocampus injury of epilepsy rats induced by kainic acid
Wang Z, Lin W, Wu SS, Ji L, Cui L (China)

p164 Impact of the CNTF-derived peptide mimetic cintrofin on a rat post-status epilepticus model
Russmann V¹, Seeger N¹, Zellinger C¹, Hadamitzky M¹, Wendt H¹, Bock E², Berezin V², Potschka H¹
(¹Germany, ²Denmark)

p165 The erythropoietin-derived peptide mimetic pHBSP affects cellular and cognitive alterations in a rat post-status epilepticus model
Seeger N, Zellinger C, Rode A, Wagner S, Stein VM, Tipold A, Roloff F, Bicker G, Russmann V, Fischborn S, Wendt H, Potschka H (Germany)

p166 The effect of responsive high frequency stimulation of the subiculum in the intra-hippocampal kainic acid seizure model in rats
Huang L, Scholz G, van Luijckelaar G (Netherlands)

p167 Fast fourier transformation analysis on the afterdischarge induced by acute kindling of the rabbit hippocampus
Tsuchiya K, Kogure S (Japan)

p168 The effects of the ketamine and dantrolene on the spatial learning in rats exposed to repeated electroconvulsive seizures as a model of epilepsy
Barun S, Gursoy ID, Erdem R, Keskin U, Aksakal FN, Kızıltas M (Turkey)

p169 The enduring effects of early-life stress on limbic epileptogenesis are mediated by HPA axis hyper-reactivity
Salzberg M, Koe A, O'Brien TJ, Morris MJ, Jones NC (Australia)

p170 Correlation of hypoxia-inducible factor-1a expression with P-glycoprotein in the mechanism of pharmacoresistance in refractory epilepsy rat model induced by Coriaria Lactone
Li Y, Zeng T, Chen L, Zhou D (China)

p171 Temporal lobe epilepsy: new biomarkers identified by proteomic analysis of hippocampi
Fernandes MJS, Lima ML, Canzian M, Amorim RP, Yacubian EMT, Carrete Jr H, Centeno RS, Cavalheiro EA, Persike DS (Brazil)



13:00-14:30 Poster Session: Basic sciences VI

Poster Area (Botticelli Room)

p172 Bisphosphonates for alleviation of phenytoin-induced bone disease in mice

Vohora D, Khanna S, Pillai KK (India)

p173 Cell recognition molecules may trigger the epileptogenesis during development in the hippocampus of epileptic mutant EL mice

Murashima YL, Yoshii M, Inoue N (Japan)

p174 Influence of caffeine on the protective activity of newer antiepileptic drugs in the 6 Hz psychomotor seizure model

Chroscinska-Krawczyk M, Walek M, Tylus B, Czuczwar SJ (Poland)

p175 Effects of subconvulsive pentylenetetrazole infusion on epileptogenesis in a status epilepticus model in sprague-dawley rats

Rattka M, Brandt C, Löscher W (Germany)

p176 Long time effect of chronic gamma-butyrolactone administration in wistar rats

Karamahmutoglu T, Carcak N, Onat F (Turkey)

p177 Investigation of calcium channel subunits expression in genetic absence epilepsy rats from Strausburg

Ketenci S, Akin D, Onat F (Turkey)

p178 “Hercules”: medical genetics and biomedical informatics infrastructure in support of early diagnosis, monitoring and treatment of children with neurological disorders in Greece

Potsika V, Tsipouras M, Kalatzis F, Pappas I, Danilatos V, Kafetzopoulos D, Tsiknakis M, Vorgia P, Fotiadis D (Greece)

p179 Relationship of the molecular geometry and quantum-chemical characteristics some aminoacids with their inhibitor possibility in CNS. Shilau G.N. Republican Scientific Practical Centre of Psychological Health, Minsk, Belarus

Shilau G (Belarus)

p180 Effects of electrical stimulation of the thalamic mediodorsal nucleus on spike and wave discharges in WAG/Rij rats

Zybina A¹, Chepurnova N¹, Titov S¹, van Luijtelaar G², Abbasova K¹ (1Russian Federation, 2Netherlands)

p181 Spontaneous spike-wave discharges in spatially extended models of epileptic dynamics

Baier G, Goodfellow M, Taylor P, Wang Y (United Kingdom)

p182 The effect of intracerebroventricular U-92032 injections on genetic absence epilepsy rats from Strasbourg

Jafarova M, Yananli HR, Sakalli EH, Onat F (Turkey)

p183 In-vivo study of the impact of amygdala kindling on the firing pattern of single neurons in a genetic absence epilepsy rat model

Carcak N¹, Ali I², Onat F¹, O'Brien T² (1Turkey, 2Australia)

p184 The effect of IL-1 and specific ICE/CASPASE-1 bloker on spike-and-wave discharges

Akin D¹, Ravizza T², Morosso M², Carcak N¹, Eryigit T¹, Vanzulli I², Gulhan Aker R¹, Vezzani A², Onat Yilmaz F¹ (1Turkey, 2Italy)



13:00-14:30 Poster Session: Paediatric epileptology I Poster Area (Botticelli Room)

p186 Involvement of chromosomal aberrations in patients with early epileptic encephalopathy

Tohyama J, Saitsu H, Shimojima K, Akasaka N, Ohashi T, Kobayashi Y, Yamamoto T, Matsumoto N, Kato M (Japan)

p187 Spectrum of Idiopathic focal epilepsies

Mukhin K, Mironov MB, Melikyan EG, Petrukhin AS (Russian Federation)

p188 A case of continuous spikes and waves during slow sleep syndrome in a Korean child

Lee J-H, Kim S-K, Lee J-H (Korea, Republic of)

p189 Benign childhood epilepsy with centrotemporal spikes (BCECTS): early response to treatment with regard to age at seizure onset and long-term outcome

Dragoumi P, Tzetzzi O, Zafeiriou DI, Paulou E, Vargiami E, Kontopoulos E (Greece)

p190 Clinical analysis of children with catastrophic epilepsy registered in the far-East Asia catastrophic epilepsy (FACE) study group

Oguni H¹, Otsuki T¹, Kobayashi K¹, Inoue Y¹, Sugai K¹, Takahashi A¹, Hirose S¹, Kameyama S¹, Yamamoto H¹, Fujii A¹, Baba K¹, Baba H¹, Hong S-C², Lee J-H², Kim H-D², Kang H-C², Luan G³, Won T-T⁴ (1^{Japan}, 2^{Korea, Republic of}, 3^{China}, 4^{Taiwan, Republic of China})

p191 A population-based study of epilepsy in children from the southern part of Switzerland

Ramelli GP (Switzerland)

p192 The prevalence of atypical presentations of benign childhood epilepsy with centrotemporal spikes

Tovia E, Goldberg-Stern H, Ben Zeev B, Heyman E, Waterberg N, Fattal-Valevski A, Kramer U (Israel)

p193 Clinical features, diagnostic pitfalls and prognosis in juvenile myoclonic epilepsy: a series of 83 patients

Jovic NJ, Kosac A (Serbia)


13:00-14:30 Poster Session: Paediatric epileptology II Poster Area (Botticelli Room)

- p194 Mental development of infants at corrected age of 24 months at high risk of impaired development and epilepsy attributed to peri-natal insults discharged from neonatal intensive care unit**
Porras-Kattz E, Barrera-Reséndiz JE, Harmony T, Avencia-Ramírez GN, Ricardo-Garcell J, Valencia-Solis E (Mexico)
- p195 Neonatal seizures with diffusion restriction lesions on brain diffusion-weighted magnetic resonance imaging: are these fifth day fits?**
Lee KY, Oh KW, Choi SH, Weon YC (Korea, Republic of)
- p196 Characteristics of benign convulsion with rotavirus gastroenteritis**
Kwon YS, Kang B, Son BK (Korea, Republic of)
- p197 Characteristics of the paediatric patients with poststroke epilepsy**
Sarecka-Hujar B, Kopyta I, Emich-Widera E, Jamroz E (Poland)
- p198 Epileptic and non epileptic seizures associated with influenza A/B and parainfluenza III in children during the 2008-20011 influenza season at Neuropaediatric Unit of UH Sestre Milosrdnice in Zagreb, Croatia**
Cvitanovic-Sojat L, Kukuruzovic M, Gjergja Juraski R, Malenica M, Kuznik K (Croatia)
- p199 Syndromic classification of epilepsy in patients with eyelid myoclonia**
Guaranha M, Macedo J, Guilhoto L, Yacubian EM (Brazil)
- p200 Visual induced seizures in reflex epilepsies and epilepsies with reflex seizures**
Brincioti M, Matricardi M, Bonanni AM, Nunziata L, Mittica A (Italy)
- p201 Visual evoked potentials and neurologic outcome in children with symptomatic epilepsy**
Shamansurov S, Sigatullina MI, Mirsaidova NA (Uzbekistan)



13:00-14:30 Poster Session: Paediatric epileptology III Poster Area (Botticelli Room)

- p202 Jeavons syndrome; occipital cortex initiating generalized epilepsy**
Otsubo H¹, Viravan S²
(¹Canada, ²Thailand)
- p203 Exercise therapy in children with benign rolandic epilepsy**
Eom S, Lee MK, Park J-H, Jeon JY, Kwon H, Kim SH, Lee YN, Kang H-C, Lee JS, Kim HD (Korea, Republic of)
- p204 Vitamin B12 deficiency: an important cause of infantile seizures**
Gökben S, Akçay A, Yılmaz S, Serdaroğlu G, Tekgül H (Turkey)
- p205 Clinical presentations and seizure recurrence in Thai children with first unprovoked seizure**
Visudtibhan A, Maksikharin A, Thampratankul L, Khongkhatithum C, Chiemchanya S, Visudhiphan P (Thailand)
- p206 Status epilepticus in childhood encephalitis: a 13 year retrospective single centre study**
Pillai S, Suleiman J, Gill D, Dale R (Australia)
- p207 SCN1A-related spectrum of focal epilepsy with febrile seizures plus in Polish family**
Szczepanik E, Goszczańska-Ciuchta A, Hoffman-Zacharska D, Terczyńska I (Poland)
- p208 Epileptic encephalopathy with epileptic atonia of the musculus mentalis during sleep**
Ogihara M¹, Wang C-Y^{1,2}, Miyajima T¹, Hoshika A¹, Kasai E¹
(¹Japan, ²Taiwan, Republic of China)
- p209 Short term prognosis of myoclonic astatic epilepsy (MAE)**
Tatishvili N, Kipiani T, Japaridze N, Shatirishvili T, Mirtskhulava V (Georgia)


13:00-14:30 Poster Session: Paediatric epileptology IV Poster Area (Botticelli Room)

- p210 Neuropsychological findings and psychiatric comorbidities in childhood idiopathic generalized epilepsies**
Savini MN, Vignoli A, Battistini MC, Turner K, Piazzini A, Raviglione F, La Briola F, Canevini MP, Lenti C (Italy)
- p211 Social status of patients with epilepsy according to the epilepsy register in selected regions of Kazakhstan (EREKA)**
Kuanova L (Kazakhstan)
- p212 Developmental abnormalities in childhood epilepsy**
Jotovska O (Macedonia, the Former Yugoslav Republic of)
- p213 Extensional changes in current-source density in benign rolandic epilepsy patients**
Yeom JS, Kim Y, Kwon O-Y (Korea, Republic of)
- p214 Adolescents' knowledge and attitudes towards epilepsy compared with asthma in Portugal**
Fernandes A, Pité H, Lopes R, Romeira A, Silva RL (Portugal)
- p215 Adaptation and validation of Liverpool Adverse Events Profile (LAEP) in paediatrics patients with epilepsy and its correlation with the level of quality life of children with epilepsy (CAVE)**
Lara-Herquedas J, Garcia-Peñas J-J, Ruiz-Falco Rojas M, Gutierrez-Solana LG, Duat-Rodríguez A, Cazorla-Calleja R, Gutierrez-Cruz N (Spain)
- p216 School aged children with partial epilepsies and migraine**
Zubcevic S, Tanovic S, Catibusic F, Uzicanin S, Smajic L (Bosnia and Herzegovina)
- p217 Neurocognitive development in pre-school-aged patients with myoclonic-astatic epilepsy (MAE, Doose syndrome)**
Kujala A, Tura S, Nyrke T, Kujala T, Arvio M (Finland)
- p218 Clinical evaluation of neuropsychological function in children with benign rolandic epilepsy**
Seo H-E, Kim S, Kwon S (Korea, Republic of)
- p219 A community-based study of developmental outcomes of childhood-onset temporal lobe epilepsy**
Wilson SJ, Micallef S, Henderson A, Rayner G, Wrennall JA, Spooner C, Harvey AS (Australia)
- p220 Mathematical performance in children and adolescents with epilepsy: preliminary results**
Thome-Costa U, Alves S, Guerreiro S, Silva L, Maia Filho H (Brazil)



13:00-14:30 Poster Session: Paediatric epileptology V Poster Area (Botticelli Room)

- p221 Lacosamide: our clinical experience in treatment of partial drug-resistant epilepsies in children**
Sanmarti FX, Abeledo A, Pineda M (Spain)
- p222 Long-term outcome of vagus nerve stimulation therapy in young children with intractable epilepsy**
Romantseva L, Ogden P, Tonsgard J, Silver K, Kohrman M, Frim D, Mazin A (United States)
- p223 First report of Taiwan child neurology society project on vagus nerve stimulation results for intractable epileptic children**
Wang C-Y, Yeh G-C (Taiwan, Republic of China)
- p224 Neurological and radiological changes in patients with schizencephaly**
Vatolin K, Kalinina L, Pykov M, Milovanova O (Russian Federation)
- p225 Hippocampal sclerosis in a case of fragile X syndrome**
Albeanu A¹, Lagae L² (1Romania, 2Belgium)
- p226 Timely treatment as a predictor of shorter duration of convulsive SE**
Shatirishvili T, Tatishvili N, Kipiani T (Georgia)
- p227 A population-based study of long-term outcome of epilepsy in children with potentially resectable lesion on neuroimaging**
Dhamija R, Moseley BD, Cascino GD, Wirrell EC (United States)
- p228 Children who have experienced >5 AEDs are more likely to respond to vagal nerve stimulation(VNS) than trials of further AEDs**
Robinson R (United Kingdom)
- p229 Efficiency and safety of using new antiepileptic drugs in treatment of focal forms of epilepsy in children**
Sivkova S, Mukhin K, Zaykova F (Russian Federation)
- p230 Efficacy and tolerability of oral Lacosamide (LCM) as adjunctive therapy in 130 paediatric patients with pharmacoresistant focal epilepsy**
Casas-Fernández C, Martínez-Bermejo A, Rufo-Campos M, Smeyers-Durá P, Alarcón-Martínez H, Ibañez-Micó S, Herranz-Fernández JL, Campistol-Plana J, Campos-Castelló J (Spain)
- p231 Mesial temporal lobe epilepsy in patients with acute lymphoblastic leukemia**
Kasai E, Ogihara M, Ozawa M, Manabe A, Hosoya R (Japan)
- p232 Frontal lobe automatisms in children with surgically verified epileptogenic zone**
Grinenko O, Golovtsev A, Kazaryan A, Melikyan A (Russian Federation)


13:00-14:30 Poster Session: Clinical neurophysiology I Poster Area (Botticelli Room)

- p233 The sleep-deprived brain in normals and patients with juvenile myoclonic epilepsy: a perturbational approach to measuring cortical reactivity**
Del Felice A (Italy)
- p234 A comparative study of heart rate variability in hot water epilepsy**
Meghana A, Sathyaprabha TN, Sanjb S, Raju TR, Satishchandra P (India)
- p235 P300 in patients with epilepsy — the difference between the target and non-target answers: pilot study**
Mihalj M, Pavelin S, Titlic M (Croatia)
- p236 Mismatch negativity for phonetic sounds in temporal lobe epilepsy**
Hara K, Hara M, Miyajima M, Matsuda A, Maehara T, Iino H, Matsushima E, Ohta K, Matsuura M (Japan)
- p237 Electrical probing of the brain for the measurement of cortical excitability**
Freestone DR, Nelson TS, Lai A, Grayden DB, Vogrin S, D'Souza W, Murphy M, Badawy R, Burkitt AN, Cook MJ (Australia)
- p238 Which physical entities of environmental visual stimuli cause EEG discharges in photosensitive epilepsy patients? A pilot study with ambulatory EEG and artificial eye**
*Kasteleijn-Nolst Trenité D¹, Piccioli M², Felici L², Di Scipio E², Cantonetti L², Parisi P², Conti L², Emmett J³
(¹Netherlands, ²Italy, ³United Kingdom)*
- p239 Complex emotional vocalizations triggered by electrical stimulation of the cerebral cortex**
Teotónio B, Massano A, Cunha C, Bento C, Santana I, Sales F (Portugal)
- p240 Mobile phone emissions modulate brain excitability in focal epilepsy patients**
Assenza G, Pellegrino G, Pasqualetti P, Antonella B, Rossini PM, Tombini M (Italy)
- p241 Eye closure and photosensitivity in patient with juvenile myoclonic epilepsy — our experience in 104 cases**
Borkovic MP, Jančić JB (Serbia)
- p242 Vestibular-evoked myogenic potentials and the postural reflexes affected by antiepileptic drugs in older people**
Lee G-H (Korea, Republic of)
- p243 SoC integrating of neural signal acquisition unit, bio-signal processor, radio-frequency transceiver, and wireless power transmission circuitries for epilepsy treatment**
Chen W-M, Yang W-C, Chen T-J, Lee S-C, Liu L-C, Su H-C, Chen W-C, Tsai T-Y, Ho M-H, Peng T-H, Liang Y-A, Chiueh H, Wu C-Y (Taiwan, Republic of China)
- p244 Characteristics, clinical and economic outcomes in MEDICAID patients 17 years and younger receiving vagus nerve stimulation (VNS) therapy for the treatment of refractory epilepsy**
Helmerts SL, Duh MS, Guérin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E (United States)



13:00-14:30 Poster Session: Clinical neurophysiology II Poster Area (Botticelli Room)

- p245 Standardised computer-based organised reporting of EEG (SCORE)**
*Beniczky S¹,
Aurlien H² (1Denmark, 2Norway)*
- p246 Imbalance of mesial synchronization in temporal lobe epilepsy**
*Ortega GJ, García de Sola R,
Pastor J (Spain)*
- p247 Synthetic aperture magnetometry-kurtosis (SAM(g2)) for presurgical evaluation for single / multiple epileptic foci in children with neocortical epilepsy**
*Sugiyama I¹, Imai K¹, Akiyama T²,
Go C², Ochi A², Widjaja E², Chuang SH²,
Snead OC², Otsubo H²
(1Japan, 2Canada)*
- p248 Multi-scale analysis of EEG signal of juvenile myoclonic epilepsy: does the low frequency activities control the discharges?**
*Zhang M, Zhang B, Jiang N, Wang F,
Chen Y (China)*
- p251 Can spike voltage topography predict the ictal patterns in temporal lobe epilepsy?**
*Parameswaran S, Radhakrishnan A,
Radhakrishnan K (India)*
- p252 Spatiotemporal analysis of the leading frequencies and their energy in EEG signals with epileptic discharges**
Sobieszek A, Olejarczyk E (Poland)
- p253 Concordance of source localization models applied on scalp- and subdural recordings and validation against outcomes of epilepsy surgery**
*Ramantani G, Schulze-Bonhage A,
Dümpelmann M (Germany)*
- p254 Indicators of favorable outcome with vagus nerve stimulation (VNS) in 50 patients with different kinds of epilepsy**
*Aubert S, Paz-Paredes A, Scavarda D,
Peragut J-C, Villeneuve N, Viallat D,
Gastaut J-L, Genton P, Lepine A,
Mosbah A, Mc Gonigal A, Gavaret M,
Chauvel P, Bartolomei F (France)*
- p255 Close-loop epilepsy prosthesis devices with spatial-temporal seizure detection and responsively therapeutic stimulation**
*Wu C-Y¹, Chiueh H¹, Chiou J-C¹,
Ker M-D¹, Shaw F-Z¹, Liang S-F¹,
Hsin Y-L¹, Liu W-T²
(1Taiwan, Republic of China,
2United States)*
- p256 Randomized controlled trial shows quality-of-life benefits with VNS added-on to best medical therapy versus best medical therapy alone in adults with drug-resistant epilepsy**
*Ryvlin P¹, Gilliam F², Nguyen D³,
Colicchio G⁴, Pizzanelli C⁴, Marrosu F⁴,
Tinuper P⁴, Zamponi N⁴, Aguglia U⁴,
Wagner L⁵, Minotti L¹, Stefan H⁶,
Boon P⁷, Sadler M³, Benna P⁴,
Perucca E⁴ (1France, 2United States,
3Canada, 4Italy, 5Netherlands,
6Germany, 7Belgium)*


13:00-14:30 Poster Session: Clinical neurophysiology III Poster Area (Botticelli Room)

- p257 Neurophysiological findings in a clinical case of Kabuki syndrome**
Torres-Caño N, Giner-Bayarri P, Moliner-Ibáñez J, Chilet-Chilet MR, Mazzillo-Ricaurte A, Cánovas-Martínez A, Ruiz-Márquez L, Rodrigo-Sanbartolomé A (Spain)
- p258 Clinical profile and outcome of consecutive 179 patients seen in the activation clinic for psychogenic nonepileptic seizures (PNES)**
Nekkare RK, Ribeiro A, Amin D, Brunnhuber F (United Kingdom)
- p259 Case report of abnormal EEG basic rhythm and its dynamic state caused by aftereffect of serious head injury with complete aphasia and right hemiplegia**
Ishikawa B, Ishikawa F, Ikeda K, Nakamura M, Muraki J, Sato M, Shimada T, Sakata O, Kawakami T, Harada H, Saito Y (Japan)
- p260 Ictal headache in non photosensitive patients**
Piccioli M, Di Scipio E, Conti L (Italy)
- p261 Use of EEG in patients with autoimmune encephalopathy**
Sachdev T, Apiwattanakul M, Unnwongse K (Thailand)
- p262 A European database on EEG and clinical information in epilepsy patients**
Schulze-Bonhage A¹, Ihle M¹, LeVanQuyen M², Witton A², Navarro V², Sales F³, Neufang M¹, Dourado A³ (1Germany, 2France, 3Portugal)
- p263 Zonisamide as add-on treatment does not affect nocturnal sleep and vigilance in patients affected by focal epilepsy: a polysomnographic study**
Romigi A, Izzi F, Placidi F, Pisani LR, Zannino S, Albanese M, Vitrani G, Liguori C, Torelli F, Marciani MG (Italy)
- p264 Electroencephalographic findings in 200 epileptic seizure patients in Lagos Nigeria**
Ojelabi OO, Osinaike O (Nigeria)
- p265 Quality management in epileptology: can it really improve care for patients?**
Ugalde-Canitrot A, Rodríguez-Albariño A, García-Caballero J (Spain)
- p266 Seizure awareness in focal epilepsy patients: data from ambulatory-EEG monitoring**
Dispenza S, Galimberti CA (Italy)
- p267 Refractory epilepsy with normal MRI: correlation between the semiology, EEG (lectroencephalogram) and ictal SPECT (single photon emission tomography)**
Guimarães P, Lopes J, Ramalheira J (Portugal)
- p268 Quantitative electric tomography (QEEG) application in a case of epileptic status no convulsive**
Giner-Bayarri P, Torres-Caño N, Moliner-Ibáñez J, Chilet Chilet MR, Ruiz-Marquez L, Rodrigo-Sanbartolome A, Zalve-Plaza G (Spain)
- p269 Digital EEG criteria in diagnostic remission in epilepsy**
Dakukina T, Misiuk N, Kozmidiadi A, Dakukina V (Belarus)



13:00-14:30 Poster Session: Genetics I

- p270 NIPA2 gene located at 15q11.2 is mutated in patients with childhood absence epilepsy**
Jiang Y, Zhang Y, Zhang P, Sang T, Wu Y, Chan P, Wu X (China)
- p271 Linear Scleroderma or Parry-Romberg Syndrome: a rare cause of epilepsy with still unknown etiology**
Smets K¹, Lambert J¹, Madou R¹, Van Paesschen W¹, Weckhuysen S^{1,2}, Suls A¹, Parizel P¹, De Jonghe P¹ (1Belgium, 2Netherlands)
- p272 Genetic analysis of SLC2A1 gene coding glucose transporter GLUT1 in Turkish idiopathic generalized epilepsy patients**
Karacan I, Ugur Iseri SA, Ozdemir O, Tuncer FN, Yucesan E, Bebek N, Baykan B, Ozbek U (Turkey)
- p273 Gain-of-function of the Inwardly-Rectifying K⁺ Channel Kir4.1 contributes to autism with seizures and intellectual disability**
Sicca F, Imbrici P, D'Adamo MC, Moro F, Bonatti F, Brovedani P, Grottesi A, Guerrini R, Masi G, Santorelli FM, Pessia M (Italy)
- p274 Phenotypic study of a family with epilepsy and episodic ataxia type 2**
Vrielynck P, Defresne P, Hamoir B, Ribai P, van Rijckevorsel K (Belgium)
- p275 The role of SCL2A1 in early onset and childhood absence epilepsies**
Muhle H¹, Helbig I¹, Frøslev TG², von Spiczak S¹, Klitten L², Dahl HA², Brusgaard K², Tommerup N², Stephani U¹, Hjalgrim H², Møller RS² (1Germany, 2Denmark)

Poster Area (Botticelli Room)

- p277 Exon-disrupting deletions of NRXN1 predispose to idiopathic generalized epilepsy**
Møller RS¹, Trucks H², Klitten LL¹, Muhle H², Weber Y², Kunz WS², Mefford HC³, Helbig I², von Spiczak S², Franke A², Schreiber S², Rückert IM², Wichmann E², Tommerup N¹, Stephani U², Lerche H², Hjalgrim H¹, Sander T² (1Denmark, 2Germany, 3United States)
- p278 Molecular investigation of Dravet and Doose syndromes: advancing the knowledge of clinical use of genetic testing for monogenic epilepsies**
Gonsales MC, Preto P, Montenegro MA, Guerreiro MM, Lopes-Cendes I (Brazil)
- p279 Mutational analysis of SCN1A in Korean Dravet syndrome patients**
Chae J-H, Lim BC, Hwang H, Kim KJ, Hwang YS (Korea, Republic of)
- p280 Genotype-phenotype correlation in patients with co-morbid epilepsy and intellectual disability**
Klitten LL, Grønberg S, Møller RS, Thomsen AL, Nikanorova M, Hjalgrim H, Tommerup N (Denmark)
- p281 Molecular and functional study of 9 families with benign familial neonatal seizures (BFNC)**
Lesca G¹, Soldovieri MV², Mignot C¹, Dorison N¹, Boutry-Kryza N¹, Miceli F², Milh M¹, Doummar D¹, Bourel E¹, Whalen S¹, Echenne B¹, Heron B¹, Sarret C¹, Auvin S¹, Tagliatela M² (1France, 2Italy)


13:00-14:30 Poster Session: Genetics II

- p282 A pilot study of copy number variation in rolandic epilepsy**
*Addis L¹, Breen G¹, Strug LP², Pal DK1 (*¹*United Kingdom,* ²*Canada)*
- p283 Whole exome sequencing in status epilepticus**
*Depandt C¹, Heinzen EL², Goldstein DB², Pandolfo M¹ (*¹*Belgium,* ²*United States)*
- p284 Association of polymorphism of the sodium channels gene SCN1A with the effectiveness of phenytoine treatment in patients with epilepsy**
*Oros MM¹, Chomolyak YY¹, Oros OP¹, Chomolyak HM¹, Reynolds GP², Yevtushenko OO¹ (*¹*Ukraine,* ²*United Kingdom)*
- p285 Influence of a functional SCN1A polymorphism on maximum and maintenance doses of antiepileptic drugs in newly diagnosed epilepsy**
Shazadi K, Sills GJ, Pirmohamed M, Marson AG (United Kingdom)
- p286 Validation of the Australian five-SNP genetic classifier of early treatment outcomes in newly-diagnosed epilepsy**
*Sills G¹, Shazadi K¹, Petrovski S², O'Brien T², Pirmohamed M¹, Marson A¹ (*¹*United Kingdom,* ²*Australia)*

Poster Area (Botticelli Room)

- p287 Human genetic polymorphisms and the risk of malaria-associated seizures in African populations**
*Kariuki SM¹, Rockett K², Clark TG², Reyburn H², Agbenyega T³, Taylor TE⁴, Williams TN^{1,2}, Newton CR^{1,2} (*¹*Kenya,* ²*United Kingdom,* ³*Ghana,* ⁴*United States)*
- p288 Development and validation of clinical assessment tools for population genetic studies of epilepsy in rural China: a GREAT study**
*Kwan P¹, Wang W¹, Ding D¹, Sander JW² (*¹*China,* ²*United Kingdom)*
- p289 The development of the DNA chip which aimed at the clinical application in epilepsy**
Sugawara T, Yoshida S, Wada K, Hirose S, Iwasa H, Kaneko S (Japan)
- p290 Finding mutations for generalised epilepsy with photoparoxysmal response by a combination of linkage and whole-exome sequencing in multiple families**
de Kovel CGF, Kateleijn-Nolst Trenité DG, Lindhout D, Sonsma A, van 't Slot R, Koeleman BPC (Netherlands)
- p291 Analysis of MDR1 and MRP2 polymorphisms in drug-resistant epilepsy (2nd report)**
Yoshida S, Sugawara T, Kojima T, Nishio T, Kaneko S (Japan)



13:00-14:30 Poster Session: Genetics III

Poster Area (Botticelli Room)

- p292 Molecular genetic studies of patients with familial generalized epilepsy with febrile seizures plus in Chinese Han populations from Sichuan province**
Zou X, Xu Y, Hu F (China)
- p293 Novel SCN2A gene mutation in a family with benign neonatal infantile seizures from Malagasy**
Boutry-Kryza N¹, Rivier C¹, Lauxmann S², Mueller S², Maljevic S², Cartault F¹, Szepetowski P¹, Lerche H², Lesca G¹ (1France, 2Germany)
- p294 A new form of progressive myoclonus epilepsy with early ataxia and scoliosis due to mutation in the Golgi protein GOSR2**
Berkovic SF¹, Corbett MA¹, Schwake M², Bahlo M¹, Dibbens LM¹, Lin M², Gandolfo L¹, Years D¹, O'Sullivan J¹, Robertson T¹, Bayly MA¹, Gardner AE¹, Vlaar AM³, Korenke GC², Bloem BR³, de Coo IF³, Verhagen JMA³, Lehesjoki A-E⁴, Saftig P², Gecz J¹ (1Australia, 2Germany, 3Netherlands, 4Finland)
- p295 Prediction method for SCN1A-related epilepsy phenotypes based on amino-acid substitution**
Nishio T, Yoshida S, Kanai K, Sugawara T, Kaneko S, Shimizu T (Japan)
- p296 Predicting SCN1A-related epilepsy phenotypes based on the predicted deleterious effect in SCN1A function with the amino-acid substitution**
Shimizu T, Takada A, Saito J, Yoshida S, Kanai K, Kaneko S, Nishio T (Japan)
- p297 Sodium channel SCN3A mutations in patients with epilepsy and mental retardation**
Liao W-P, Wang P, Shi Y-W, Li B-M, Liu X-R, Yi Y-H, Deng W-Y, Gao M-M, Su T (China)

- p298 Familial movement-induced reflex epilepsy: a novel genetic epilepsy syndrome**
Crompton D, Schirwani S (United Kingdom)
- p299 Exploring the causative role of PCDH19 (Xq22) in female patients with epilepsy**
Hardies K¹, Suls A¹, Weckhuysen S², Van Dyck T¹, Janssen A¹, Keleman A³, Fogarasi A³, Karcagi V⁴, De Jonghe P¹ (1Belgium, 2Netherlands, 3Hungary, 4Germany)
- p300 "Borderline" generalised epilepsy with febrile seizures plus (GEFS+)**
Thomas RH, Johnston JA, Hammond CL, Bagguley S, White C, Smith PE, Rees MI (United Kingdom)
- p301 Unverricht-Lundborg disease. Report of a new mutation**
Freitas J, Pinto E, Duarte A, Amaral O, Chaves J, Lopes-Lima J (Portugal)
- p302 First report and description of patients with Dravet syndrome and genetic confirmation of mutation on neuronal voltage-gated sodium channel alpha subunit type 1 gene in Chile**
Mesa JT, Witting S, Mesa MT, Devilat M, Hernandez M, Lopez C, Pinochet C, Troncoso M (Chile)
- p303 Spectrum and frequency of SCN1A mutations in Dravet syndrome patients: the first attempt of molecular diagnostic in Poland**
Hoffman-Zacharska D, Terczynska I, Tataj R, Szczepanik E (Poland)


13:00-14:30 Poster Session: Genetics IV
Poster Area (Botticelli Room)
p304 A genomic deletion spanning part of LG11 associated with autosomal dominant lateral temporal epilepsy

Fanciulli M, Santulli L, Errichiello L, de Falco A, Rigon L, Striano P, Michelucci R, Striano S, de Falco F, Nobile C (Italy)

p305 No difference in clinical features between familial and non familial partial epilepsy

Eltawil S, Gaber A, El Nahhas N, Amal F, Hemeda M, El Etrebi MA (Egypt)

p306 Is benign familial infantile epilepsy (BFIE) linked to chromosome 16p11.2-q12.1 the result of an unusual mutational mechanism?

Heron SE¹, Gardner A¹, Corbett M¹, Gécz J¹, Grinton BE¹, Zuberi SM², Pridmore C¹, Haan E¹, Kivity S³, Afawi Z³, Korczyn AD³, Berkovic SF¹, Scheffer IE¹, Dibbens LM¹, Mulley JC¹ (1Australia, 2United Kingdom, 3Israel)

p307 Clinical genetic studies in benign childhood epilepsy with centrotemporal spikes (BECTS)

Tsai M-H¹, Vears D¹, Sadleir L², Berkovic SF¹, Smith R¹, Scheffer IE¹ (1Australia, 2New Zealand)

p308 Pharmacogenomic study of phenobarbital and phenytoin: from kinetic to dynamic targets

Chiou MH, Huang HC, Kao YH, Hung CC, Liou HH (Taiwan, Republic of China)

p309 Investigating the expression of inflammation related genes in temporal lobe epilepsy pathogenesis

Ozdemir O, Bebek N, Aydin Sayitoglu M, Yücesan E, Gürses C, Karacan I, Sencer A, Izin I (Turkey)

p310 Audit of the use of array CGH in epilepsy patients seen at a tertiary clinic

Srikantha M, Nashef L (United Kingdom)

p311 Electro-clinical findings in dupXq28 syndrome

Peron A, Vignoli A, Bellini M, Ballarati L, Caselli R, Bonaglia C, Giardino D, La Briola F, Banderali G, Canevini MP (Italy)

p312 Expression of glutamate transporters in human mesial temporal lobe epilepsy with hippocampal sclerosis: a preliminary study

Branco RC, Leal B, Rangel R, Chaves J, Bettencourt A, Carvalho C, Lopes Lima J, Silva AM, Costa PP, Silva BM (Portugal)

p313 The use of stereophotogrammetry to detect copy number variation in people with epilepsy

Chinthapalli VK¹, Bartolini E², Novy J¹, Suttie M¹, Hennekam R³, Marini C², Depondt C⁴, Guerrini R², Hammond P¹, Sisodiya S¹ (1United Kingdom, 2Italy, 3Netherlands, 4Belgium)

p314 Gene hunting for early-onset epilepsies using genome-wide CNV analysis

Holmgren P¹, Weckhuysen S^{1,2}, Smets K¹, Suls A¹, De Jonghe P¹ (1Belgium, 2Netherlands)



13:00-14:30 Poster Session: Neuropsychology/psychiatry I Poster Area (Botticelli Room)

MONDAY 29TH AUGUST

p315 Deficits in emotion recognition and executive functions, and mild mnemonic deficits after limbic encephalitis

Kaempf M, Bast T, Wendling A-S, Dietel T, Olze A, Strobl K, Fahrbach J (Germany)

p316 Emotional experience and emotion recognition in mesial temporal lobe epilepsy patients

Bonora A, Meletti S, Tocchini S, Nichelli P, Benuzzi F (Italy)

p318 Increased mesiotemporal delta activity characterizes virtual navigation in humans

Borbély C, Clemens Z, Erss L, Rásonyi G, Halász P (Hungary)

p320 Theory of mind and emotional-behavior distress in patients with temporal lobe epilepsy

Giovagnoli AR, Reati F, Chiavari E, Riva A, Franceschetti S, Villani F, Spreafico R, Avanzini G (Italy)

p321 Correlation of clinical parameters and cognitive aspects of quality of life in patients with complex partial epilepsy

Ilic J, Lukic S, Spasic M (Serbia)

p322 Differences in quality of life between sub-groups of patients with treatment-resistant temporal lobe epilepsy

Cisneros-Franco JM, Martinez-Rosas AR, Gomez-Perez ME, San Juan-Orta D, Rubio-Donnadieu F, Alonso-Vanegas MA (Mexico)

p323 Epilepsy type affects health-related quality of life in young patients with controlled seizures

Cavanna AE¹, Rizzo R², Gulisano M², Cali P², Robertson MM¹, Eddy CM¹ (¹United Kingdom, ²Italy)

p324 Induction of psychogenic nonepileptic seizures: comparison between simultaneous hyperventilation and photic stimulus versus IV saline placebo


Mesa T, Rios L, Chicharro A, Muñoz M (Chile)


13:00-14:30 Poster Session: Neuropsychology/psychiatry II Poster Area (Botticelli Room)

- p325 Clinical characteristic of anxiety in epileptic patients using state-trait anxiety inventory**
Park H-M, Kim S-H, Kim S-J (Korea, Republic of)
- p326 A new Italian instrument for the assessment of irritability in patients with epilepsy**
Piazzini A, Turner K, Ferraroni M, Edefonti V, Bravi F, Gardella E, Zambrelli E, Vignoli A, Chiesa V, Pincherle A, Canevini MP (Italy)
- p327 Prevalence of depression in patients suffering from epilepsy in comparison with chronic somatic disorders in Ukraine**
Kal'bus O (Ukraine)
- p328 The influence of clinical characteristics, interictal EEG and neuroimaging findings to associated psychiatric disorders in patients with focal epilepsies**
Buder N, Jovanovic M, Milovanovic M, Simonovic P, Djokic R (Serbia)
- p329 Psychiatric disorders in patients with pharmacoresistant and controlled focal epilepsy**
Jovanovic M, Buder N, Milovanovic M, Simonovic P, Vrbaski J (Serbia)
- p330 Epilepsy as a cause of anorexia — case report special psychiatric hospital “G. Toponica”**
Tomic S (Serbia)
- p331 Characteristics of epileptic psychosis**
Shingo Y, Motooka H, Ito Y, Morita T, Ishida S, Uchimura N (Japan)
- p332 Epileptic psychosis in comparison with schizophrenia using PANS**
Motooka H, Yasumoto S, Morita T, Ito Y, Sato M, Ishida S, Uchimura N (Japan)
- p333 Depression and anxiety symptoms in patients with epilepsy**
Milovanovic M, Martinovic Z, Jovanovic M, Buder N, Radivojevic V, Simonovic P (Serbia)
- p334 Epilepsy and mood disorders**
Kruja J, Dangellia A, Zekja I, Grabova S, Mijo S (Albania)
- p335 Screening symptoms of depression and suicidal ideation in people with epilepsy using the beck depression inventory**
Salgado PCB, Yasuda CL, Pereira FR, Cendes F (Brazil)
- p336 Dissociative experiences in epilepsy patients**
Hara K¹, Adachi N¹, Ito M¹, Okazaki M¹, Adachi T¹, Akanuma N², Matsuura M¹, Kato M¹, Onuma T¹ (1Japan, 2United Kingdom)
- p337 One-year seizure prognosis with antidepressant treatment**
Okazaki M, Adachi N, Ito M, Watanabe M, Watanabe Y, Kato M, Onuma T (Japan)



Inovelon adds to family life



by michaela,
aged 13

LGS patient

Prescribing information
can be found overleaf

Date of preparation: June 2011

Code: INO-UK2223



hvc
human health care



INOVELON® ▼
rufinamide

Inovelon® (rufinamide) prescribing information.

Please refer to the SPC before prescribing.

Presentation: Film coated tablets containing 100 mg, 200 mg or 400 mg rufinamide. **Indication:** Adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut Syndrome in patients 4 years and older. **Dose and administration:** For oral use. Inovelon should be administered twice daily in two equally divided doses with water and preferably with food in the morning and in the evening. Inovelon can be crushed and administered with half a glass of water. Children 4 years of age or older weighing <30 kg not receiving valproate; initial daily dose is 200 mg in two divided doses and may be increased by 200 mg/day increments, as frequently as every two days, up to a maximum dose of 1000 mg/day. Children 4 years of age or older weighing <30 kg receiving valproate; initial daily dose is 200 mg in two divided doses and may be increased by 200 mg/day after a minimum of two days, up to a maximum dose of 600 mg/day. Adults and children 4 years or older of ≥30 kg; initial daily dose is 400 mg in two divided doses and may be increased by 400 mg/day increments, as frequently as every two days, up to a maximum of 3200 mg/day based on patient's weight (see SPC).

Elderly and patients with renal or hepatic impairment: No dosage adjustment required in elderly and renal impairment. Not recommended in severe hepatic impairment. **Contra-Indications:** Hypersensitivity to rufinamide, triazole derivatives or any excipients. **Pregnancy:** Inovelon should not be used during pregnancy unless clearly necessary. **Lactation:** Excretion into human breast milk unknown. Lactation should be avoided during maternal treatment with Inovelon. **Warnings and Precautions:** Cases of status epilepticus have been observed during clinical studies, which led to rufinamide discontinuation in 20% of the cases. The benefit risk ratio of the therapy should be reassessed if patients develop new seizure types and/or experience an increased frequency of status epilepticus. Withdraw gradually to reduce possibility of seizures on withdrawal and reduce dose by approximately 25% every two days. Inovelon has been associated with dizziness, somnolence, ataxia and gait disturbances which could increase the occurrence of accidental falls in this population, therefore patients and carers should exercise caution until they are familiar with the potential effects of Inovelon. Serious antiepileptic drug hypersensitivity syndrome has occurred with rufinamide. Signs, symptoms and manifestations included fever and rash associated with other organ system involvement, lymphadenopathy, liver function tests abnormalities and haematuria. Other organ system signs and symptoms may occur. If this reaction is suspected, rufinamide should be discontinued and alternative treatment started. Closely monitor patients on rufinamide with unexplained rash. Rufinamide produced a decrease in QTc interval in a thorough QT study. However, the underlying mechanism and safety relevance is not known. Clinicians should use clinical judgment when assessing whether to prescribe rufinamide to patients at risk from further shortening of their QTc duration. Women of child-bearing potential must use contraceptive measures during treatment with Inovelon. Inovelon tablets contain lactose, therefore patients with rare hereditary problems of galactose intolerance,

the Lapp lactase deficiency or glucose-galactose malabsorption should not take Inovelon. **Drug Interactions:** Rufinamide concentration may be decreased by co-administration with carbamazepine, phenobarbital, phenytoin, vigabatrin or primidone. Significant increases in rufinamide plasma concentrations may occur when co-administered with valproate. Consideration should be given to a dose reduction in patients <30 kg who are initiated on valproate therapy. No significant changes in rufinamide concentration when co-administered with lamotrigine, topiramate or benzodiazepines. Rufinamide appears to have no clinically relevant effect on carbamazepine, lamotrigine, phenobarbital, topiramate or valproate steady state concentrations. Rufinamide may decrease phenytoin clearance and increase concentrations of co-administered phenytoin, therefore reducing the dose of phenytoin should be considered. Rufinamide decreases the AUC of a combined oral contraceptive (ethinylloestradiol 35 µg and norethindrone 1 mg). Women of child-bearing potential using hormonal contraceptives should use an additional safe and effective contraceptive method. Rufinamide does not inhibit the activity of cytochrome P450 enzymes thus clinically significant interactions mediated through the inhibition of cytochrome P450 system by rufinamide are unlikely to occur. Rufinamide has been shown to induce the CYP3A4 enzyme. Carefully monitor patients on drugs metabolised by the CYP3A enzyme for two weeks at start of, or after the end of treatment with Inovelon, or after a marked change in the dose. Dose adjustments should be considered when rufinamide is co-administered with drugs with narrow therapeutic window such as warfarin and digoxin. No effects on the pharmacokinetics of olanzapine. No interaction data with alcohol. **Side effects:** The most common adverse reactions in the clinical development program were headache, dizziness, fatigue, and somnolence. Adverse reactions associated with Inovelon in clinical studies: Very common effects (≥1/10): somnolence, headache, dizziness, nausea, vomiting, fatigue. Common effects (≥1/100, <1/10): pneumonia, influenza, nasopharyngitis, ear infection, sinusitis, rhinitis, anorexia, eating disorder, decreased appetite, anxiety, insomnia, status epilepticus, convulsion, coordination abnormal, nystagmus, psychomotor hyperactivity, tremor, diplopia, vision blurred, vertigo, epistaxis, abdominal pain upper, constipation, dyspepsia, diarrhoea, rash, acne, back pain, oligomenorrhoea, gait disturbance, weight decrease, head injury, contusion. Uncommon (≥1/1000, <1/100): hypersensitivity and hepatic enzyme increase. **Legal Category:** POM. **Presentation:** Aluminium/aluminium blisters. **Basic UK NHS cost:** Inovelon 100 mg: packs of 10 £5.15, Inovelon 200 mg: packs of 60 £61.77, Inovelon 400 mg: packs of 60 £102.96. **Irish price to wholesaler:** Inovelon 100 mg: packs of 10 €6.26, Inovelon 200 mg: packs of 60 €74.47, Inovelon 400 mg: packs of 60 €143.95. **Marketing authorisation numbers:** Inovelon 100 mg: packs of 10 EU/1/06/378/001, Inovelon 200 mg: packs of 60 EU/1/06/378/009, Inovelon 400 mg: packs of 60 EU/1/06/378/014. **Marketing authorisation holder:** Eisai Ltd. **Further Information from/Marketed by:** Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Herts, AL10 9SN, UK. **Date of preparation:** January 2011.

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk.
Adverse events should also be reported to Eisai Ltd on 0208 600 1400/0845 676 1400 or Lmedinfo@eisai.net



hvc
human health care

 **INOVELON**[®]
rufinamide

**TUESDAY 30TH AUGUST 2011****13:00-14:00 Poster Session: Drug therapy I****Poster Area (Botticelli Room)****p338 The metabolism and elimination pathway through glucuronidation of eslicarbazepine acetate and its metabolites**

Loureiro AI, Fernandes-Lopez C, Bonifacio MJ, Wright LC, Soares-da-Silva P (Portugal)

p339 Incidence of adverse events in relation to starting-dose and titration regimen of eslicarbazepine acetate as add-on treatment in patients with partial-onset seizures

Guekht A¹, Gama H², Öztiryaki AH², Moreira J², Mota F², Nunes T², Soares-da-Silva P² (1Russian Federation, 2Portugal)

p340 Steady-state pharmacokinetics of eslicarbazepine acetate: integrated pool analyses from three double-blind Phase III clinical studies

Falcão A, Rocha JF, Costa R, Lopes N, Nunes T, Soares-da-Silva P (Portugal)

p341 To what extent can eslicarbazepine acetate influence the plasma levels of combined antiepileptic drugs? An evaluation based on three double-blind Phase III clinical studies

Bialer M¹, Falcão A², Costa R², Lopes N², Nunes T², Soares-da-Silva P² (1Israel, 2Portugal)

p342 Methods used to evaluate cognitive effects of eslicarbazepine acetate add-on therapy in epileptic children of age 6-16: the design of a placebo-controlled clinical trial

Capovilla G¹, Pinto R², Moreira J², Mota F², Nunes T², Soares-da-Silva P² (1Italy, 2Portugal)

p343 The design of a double-dummy, active-controlled, multi-national Phase-III non-inferiority trial in 900 patients with partial-onset seizures: eslicarbazepine acetate versus controlled-release carbamazepine in monotherapy

Trinka E¹, Pinto R², Moreira J², Mota F², Nunes T², Soares-da-Silva P² (1Austria, 2Portugal)

p344 The design of a phase III clinical study of eslicarbazepine acetate in elderly patients with partial-onset seizures in epilepsy

Nunes T¹, Steinhoff BJ², Costa R¹, Pinto R¹, Lopes N¹, Soares-da-Silva P¹ (1Portugal, 2Germany)

p345 The effect of eslicarbazepine acetate 800 mg and 1200 mg once-daily on the pharmacokinetics of a combined oral contraceptive in healthy female volunteers

Vaz-da-Silva M, Öztiryaki AH, Gama H, Mota F, Nunes T, Soares-da-Silva P (Portugal)

p346 In healthy subjects, concomitant use of carbamazepine with eslicarbazepine acetate can decrease exposure to eslicarbazepine: lack of pharmacokinetic effects of eslicarbazepine acetate on carbamazepine and its 10,11-epoxide metabolite confirms findings from clinical phase III studies

Perucca E¹, Fauchoux N², Falcão A³, Costa R³, Nunes T³, Soares-da-Silva P³ (1Italy, 2France, 3Portugal)

p347 One year experience with eslicarbazepine acetate on a community hospital in Porto, Portugal

Loureiro R, Freitas J, Correia F, Lopes J, Ramalheira J, Chaves J, Lopes-Lima J (Portugal)

p348 A comparison of sodium levels in patients switched from oxcarbazepine to eslicarbazepine acetate

Oehl B, Carius A, Fauser S, Lanz M, Leonhardt G, Schulze-Bonhage A (Germany)


13:00-14:00 Poster Session: Drug therapy II
Poster Area (Botticelli Room)

- p349 A clinical EEG study in pharmacoresistant epilepsy patients treated with lacosamide**
Giorgi FS, Pelliccia V, Pizzanelli C, Guida M, Di Coscio E, Carnicelli L, Perini D, Maestri M, Bonanni E, Ludice A (Italy)
- p350 Efficacy and tolerability of lacosamide as adjunctive therapy in adult patients with drug-resistant focal epilepsy**
Vignoli A, Chiesa V, La Briola F, Gardella E, Zambrelli E, Canevini MP (Italy)
- p351 Efficacy and tolerability of lacosamide as adjunctive therapy in patients with pharmacoresistant focal epilepsy**
Cappanera S, Cesaroni E, Zamponi N (Italy)
- p352 Adjunctive therapy with vinpocetin in children with refractory partial epilepsy: a pilot study in Mexico**
Garza-Morales S, Hernandez-Hernandez M, Rodriguez-Chicatti D, Nekrasov V, Sitges M (Mexico)
- p353 Long term treatment with Lacosamide**
Kurth C, Steinhoff BJ (Germany)
- p354 Improvement of lacosamide efficacy by optimized comedication: preliminary results from a prospective open-label investigation**
Arnold S, Beige A (Germany)
- p355 Intravenous lacosamide in refractory status epilepticus (SE)**
Mnatsakanyan L, Chung JM, Tsimerinov EI, Eliashiv DS (United States)
- p356 Efficacy and tolerability of zonisamide as adjunctive therapy in the treatment of refractory epilepsy in age of development**
Daniela L, Palermo C, Losito E, Rossi V, Leo G, Lettori D, Battaglia DI (Italy)
- p357 Clinical experience with lacosamide in patients with pharmacoresistant partial epilepsy: an audit in epilepsy clinics from the South East of England**
Flores L, Moran N, Quirk J, Ramkoleea P, Von Oertzen T, Elwes R, Nashef L, Mullatti N, Richardson M, Delamont S (United Kingdom)
- p358 The effectiveness of topiramate in migraine prevention**
Ristic TS, Ristic D, Marinkovic I, Djordjevic G, Vukasinovic N (Serbia)
- p359 Long-term maintenance of efficacy and tolerability with retigabine (ezogabine) 600-1200 mg/day over 24 months**
*Eger CE¹, Brodie MJ², Lee W-JK³, Cyr T³, DeRossett SE³
 (1Germany, 2United Kingdom, 3United States)*
- p360 Pharmacological effects of retigabine (ezogabine) on bladder function**
*DeRossett SE¹, Brickel N², Hall ST¹
 (1United States, 2United Kingdom)*



13:00-14:00 Poster Session: Drug therapy III

Poster Area (Botticelli Room)

p361 Antiepileptic drug treatment strategy in children with epilepsy: a retrospective study

Hulshof H, Weijnenberg A, Buijtenhuijs K, Brouwer O, Callenbach P (Netherlands)

p362 Does therapeutic strategy have impact on quality of life in patients with complex partial epilepsy failing on a single drug?

Lukic S, Ilic J, Spasic M (Serbia)

p363 Causes of treatment gap in a rural Indian population in the year 2011: should we continue to blame it on lack of awareness?

Singh MB, Bhatia R, Padma MV, Tripathi M, Prasad K, Behari M (India)

p364 Influence of genetic variants in EPHX1 gene on the CBZ doses in the patient from R. Macedonia

Sterjev Z, Kiteva G, Nestorovska AK, Matevska N, Serafimoska Z, Dimovski AJ, Suturkova L (Macedonia, the Former Yugoslav Republic of)

p365 Bromide in patients with SCN1A-mutations manifesting as Dravet syndrome and its borderline variants

Lotte J¹, Haberlandt E², Staudt M¹, Kluger G¹ (¹Germany, ²Austria)

p366 Treatment of epilepsy in adults: expert opinion in China

Hong Z (China)

p367 The consensus on the application of antiepileptic drugs before and after epilepsy surgery

Li S, Zhang G (China)

p368 Investigate the effect of continuous sedation for refractory epileptic status in China

Tian L, Xue X, Zhou D (China)

p369 Evaluation of different antiepileptic drugs strategy following epilepsy surgery: a retrospective study

Zeng T, An D, Zhou D (China)

p370 Antiepileptic drug use in Austrian nursing home residents

Huber DP, Griener R, Moroder T, Trinkla E (Austria)

p371 How do new anti-epileptic drugs impact the therapy of refractory epilepsy at the municipal hospital in Sakai?

Ninomiya H, Kato A, Kishima H, Yoshimine T (Japan)

p372 Comparative efficacy of combination drug therapy in refractory epilepsy

Poolos NP, Warner LN, Humphreys S, Williams S (United States)


13:00-14:00 Poster Session: Drug therapy IV
Poster Area (Botticelli Room)

p373 Effects of eslicarbazepine acetate, eslicarbazepine, carbamazepine and oxcarbazepine in the maximal electroconvulsive shock test in the mice

Pires N, Palma N, Loureiro AI, Bonifacio MJ, Wright LC, Soares-da-Silva P (Portugal)

p374 Effects of eslicarbazepine acetate, eslicarbazepine, carbamazepine and oxcarbazepine in the 6-Hz psychomotor seizure model in the mice

Torrão L, Machado R, Pires N, Palma N, Bonifácio MJ, Wright LC, Soares-da-Silva P (Portugal)

p375 Effects of eslicarbazepine, R-licarbazepine, oxcarbazepine and carbamazepine on glycine GlyR α 3 receptor-mediated inward currents

Wright LC¹, Bulling A², Hebeisen S², Konrad D², Soares-da-Silva P¹ (1Portugal, 2Switzerland)

p376 Effects of eslicarbazepine acetate on acute and chronic Latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus

Sierra-Paredes G¹, Sierra-Marcuño G¹, Loureiro AI², Wright LC², Soares-da-Silva P² (1Spain, 2Portugal)

p377 Stiripentol exhibits higher anticonvulsant properties in immature brain

Auvin S, Lecoince C, Gressens P (France)

p378 Incidence of valproic acid-induced hyperammonemic encephalopathy

Dominguez Bertalo J, Carrasco S, Burriel L, Alvarez MJ, Gudín M, Vaamonde J (Spain)

p379 Adverse events of antiepileptic drugs, across indications: can randomised controlled trial data from non-epilepsy indications be included in meta-analysis for AEDs used in epilepsy?

Shukralla AA, Tudur-Smith C, Marson AG (United Kingdom)

p380 Non epileptic seizures induced by pharmacological overtreatment in patients with refractory epilepsy

Benna P, Montalenti E (Italy)

p381 Gender specific association of decreased bone mineral density (BMD) with epilepsy

Markoula S, Sioka C, Chatzistefanidis D, Exarchopoulos T, Maranis S, Kalef-Ezra J, Fotopoulos A, Kyritsis AP (Greece)

p382 Polypharmacy and generalized dystonia; a case report

Cengiz N, Demir E (Turkey)

p383 Metabolic syndrome among overweight or obese epileptic patients treated with valproate: a cross-sectional study

Fang J, Si Y, Chen S, An D, Mu J, Zhou D (China)

p384 Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs

Šimko J, Horáček J, Kremláček J (Czech Republic)



13:00-14:00 Poster Session: Paediatric epileptology VI Poster Area (Botticelli Room)

- p385 Benign childhood epilepsy with centrotemporal spikes: cognitive, emotional and behavioral comorbidities, and the quality of life**
Chen Q, Yan X-X, Zhang G, Shang N-X, Wang Y, Li E-Z, Xu K (China)
- p386 Cognitive effects of interictal epileptiform discharges in children**
Ebus S¹, Arends J¹, Hendriksen J¹, Van der Horst E¹, de la Parra N¹, Hendriksen R¹, Santegoeds E¹, Boon P^{1,2}, Aldenkamp B¹ (1Netherlands, 2Belgium)
- p387 Various suppression-burst EEG patterns seen in epileptic encephalopathies and other conditions**
Yamamoto H, Okumura A, Miyamoto Y, Fukuda M (Japan)
- p388 Parental reactions and needs in benign childhood focal seizures**
Valeta T (United Kingdom)
- p389 Impaired language performance as a precursor or consequence of Rolandic epilepsy?**
Overvliet GM, Aldenkamp A, Klinkenberg S, Vles J, Hendriksen J (Netherlands)
- p390 Neuropsychological outcome following benign myoclonic epilepsy of infancy**
Ong H-T, Lim K, Tay S, Low P-S (Singapore)
- p391 Epilepsy and ADHD in children: psychosocial aspects and behavior problems**
Duran MHC, Neri ML, Medeiros LL, Guimarães CA, Guerreiro MM (Brazil)
- p392 The sleep and behavioral problems in treated and untreated children with benign childhood epilepsy with centrotemporal spikes**
Samaitiene R, Juozapavicius A, Bacevicius G (Lithuania)
- p393 Reading performance in children with rolandic epilepsy correlates with nocturnal epileptiform activity during wake**
Ebus S, Overvliet G, Arends J, Aldenkamp B (Netherlands)
- p394 Language and autistic regression associated with EEG epileptiform abnormalities: improvement after pharmacological treatment**
Brovedani P¹, Chilosi AM¹, Ferrari A¹, Guerrini R¹, Deonna T² (1Italy, 2Switzerland)


13:00-14:00 Poster Session: Paediatric epileptology VII Poster Area (Botticelli Room)

- p395 Diffusion-weighted imaging measures do not distinguish epileptogenic tubers in children with tuberous sclerosis and epileptic spasms**
Emsell L^{1,2}, Mohamed A¹, Harvey S¹
(¹Australia, ²Belgium)
- p396 KCNQ2 and KCNQ3 mutations and deletions in benign familial neonatal seizures**
Balestri M¹, Abi Warde T², Bellini G¹, Travaglini L¹, Gennaro E¹, Miraglia del Giudice E¹, Weber Y³, Vigeveno F¹, Nabbout R², Cilio MR¹
(¹Italy, ²France, ³Germany)
- p397 Retrospective records review of european paediatric patients receiving vagus nerve stimulation (VNS) therapy for 12 months or more**
Arzimanoglou A¹, Lagae L²
(¹France, ²Belgium)
- p398 EEG characteristics predict subsequent epilepsy in children with febrile seizure**
Kanemura H, Sano F, Yamashiro D, Sugita K, Aihara M (Japan)
- p399 High-Frequency Oscillations in Benign Partial Epilepsy of Childhood**
Kobayashi K, Yoshinaga H, Toda Y, Inoue T, Endoh F, Oka M, Ohtsuka Y (Japan)
- p400 Correlation between patterns of focal epileptiform discharges and brain lesion in children with focal epilepsy**
Kim T-H, Lee Y-J, Kim Y-M, Nam S-O
(Korea, Republic of)
- p401 Refractory and severe status epilepticus in a patient with ring chromosome 20 syndrome**
Hirano Y, Oguni H, Osawa M (Japan)
- p402 Epilepsy onset related with infection in a girl with ring chromosome 20**
Ikegami M, Takahashi Y, Ikeda H, Ikeda H, Imai K, Mogami Y, Takayama R, Inoue Y (Japan)
- p403 Clinical and EEG study of absence seizures in Dravet syndrome**
Tsuda Y, Oguni H, Sakauchi M, Osawa M (Japan)
- p404 Mutation in CDKL5 gene (cyclin-dependant kinase-like 5): retrospective analysis of electroclinical (video EEG) and developmental phenotype in 8 patients**
Lepine A, Villeneuve N, Daquin G, Caietta E, Chabrol B, Bartolomei F, Milh M (France)
- p405 Georgian children with epilepsy having sleep problems: a pilot study**
Ediberidze T, Maisuradze L, Gogatishvili N, Grigolia D, Kvernadze D, Japharidze G, Mamukadze S, Karaulashvili A, Gagoshidze T, Kasradze S (Georgia)



13:00-14:00 Poster Session: Paediatric epileptology VIII Poster Area (Botticelli Room)

p406 Amplitude integrated EEG (aEEG) in comatose children with acute CNS infections: a prospective exploratory study in a paediatric intensive care unit (PICU)

Singhi P, Jindal A, Singhi S, Jayashree M (India)

p407 Levetiracetam add-on therapy in children with refractory epilepsy

Hung K-L, Liaw H-T, Lim A-T (Taiwan, Republic of China)

p408 Refractory status epilepticus: experience at a tertiary care hospital

Lukich V, Denzler I, Aberastury M, Vaccarezza M, Silva W, Maxit C, Agosta G (Argentina)

p409 Reversible tonic seizures induced by midazolam in children with refractory status epilepticus

Muro VL, Connolly MB, Huh L (Canada)

p410 Seizures induced injury in developing brain

Globa O, Sorokina E, Maslova O, Pinelis V (Russian Federation)

p411 Electrical status epilepticus during slow sleep in various disorders

Stevanovic G, Ignjatovic P (Serbia)

p412 Clinical profile and short term outcome in convulsive status epilepticus In infancy and childhood

Marthati MB (India)

p413 Descriptive study of clinical profile and response to treatment with methyl prednisolone pulses in children with electrical status epilepticus in sleep (ESES)

Wanigasinghe J, de Silva D (Sri Lanka)

p414 Ketogenic diet improves refractory status epilepticus

Lee J, Lee OJ, Nam SH, Lee M (Korea, Republic of)


13:00-14:00 Poster Session: Paediatric epileptology IX Poster Area (Botticelli Room)

- p415 Plasma leptin, neuropeptide Y, ghrelin and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate**
Tokgoz H, Aydin K, Oran B, Kiyici A (Turkey)
- p416 Association between urolithiasis and therapy with topiramate or zonisamide: therapy? prophylaxis?**
Luebbig A¹, Lotte J¹, Janello C¹, Mueller A¹, v. Stuelpnagel C¹, Luef G², Haeusler M¹, Staudt M¹, Kluger G¹ (1Germany, 2Austria)
- p417 Serum and CSF zinc levels in children with first febrile convulsion admitted in Rasht 17th Shahrivar paediatric hospital, Iran**
Bidabadi E, Mashouf M, Roshankar A (Iran, Islamic Republic of)
- p418 Management & outcome of epileptic spasms under age 3 years: single center US experience**
Guilhoto LM^{1,2}, Vendrame M¹, Loddenkemper T¹, Aakash A¹, Kothare S¹ (1United States, 2Brazil)
- p419 Intense pharmacovigilance in paediatric patients with focal epilepsy treated with carbamazepine monotherapy**
Rodriguez Clavijo BD, Medina Malo C (Colombia)
- p420 A European registry of anti-epileptic drug use in patients with Lennox-Gastaut syndrome: update of current status**
Nikanorova M¹, Panzer A², Chouette J³ (1Denmark, 2Germany, 3United Kingdom)



13:00-14:00 Poster Session: Epidemiology I

Poster Area (Botticelli Room)

p421 Epilepsy, poverty and childhood under-nutrition in rural Ethiopia
Vaid N¹, Fekadu S², Alemu S², Phillips D¹, Prevett M¹ (¹United Kingdom, ²Ethiopia)

p422 Etiologic features of newly diagnosed epilepsy: hospital-based study of 892 consecutive patients in West China
Si Y, Liu L, Hu J, Mu J, Zhou D (China)

p423 The treatment gap of active convulsive epilepsy in rural West China
Hu J, Liu L, Si Y, Mu J, Zhou D (China)

p424 Case management of epilepsy in rural villages of Mali, a three years cohort study
Bruno E¹, Nimaga K², Vignoles P³, Foba I², Ba H², Doumbo O², Gerard D³, Preux P-M³, Farnarier G³ (¹Italy, ²Mali, ³France)

p425 Possible reasons for treatment gap in a rural community in south India and the impact of Comprehensive Rural Epilepsy Study in South India (CRESSI) on reducing the treatment gap
Murthy JM, Seshadri V (India)

p426 Post-traumatic seizures in a new rural neurosurgery service: patterns and risk factors
Rabiu T (Nigeria)

p427 Bridging the treatment gap for epilepsy in Lao PDR
Barennes H^{1,2}, Chivorakul P¹, Harimanana A¹, Sengkhayong K¹, Vorachit S¹, Rajoanarivo C¹ (¹Lao People's Democratic Republic, ²France)

p428 Public awareness and attitude toward epilepsy in Saudi Arabia
Mudhafar O, Al-Hameed M (Saudi Arabia)

p429 Causes and outcome of hospital admission among people with epilepsy in a rural district hospital in Kenya
Maraga E¹, Ngari M¹, Ngugi A¹, Odhiambo R¹, Kariuki S¹, Newton CRJ^{1,2} (¹Kenya, ²United Kingdom)

p430 First population-based survey of epilepsy in Gabon, Central Africa
Ngoungou EB¹, Preux P-M² (¹Gabon, ²France)


13:00-14:00 Poster Session: Epidemiology II
Poster Area (Botticelli Room)
p431 First unprovoked seizure one-year mortality: a monocentric prospective cohort study

Giovannini G, Monti G, Mirandola L, Pugnaghi M, Nichelli P, Meletti S (Italy)

p432 Mortality in Georgian population with diagnosed epilepsy

*Kobulashvili T¹, Lomidze G¹, Kasradze S¹, Sander JW²
(¹Georgia, ²United Kingdom)*

p433 Drug-resistant epilepsy after a first unprovoked seizure in adolescence and adulthood: a prospective cohort study

Monti G, Giovannini G, Pugnaghi M, Mirandola L, Nichelli P, Meletti S (Italy)

p434 Validation of a novel digital animation seizure-screening questionnaire suitable for population-based research

D'Souza W, Harvey S, Freeman J, Cook MJ (Australia)

p435 Implementation of the new ILAE criteria for AED resistance in current practice: observational study among French and Spanish neurologists (ESPERA)

*Vespignani H¹, de Toffol B¹, de Zélicourt M¹, Laurendeau C¹, Fagnani F¹, Lahuerta J², Murat C¹, Lévy-Bachelot L¹, Villanueva V²
(¹France, ²Spain)*

p436 Incidence and risk factors for sudden unexpected death in epilepsy (SUDEP): a Tyrolean case control study

Bergmann M, Granbichler C, Ndayisaba JP, Oberaigner W, Kuchukhidze G, Trinka E (Austria)

p437 Accuracy of epilepsy survey by trained medical record administrators

Kang BS, Lee S-Y, Yi SD, Cho Y-W, Jang SH, Yoo J-K, Jung K-Y (Korea, Republic of)

p438 The French sentinel network on the epilepsy-related mortality

Picot M-C, Faucañié M, Balsan J, Arzimanoglou A, Ryvlin P (France)



13:00-14:00 Poster Session: Epidemiology III

Poster Area (Botticelli Room)

p439 Long-term outcome in epilepsy: 25 year follow-up of a general population cohort with incident epilepsy

Neligan A¹, Bell GS¹, Giavasi C¹, Johnson AL¹, Goodridge DM¹, Shorvon SD¹, Sander JW^{1,2}
(¹United Kingdom, ²Netherlands)

p440 The decision of an Australian epilepsy NGO to invest in epidemiology research

Todd L, Ireland C, Gardner G (Australia)

p441 A prospective study evaluating the recurrence of Takotsubo cardiomyopathy related to seizures

Ferrao Santos S, Dubuisson N, Dupuis F, Dupuis M, Evrard F, van Rijckevorsel K (Belgium)

p442 Innovation in researching the social impact of epilepsy in Australia: a longitudinal study

Walker CE, Brown K, Peterson CL, Shears G, Pfeiffer W, Vowels L, Brockett P (Australia)

p443 Variation of month and season of birth in an Irish epilepsy population

O'Connor G, Chaila E, Delanty N (Ireland)

p444 Hospitalization for psychiatric disorders before and after onset of unprovoked seizures

Adelöw C, Andersson T, Ahlbom A, Tomson T (Sweden)

p445 Attitude towards school and schoolwork in Norwegian youth with epilepsy a population based study — the Akershus health profile study

Løssius MJ, Clench-Aas J, Alfstad KÅ, Gjerstad L (Norway)

p446 Perceptions of epilepsy in Turkey, viewed in the light of two different city from west to east

Degirmenci Y, Canbaz Kabay S, Yilmaz Z, Bakar C, Ozisik Karaman HI (Turkey)

p447 Prevalence of Dravet syndrome among children reported with a convulsion after vaccination, in a nationwide ten-year cohort

Verbeek NE, van Kempen MJA, Jansen FE, Lindhout D, van der Maas NAT, Brilstra EH (Netherlands)

p448 Higher risk of febrile seizures in boys — gender differences in a large Danish cohort

Christensen J, Li J, Sidenius P, Olsen J, Vestergaard M (Denmark)



13:00-14:00 Poster Session: Adult epileptology VI

Poster Area (Botticelli Room)

- p449 Clinical, neurophysiologic, neuropsychological features and MRS findings of a Chinese pedigree with familial cortical tremor and epilepsy**
Yu P, Zhu G, Wu X, Xu L, Tang X, Zhao T, Hong Z (China)
- p450 The new ILAE-proposal for a revised terminology and concepts for an organization of seizures and epilepsies: comments of the Königstein Working Group of Epileptology**
Krämer G¹, Bast T², Baumgartner C³, Brandl U², Koch-Stöcker S², Köhling R², Korinthenberg R², Krägeloh-Mann I², Lerche H², Kurlemann G², Neubauer BA², Pohlmann-Eden B⁴, Schmitt B¹, Schmitz B², Steinhoff BJ², Stephani U², Witte OW² (1Switzerland, 2Germany, 3Austria, 4Canada)
- p451 Myoclonic status epilepticus in nonepileptic patients**
Baysal L, Alpaydin S, Onbasi H, Acarer A, Bademkiran F, Bayam FE, Aydogdu I (Turkey)
- p452 X monosomy with non-convulsive status epilepticus**
Ikeda H, Imai K, Ikeda H, Shigematsu H, Takahashi Y, Inoue Y (Japan)
- p453 Idiopathic generalised epilepsy with phantom absences: same focal and generalised epileptic discharges in a brother and sister**
Alpaydin S, Baysal L, Aydogdu I, Arac N (Turkey)
- p454 Propagation of generalised discharges in idiopathic generalised epilepsy: the implications**
Kibuuka M (United Kingdom)
- p455 Language dominance in adult patients that underwent functional hemispherectomy**
Fernández S, Donaire A, Bargalló N, Rumià J, Setoain X, Aparicio J, Maestro I, Boget T, Carreño M (Spain)
- p456 Missed aim: pharmacoresistant partial epilepsy transformed to epilepsy partialis continua years after epilepsy surgery**
Szucs A, Rásonyi G, Halász P, Erőss L, Vajda J (Hungary)
- p457 Rare autonomic symptoms as the predominant manifestation of epileptic seizures**
Massano AL, Teotonio R, Lemos J, Bento C, Sales F (Portugal)
- p458 Case of ictal tremor with temporal lobe epilepsy**
Tyrlíkova I¹, Kuba R¹, Sykora P², Brázdil M¹, Rektor I¹ (1Czech Republic, 2Slovakia)
- p459 Ictal water drinking as a localizing sign**
Ikeda H, Hiyoshi T, Koide Y, Ikeda H, Inoue Y (Japan)
- p460 Ecstatic epileptic seizures: a potential window on the neural basis for human self-awareness**
Picard E¹, Craig AD² (1Switzerland, 2United States)
- p461 Peri-ictal bed leaving in temporal lobe epilepsy: incidence and lateralizing value**
Musilová K, Kuba R, Brázdil M, Tyrlíková I, Rektor I (Czech Republic)



13:00-14:00

Poster Session: Adult epileptology VII

Poster Area (Botticelli Room)

p462 Treatments of localization-related symptomatic epilepsies

Kiteva-Trencevska G (Macedonia, the Former Yugoslav Republic of)

p463 Multiple organ dysfunction system in 195 adult patients with convulsive status epilepticus

Li J-M, Zhu Y, Chen L, Zhou D (China)

p464 Plasma N-terminal brain-type natriuretic peptide level can distinguish seizure from syncope in adults

Park K-I, Chung J-M (Korea, Republic of)

p465 Haemostatic parameters of newborns from mothers with epilepsy

Vlasov P (Russian Federation)

p466 Inflammatory response induced by seizure

Son HS, Lee S-Y (Korea, Republic of)

p467 Clinical profile of epilepsy in elderly: a study from Eastern India

Roy T, Pandit A, Ganguly G, Roy B, Das S (India)

p468 Neurocysticercosis: leading cause of focal seizures in North India

Alam A, Mehndiratta MM, Pandey S, Bhaskar KR (India)

p469 Long-term evolution of adult epileptic patients with malformations of cortical development

Gomez Ibañez A, Gasca Salas C, Carmona Iragui M, Urrestarazu Bolumburu E, Viteri Torres C (Spain)

p470 Recurrent epileptic seizures induced by cranial trauma: a distinct feature of megalencephalic leucoencephalopathy with subcortical cysts

Pasini E, Riguzzi P, Volpi L, Rubboli G, Michelucci R (Italy)

p471 Epilepsy in primary cerebral tumours: preliminary results of the PERNO study (project of emilia romagna region on neuro-oncology)

Michelucci R (Italy)

p472 Development of vascular epilepsy in patients with malignant stroke of middle cerebral artery (MCA)

Santamarina E, Sueiras M, Torne R, Toledo M, Rovira R, Sahuquillo J, Riveiro M, Lainez E, Salas Puig X, Alvarez Sabin J (Spain)

p474 Pregnancy outcomes of women with epilepsy

Zhidkova I (Russian Federation)


13:00-14:00 Poster Session: Adult epileptology VIII
Poster Area (Botticelli Room)

- p475 Unusual or unrecognized seizure triggers in patients with refractory focal epilepsy**
Kuester G, Campos M, Lobos C, Olate L (Chile)
- p476 PatientsLikeMe® epilepsy community: an insight into symptoms and side effects reported online by patients with epilepsy**
de la Loge C¹, Dimova S¹, Phillips G², Mueller K³, Lafosse C⁴, Wicks P² (1Belgium, 2United States, 3Germany, 4France)
- p477 Depression evaluation of patients with epilepsy through BDI-II question form**
Sušak R, Bielen I, Čandrić M, Jurić S, Planjar-Prvan M, Dogan D, Vladetić M, Butković-Soldo S (Croatia)
- p478 Epileptic and non-epileptic panic attacks: how to get the most accurate diagnosis?**
Volpi L, Bartolini Y, Forlivesi S, Rubboli G, Riguzzi P, Michelucci R (Italy)
- p479 Epilepsy since antiquity till present: a short walk through the history of the “sacred disease”**
Maximov GK (Bulgaria)
- p480 Clinical profile of psychogenic nonepileptic seizures: a study of 60 cases**
Gupta M, Khwaja GA, Chowdhury D, Patidar Y, Batra A (India)
- p481 Ictal triphasic waves unmasked by gabapentin weaning manifesting as increased confusion with emotional lability: case report with literature review**
Kaufman KB, Struck PJ, Wong S, Wu B (United States)
- p482 A provable diagnosis of epilepsy based on boolean logic and the Internet**
Andreev VM (Russian Federation)
- p483 An apparent symptomatic focal epilepsy in a patient with malignant insulinoma associated to glucagonoma**
Balestrini S, Foschi N, Arnaldi G, Bearzi I, Provinciali L (Italy)
- p484 SUDEP after epileptic seizure in limbic encephalitis caused by acute myocardial ischemia documented by autopsy**
Rizzi B, Zucco R, Bernardi A, Ghidoni E, Marcello N, De Berti G, Ragazzi M, Gardini G, Pardi P (Italy)
- p485 No evidence for lacosamide binding to collapsin response mediator protein 2 (CRMP-2)**
Wolff C¹, Carrington B², Van der Perren C¹, Vandendriessche A¹, Famelart M¹, Varrin-Doyer M³, Gillard M¹, Foerch P¹, Honnorat J³, Lawson A², Kursula P⁴, Miller K¹ (1Belgium, 2United Kingdom, 3France, 4Finland)
- p486 First occurrence of psychogenic non-epileptic seizures during presurgical video-EEG monitoring**
Staeck A, Scholly J, Steinhoff BJ (Germany)



13:00-14:00 Poster Session: Adult epileptology IX

Poster Area (Botticelli Room)

p487 Epilepsy in elderly patients with dementia
De Maria G, Guarneri B, Antonini L (Italy)

p488 Improved sleep quality in medically refractory patients undergoing epilepsy surgery — a clinical and polysomnographic study
Zanzmera P, Shukla G, Gupta A, Goyal V, Srivastava A, Behari M (India)

p489 Eye closure sensitivity in a population of juvenile myoclonic epilepsy
Sofia V, Pappalardo I, Garifoli A, Lingenti V, Leonardi CG, Vitale G, Giuliano L, Chiara S, Zappia M (Italy)

p490 Health related quality of life in patients with nocturnal frontal lobe epilepsy compared with temporal lobe epilepsy patients
Di Vito L, Vignatelli L, Bisulli F, Stipa C, Naldi I, Leta C, Pittau F, Licchetta L, Tinuper P (Italy)

p491 Effect of juvenile myoclonic epilepsy on sleep: a polysomnographic study
Krishnan P, Sinha S, Taly AB, Parthasarathy S, Ramachandra CT (India)

p492 Sleep abnormalities in juvenile myoclonic epilepsy: a sleep questionnaire based study
Krishnan P, Sinha S, Taly A, Parthasarathy S, Ramachandra C (India)

p493 Subjective sleep disturbance in patients with epilepsy
No YJ, Kim JY, Shin DJ, Kwon J-H, Lee S-A (Korea, Republic of)

p494 Does age at seizure onset influence the natural history of juvenile myoclonic epilepsy?
Giannakodimos S, Stathopoulos P, Alexoudi A, Karageorgiou CE (Greece)

p495 Analysis of daytime sleepiness and sleep quality in refractory temporal lobe epilepsy patients
Watanabe N, Campiolo G, Pizzatto R, Lin K, Walz R, Guarnieri R, Bicalho MA, Sukys-Claudio L (Brazil)

p496 A long-term follow-up study of 100 patients with nocturnal frontal lobe epilepsy (NFLE)
Bisulli F, Licchetta L, Di Vito L, Naldi I, Leta C, Stipa C, Mostacci B, Provini F, Vignatelli L, Tinuper P (Italy)

p497 Reciprocal relationship of an overlooked comorbidity: OSAS and epilepsy
Izzi F, Romigi A, Placidi F, Vitrani G, Del Bianco C, Albanese M, Evangelista E, Marchi A, Sarpa MG, Marciani MG (Italy)

p498 Clinical characteristics of Ictal asystole in temporal lobe epilepsy
Akamatsu N, Tsuji S, Kohno R, Abe H (Japan)



13:00-14:00 Poster Session: Adult epileptology X

Poster Area (Botticelli Room)

- p499** **Konquest: Keppra versus older AEDS and neuropsychiatric, neurocognitive and quality of life outcomes in treatment of epilepsy as substitution monotherapy**
Hakami TM, Todaro M, Roten A, Bright T, Germaine D, Petrovski S, MacGregor L, Gasko H, Matkovic Z, Gorelix A, Liew D, Yerra R, O'Brien TJ (Australia)
- p500** **Effectiveness of rituximab in a case of autoimmune encephalitis**
Villegas Martínez I, de Gea García JH, Tortosa Conesa D, Nuñez Ruiz R, Fernandez Vivas M, Navarro Lozano M, Sarrasqueta Baquidano J, Buendia Martinez J (Spain)
- p501** **Focal refractory epilepsy: should valproic acid- lamotrigine combination be tested previous to establishing diagnosis?**
Chicharro A, Gaete G, Vargas P, de Marinis A (Chile)
- p502** **The design of a double-blind, randomized, historical control study of the safety and efficacy of eslicarbazepine acetate monotherapy in subjects with partial epilepsy not well controlled by current antiepileptic drugs**
Blum D, Organisak L, Cheng H, Versavel M, French J (United States)
- p503** **Long-term safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled POS: results from a phase III open-label extension trial**
Husain A, Faught E, Chung S, Isojarvi J, McShea C, Doty P (United States)
- p504** **Stable and unstable treatment patterns in epilepsy and their direct cost impact: pharmetrics analysis of AED add-on therapy, switches, and discontinuations**
Richy F¹, Clark C², Makaroff L¹, Gervasoni C¹, Kaufman D² (1Belgium, 2United States)
- p505** **Long-term adjunctive lacosamide in patients with uncontrolled partial-onset seizures: results from the SP774 phase III open-label extension trial**
Rosenow F¹, Kelemen A², Ben-Menachem E³, McShea C⁴, Isojarvi J⁴, Doty P⁴ (1Germany, 2Hungary, 3Sweden, 4United States)
- p506** **Lacosamide: long-term safety and efficacy in partial-onset seizures**
Rosenfeld W¹, Fountain N¹, Kaubrys G², Ben-Menachem E³, McShea C¹, Isojarvi J¹, Doty P¹ (1United States, 2Lithuania, 3Sweden)
- p507** **An ongoing post-marketing study evaluating lacosamide as adjunctive therapy to one baseline antiepileptic drug in epilepsy patients: SP0973 VITOBA study (VimpaT added to one baseline AED)**
Runge U, Mayer T, Arnold S, Kumke T, Noack-Rink M (Germany)
- p508** **Adjunctive zonisamide in clinical practice: results from the non-interventional ZADE study**
Stefan H¹, Bauer B², Kockelmann E¹, Helmstaedter C¹ (1Germany, 2United Kingdom)



p509 OZONE: a prospective, observational, open-label study of patients with partial epilepsy treated with adjunctive zonisamide therapy in everyday clinical practice in France

Dupont S, Biraben A, Lavernhe G, Marquet T, Allaf B (France)

p510 A 12-month observational nordic study in epilepsy patients prescribed zonisamide in everyday clinical practice: preliminary results from ZENIT

*Nakken KO¹, Friberg S²
(¹Norway, ²Sweden)*

p511 An opportunity of combined influence of depakin-chrono sphaera with antioxidant mexidol on epileptic system in clinic-experimental study

Avakyan G (Russian Federation)



13:00-14:00

Poster Session: Alternative therapies I

Poster Area (Botticelli Room)

p512 Encapsulated galanin releasing cells suppress focal epileptic activity in the hippocampus

Nikitidou L¹, Torp M², Fjord-Larsen L², Kusk P², Wahlberg L², Kokaia M¹
(¹Sweden, ²Denmark)

p513 Caregiver seizure management system in canine epilepsy

Coles LD, Cloyd JC, Patterson EE, Higgins J, Bland M, Sheffield WD, Worrell G (United States)

p514 Comparison of targets for neural transplantation in the basal ganglia and identification of suitable cell sources in an acute seizure model

Bröer S, Backofen-Wehrhahn B, Roloff F, Bicker G, Löscher W, Gernert M (Germany)

p515 Optogenetic inhibition of epileptiform activity in acute hippocampal slices

Ledri M¹, Sørensen AT¹, Nikitidou L¹, Kirik D¹, Deisseroth K², Kokaia M¹
(¹Sweden, ²United States)

p516 Strength physical exercise program in rats with epilepsy is protective against seizures

Arida R, Peixinho LF, Fernandes J, Novaes F, Cassilhas R, Mello MT, Scorza FA, Gomes da Silva S, Cavalheiro EA (Brazil)

p517 Pilot-trial: high frequency, poisson distributed cortical stimulation in a screening model for epileptic seizures

Buffell, Meurs A, Raedt R, Vonck K, Boon P (Belgium)

p518 Local drug delivery of Levetiracetam in the rat model of acquired epilepsy using PLGA biodegradable polymer sheet implantations

Beattie NJ^{1,2}, Suhr C¹, O'Brien T¹, Morris M¹, Wallace G¹, Moulton S¹, Viry L¹, Cook M¹ (¹Australia, ²United Kingdom)

p519 Electrophysiological responses to vagus nerve stimulation in rats

Mollet L, Raedt R, El Tahry R, Delbeke J, De Herdt V, Meurs A, Wadman W, Vonck K, Boon P (Belgium)

p520 Hippocampal deep brain stimulation early during epileptogenesis affects spontaneous seizures in the kainic acid rat model

Van Nieuwenhuyse B¹, Vonck K¹, Wyckhuys T¹, Raedt R¹, Meurs A¹, Wadman W², Boon P¹
(¹Belgium, ²Netherlands)

p521 Substantiation of rTMS parameters to reduction of experimental convulsions

Kistsen V, Romanovskii D, Evstigneev V, Dubovik B (Belarus)

TUESDAY 30TH AUGUST



13:00-14:00 Poster Session: Alternative therapies I

Poster Area (Botticelli Room)

- p522 Impacts of a therapeutic model of recreation**
Ireland C, Todd L (Australia)
- p523 The ketogenic diet and EEG-background changes**
Theunissen E¹, Ebus S¹, Lambrechts D¹, Krijn R¹, Arends J¹, Boon P^{1,2}, Ossenblok P¹ (¹Netherlands, ²Belgium)
- p524 Efficacy and acceptability of a nutritionally complete ketogenic formula used to administer the classical 4:1 ketogenic diet in children with refractory epilepsy**
Butler R, Neal E (United Kingdom)
- p525 Safety and efficacy of the ketogenic diet for refractory infantile spasms**
Wilfong AA, Matamoros R, Samuels ER, Schultz RJ (United States)

- p526 Anticonvulsant African plants**
Ngo Bum E, Ngo Mune R, Ze M, Moto F, Ngoupaye GT, Taiwe GS, Dimo T, Rakotonirina A, Rakotonirina SV (Cameroon)
- p527 Pushing the frontier — easier, safer and more efficacious Ketogenic diet**
Nathan J, Nathan S, Chadha B, Khedekar D (India)
- p528 Ketogenic diet benefits to Dravet syndrome patients: a prospective pilot study**
Nabbout R, Copioli C, Chipaux M, Chemaly N, Desguerres I, Dulac O, Chiron C (France)


13:00-14:00 Poster Session: Neuroimaging I
Poster Area (Botticelli Room)

p529 Presurgical diagnosis of the epileptogenic focus using near-infrared spectroscopy mapping
Watanabe E, Ismail MM, Yokota H, Oguro K (Japan)

p530 High-density electric source imaging (ESI) in focal epilepsy: a prospective study of 150 operated patients
Seeck M, Brodbeck V, Lascano A, Spinelli L, Vuillemoz S, Wissmeyer M, Pollo C, Schaller K, Michel C (Switzerland)

p531 Multimodality approach in presurgical evaluation of epilepsy
Storti SF, Formaggio E, Cerini R, Bongiovanni L, Fiaschi A, Manganotti P (Italy)

p532 The correlation between ictal semiology and MEG localization in frontal lobe epilepsy
Wu X^{1,2}, Hermann S¹, Rampp S¹, Zhou D² (1Germany, 2China)

p533 Signal changes in MRI in patients with focal status epilepticus
Vivanco-Hidalgo RM, Gonzalez S, Capellades J, Herraiz J, Roquer J, Rocamora R (Spain)

p534 3-TESLA MRI study in focal epilepsy. A prospective study
Sarria-Estrada S, Toledo M, Salas-Puig X, Santamarina E, Auger C, Rovira A (Spain)

p535 Identification of epileptic focus with multi-channel near-infrared spectroscopic topography (optic topography)
Maruta Y, Fujii M, Imoto H, Nomura S, Matsushige T, Ichiyama T, Yamakawa T, Suzuki M (Japan)

p536 Loss of network efficiency associated with cognitive decline in chronic epilepsy
Vlooswijk MCG, Vaessen MJ, Jansen JFA, de Krom MCFTM, Majoie HJM, Hofman PAM, Aldenkamp AP, Backes WH (Netherlands)

p537 Increased and decreased central type benzodiazepine receptor bindings associated with seizure outcomes in epileptogenic cavernous angioma and frontal cortical dysplasia
Kondo A, Matsuda K, Baba K, Tottori T, Nakamura F, Usui N, Terada K, Usui K, Mihara T, Agari T, Date I, Inoue Y (Japan)

p538 White matter network abnormalities are associated with cognitive decline in chronic epilepsy
Vaessen M, Jansen J, Vlooswijk M, Hofman P, Majoie M, Aldenkamp A, Backes W (Netherlands)

p539 Novel multimodal functional neuroimaging approach for non-invasive primary sensorimotor cortex mapping
Bourguignon M¹, Jousmäki V², Op de Beeck M¹, Van Bogaert P¹, Nouali M¹, Metens T¹, Lubicz B¹, De Tiège X¹, Goldman S¹ (1Belgium, 2Finland)



13:00-14:00 Poster Session: Neuroimaging II

Poster Area (Botticelli Room)

p540 Positive BOLD response in the brain's default mode network anticipates spike and wave discharges in idiopathic generalized epilepsy

Mirandola L, Benuzzi F, Pugnaghi M, Farinelli V, Tassinari CA, Capovilla G, Cantalupo G, Beccaria F, Nichelli P, Meletti S (Italy)

p541 Haemodynamic changes pre-and post-surgical investigation in patients with hemimegalencephaly

Nakagawa E, Ishiyama A, Sukigara S, Takeshita E, Okazaki T, Hiyane M, Fukumura S, Sugai K, Sasaki M, Takahashi A, Otsuki T (Japan)

p542 Reorganisation of verbal and visual memory following anterior temporal lobe resection: results of a longitudinal fMRI study

Bonelli S^{1,2}, Thompson PJ¹, Yogarajah M¹, Powell R¹, Samson R¹, Mc Evoy A¹, Symms M¹, Koeppe MJ¹, Duncan JS¹ (1^{United Kingdom}, 2^{Austria})

p543 EEG-fMRI BOLD responses associated with interictal epileptiform spikes ipsilateral and contralateral to the seizure onset zone in patients with mesial temporal lobe epilepsy

Coan AC, Beltramini GC, Campos BM, Covolan RJM, Cendes F (Brazil)

p544 Detection and localization of epileptiform activity using combined parametric multi channel analysis and pattern recognition technologies with sLORETA on EEG fMRI data

Efrat NM, Dagan A, Friedman A, Shallom I (Israel)

p545 Changes in structural and functional connectivity of the hippocampus-extratemporal networks in unilateral temporal lobe epilepsy with hippocampal sclerosis: a combined structural and functional MRI study

Kim JH, Shon Y-M (Korea, Republic of)

p546 Localisation of focal epileptic activity with EEG-fMRI informed by EEG voltage maps

Grouiller F¹, Thornton R², Groening K³, Spinelli L¹, Duncan JS², Schaller K¹, Siniatchkin M³, Lemieux L², Seeck M¹, Michel CM¹, Yulliamoz S^{1,2} (1^{Switzerland}, 2^{United Kingdom}, 3^{Germany})

p547 MR spectroscopic imaging and diffusion-weighted MRI for detection of thalamus in coriaria lactone (CL)-induced status epilepticus in rhesus monkeys

Xiaoyun Z, Zhiyong Y, Dong Z, Hongxia L (China)

p180 Effects of electrical stimulation of the thalamic mediodorsal nucleus on spike and wave discharges in WAG/Rij rats

Zybina A¹, Chepurnova N¹, Titov S¹, van Luijckelaar G², Abbasova K¹ (1^{Russian Federation}, 2^{Netherlands})

p549 The effect of topiramate on cognitive activation: a cross-sectional fMRI study

Yasuda CL^{1,2}, Vollmar C¹, Centeno M¹, Stretton J¹, Symms MR¹, O Muircheartaig J¹, Barker GJ¹, Cendes F², Richardson MP¹, Thompson P¹, Duncan JS¹, Koeppe MJ¹ (1^{United Kingdom}, 2^{Brazil})

p550 Resting-state fMRI study in treatment-naïve temporal lobe epilepsy patients with depressive symptoms

Chen S (China)


13:00-14:00 Poster Session: Neuroimaging III
Poster Area (Botticelli Room)
p551 Image bias correction profoundly influences voxel-based morphometry in mesial temporal lobe epilepsy

Focke N, Helms G, Nitsche MA, Paulus W (Germany)

p552 FDG-PET and MEG versus SEEG in paediatric epilepsy surgery candidates

Montavont A, Ostrowsky K, Kahane P, Jung J, Bouvard S, Bouet R, Kéo-Kozal P, de Bellescize J, Panagiotakaki E, Gauthier-Morel D, Arzimanoglou A, Ryvlin P (France)

p553 The role of voxel based morphometry (VBM) in the detection of cortical dysplasias within the temporal pole in patients with the intractable mesial temporal epilepsy

Pail M, Mareček R, Slaná B, Hermanová M, Tyrliková I, Kuba R, Brázdil M (Czech Republic)

p554 Taylor's hypothesis revisited: a VBM study of gender and hemispheric differences in temporal lobe epilepsy

Castilho Garcia de Santana MT, Parolin Jackowski A, dos Santos Britto F, Barbosa Sandim G, Sales Ferreira Caboclo LO, Silva Centeno R, Carrete Júnior H, Targas Yacubian EM (Brazil)

p555 Frontal and thalamic dysfunction in juvenile myoclonic epilepsy: a magnetic resonance spectroscopy and neuropsychological study

Cevik N, Baybas S, Dirican A, Bayramoglu S, Sozmen V, Ozturk M, Keskinilic C, Cimilli T, Dirican A (Turkey)

p556 Psychogenic non-epileptic seizures: a cortical thickness and VBM study

Labate A, Cerasa A, Gambardella A, Mula M, Gioia C, Aguglia U, Quattrone A (Italy)

p557 DTI voxel based analysis in patients with idiopathic generalized epilepsy

Betting LE, Yasuda CL, Min LL, Lopes-Cendes I, Guerreiro MM, Guerreiro CAM, Cendes F (Brazil)

p558 Focal structural abnormalities in juvenile myoclonic epilepsy: a voxel-based DTI study

Sinha S, Saini J, Bagepally BS, Ramachandraiah TC, Prasad C, Taly AB, Satishchandra P (India)

p559 Divergence of expressive and receptive language localization with magneto encephalography in patients with medically refractory partial epilepsy

Eliashiv D, Gage N, Lacey K, Patti Q, Otis S, Chung JM (United States)

**13:00-14:00 Poster Session: Neuroimaging IV****Poster Area (Botticelli Room)****p560 Overlay of interictal epileptic networks and cortical abnormalities in mesiotemporal lobe epilepsy**

Hauf M, Estermann L, Scheidegger O, Schindler K, Jann K, Koenig T, Wiest R (Switzerland)

p561 High resolution MRI texture analysis of hippocampal tissue: histopathological correlations in mesial temporal lobe epilepsy

Alegro MC, Amaro Jr E, Silva AV, Bando SY, Lopes RD, Moreira-Filho CA (Brazil)

p562 Nonverbal memory in patients with mesial temporal lobe epilepsy and amygdala lesions

Zamarian L¹, Kuchukhidze G¹, Siedentopf C¹, Koppelstaetter F¹, Gneiss C¹, Walser G¹, Bergmann M¹, Prieschl M¹, Broicher S², Delazer M¹, Jokeit H², Luef G¹, Unterberger I¹, Trinka E¹ (¹Austria, ²Switzerland)

p563 Imaging the interaction: working memory, epileptic discharges and performance

Chaudhary UJ, Centeno M, Carmichael DW, Vollmar C, Rodionov R, Bonelli S, Stretton J, Pressler R, Eriksson SH, Sisodiya SM, Duncan JS, Lemieux L, Koepp M (United Kingdom)

p564 Facial emotion processing in patients with mesial temporal lobe epilepsy and amygdala lesions

Kuchukhidze G¹, Zamarian L¹, Koppelstaetter F¹, Unterberger I¹, Siedentopf C¹, Gneiss C¹, Walser G¹, Bergmann M¹, Prieschl M¹, Broicher S², Delazer M¹, Jokeit H², Luef G¹, Trinka E¹ (¹Austria, ²Switzerland)

p565 Frontal lobe activity during encoding in temporal lobe epilepsy

Sidhu MK, Stretton J, Winston G, Bonelli S, Centeno M, Vollmar C, Thompson P, Symms M, Koepp M, Duncan JS (United Kingdom)

p566 Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy

Hirvonen J, Kreisl WC, Fujita M, Dustin I, Khan O, Appel S, Zhang Y, Morse C, Pike VW, Innis RB, Theodore WH (United States)

p567 Association between basal ganglia and large scale brain networks in epilepsy

Rektor I, Tomčík J, Mikl M, Mareček R, Brázdil M, Rektorová I (Czech Republic)

p568 Epilepsy-induced changes in effective connectivity in the non-epileptic temporal lobe of patients with unilateral mesiotemporal epilepsy

Trotta N, Goldman S, Legros B, Baete K, Van Laere K, Van Bogaert P, De Tiège X (Belgium)


13:00-14:00 Poster Session: Neuroimaging V
Poster Area (Botticelli Room)
p569 Fingerprints of brain activation in epileptic syndromes and encephalopathies

Siniatchkin M, Moeller F, Stephani U (Germany)

p570 Evaluation of white matter abnormalities in patients with focal cortical dysplasia using qualitative analysis of fractional anisotropy maps

Princich JP, Consalvo D, Kauffman M, Seifer G, Blenkmann A, Kochen S (Argentina)

p571 Magnetic resonance imaging localizes the epileptogenic zone in tuberous sclerosis complex

Kyncl M¹, Krsek P¹, Jahodova A¹, Kudr M¹, Komarek V¹, Jayakar P², Dunoyer C², Resnick T², Altman N², Duchowny M² (¹Czech Republic, ²United States)

p572 Cortical representation of high-frequency oscillations in Landau-Kleffner syndrome revealed by magnetic source imaging

Op De Beeck M, Bourguignon M, Carrette E, Boon P, Verhelst H, Goldman S, Van Bogaert P, De Tiège X (Belgium)

p573 MRI in hypsarrhythmia

Khalid E, Sinha S, Siddiqui S, Marasigan MR, Alcalá WO, Siddiqui KA (Saudi Arabia)

p574 Imaging the effects of age of onset and duration of epilepsy in frontal lobe epilepsy

Centeno M, Vollmar C, Jonathan O, Stretton J, Bonelli S, Symms M, Thompson P, Kumari V, Barker G, Duncan JS, Richardson M, Koeppe M (United Kingdom)

p575 Everolimus therapy reduces the volume of tubers of patients with tuberous sclerosis complex (TSC)

Franz DN, Agricola KD, Tudor CA, Krueger DA (United States)

p576 Hemiconvulsion-hemiplegia epilepsy (HHE) syndrome: longitudinal MRI findings in 13 children

Barcia G, Desguerre I, Barnerias C, Gitiaux C, Dulac O, Bodaert N, Nabbout R (France)

p577 Case report: two patients with late onset and atypical Sturge-Weber syndrome

Sacko A, Perin B, Bisdorff-Bresson A, Auvin S, Monet P, Krystkowiak P, Godefroy O (France)



13:00-14:00 Poster Session: Neuroimaging VI

Poster Area (Botticelli Room)

p578 Diffusion tensor MRI of damage-induced plasticity during epileptogenesis in the rat hippocampus

Sierra A, Laitinen T, Gröhn O, Pitkänen A (Finland)

p579 Resting-state functional connectivity analysis of post-traumatic epilepsy patients

Ferreira HA, Rua C, Loureiro J, Lacerda L, Manaças RM, Gonçalves-Pereira PM, Andrade A (Portugal)

p580 Hippocampal activation in simultaneous intracranial EEG-fMRI: a case report

Pugnaghi M^{1,2}, Chaudhary UJ¹, Rodionov R¹, Diehl B¹, Mc Evoy A¹, Walker M¹, Duncan JS¹, Carmichael DW¹, Lemieux L¹ (¹United Kingdom, ²Italy)

p581 Manganese-Enhanced MRI evaluation of Coriaria Lactone-induced neuronal activation in rhesus hippocampus

Yang T, Hong Z, Li H, Gong Q, Zhou D (China)

p582 Combining EEG and fMRI in epilepsy

Formaggio E, Storti SF, Bertoldo A, Manganotti P, Toffolo GM (Italy)

p583 Diffusion tensor analysis of temporal and extratemporal tracts and its correlation to the clinico-electrophysiologic-imaging features in drug resistant temporal lobe epilepsy

Radhakrishnan A, James J, Ramesh A, Kesavadas C, Thomas B, Radhakrishnan K (India)

p584 Reorganization of cerebral networks for fear faces memory in children with temporal lobe epilepsy: preliminary fMRI findings

Pinabiaux C, Jambaqué I, Chiron C, Rodrigo S, Delalande O, Martine F, Hertz-Pannier L, Noulhiane M (France)

p585 Functional connectivity and epilepsy: a non-linear resting state fMRI investigation of temporal lobe, frontal lobe and idiopathic generalized epilepsy

Santarnecchi E¹, Polizzotto NR², Vatti G¹, Marino D¹, Pucci B¹, Rossi A¹, Rocchi R¹ (¹Italy, ²United States)

p586 Clinical language fMRI with real-time monitoring in temporal lobe epilepsy: validation of on-line processing methods

Williams EJ, Stretton J, Centeno M, Bartlett P, Burdett J, Symms M, Koeppe M, Duncan JS, Micalef C (United Kingdom)

p587 Different functional connectivity of thalamo-hippocampus circuitry in temporal lobe epilepsy with and without hippocampal sclerosis: a resting-state fMRI study

Chen Q¹, Lv S¹, Zou L¹, Gong Q¹, Dai G², Xue X¹, Zhou D¹ (¹China, ²United States)





WEDNESDAY 31ST AUGUST 2011

13:00-14:30 Poster Session: Epilepsy surgery I

Poster Area (Botticelli Room)

- p588 Surgical and developmental outcome after callosotomy for West syndrome without MRI lesion**
Baba H, Toda K, Ono T (Japan)
- p589 Paediatric epilepsy surgery in Russia: a 5-year experience from a single institution**
Melikyan A, Arkhipova N, Kazaryan A, Golovtsev A, Pronin I, Grinenko O, Kotelnikova T, Bucharin E, Buklina S, Nagorskaya I, Kozlova A (Russian Federation)
- p590 Seizure and developmental outcomes of epilepsy surgery in children with epileptic encephalopathy**
Lee Y-J, Kang H-C, Lee JS, Eom S, Kim DS, Kim HD (Korea, Republic of)
- p591 Life after hemispherectomy in childhood**
van Schooneveld M, Jennekens-Schinkel A, van Nieuwenhuizen O (Netherlands)
- p592 Epilepsy surgery in children with electrical status epilepticus during sleep**
García-Fernández M, Pérez-Jiménez MÁ, Fournier del Castillo MC, Serratosa JM, Villarejo-Ortega F (Spain)
- p593 Results of surgery for temporal lobe epilepsy in children**
Miserocchi A, Fuschillo D, Schiariti M, Gozzo F, Castana L, Cardinale F, Cossu M, Lo Russo G (Italy)
- p594 Glioneuronal tumors: clinical and cognitive outcome in a child and adolescent population**
Cesaroni E, Cappanera S, Passamonti C, Zamponi N (Italy)
- p595 Impact of surgery on quality of life and clinical improvement: results in the first eight surgical cases for drug resistant epilepsy in paediatric patients in El Salvador**
Valencia C, Muñoz M, Farela A, Martín-Menjívar A (El Salvador)
- p596 Evolution of functional hemispherectomy**
Al Thubaiti IE, Semari A, Baz S, Aotaibi F, Ymani S, Dalaan H (Saudi Arabia)
- p597 Evaluation of efficacy and safety of callosotomy in children with refractory seizures**
Pizarro-Castellanos M, Garza-Morales S, Chico-Ponce de Leon F, Gordillo F (Mexico)
- p598 Successful anatomical hemispherectomy in a 3.4kg infant with intractable epilepsy and hemimegalencephaly**
Pillai SC, Kern M, Murrell D, Dexter M, Gill D (Australia)


13:00-14:30 Poster Session: Epilepsy surgery II
Poster Area (Botticelli Room)

- p599 Cost savings after successful epilepsy surgery are significant but only apparent after 3 years**
Campbell P, Cunningham J, Heaney D (United Kingdom)
- p600 Seizure outcome in patients with epileptogenic lesions two years after epilepsy surgery in Sweden**
Rydenhag B, Malmgren K, Flink R (Sweden)
- p601 Is epilepsy surgery possible in countries with limited resources?**
Malla BR (India)
- p602 The use of anti-epileptic drugs ten years after resective epilepsy surgery: a population-based, prospective, longitudinal study**
Edelvik A, Rydenhag B, Flink R, Malmgren K (Sweden)
- p603 Socioeconomic status and hippocampal sclerosis in medically intractable epilepsy**
Baxendale S, O'Sullivan J, Heaney D (United Kingdom)
- p604 Beyond the learning curve in epilepsy surgery: the institutional and individual perspective**
Vilanilam GC, Abraham M, Menon G, Rao RM, Nair S, Radhakrishnan K (India)
- p605 Discontinuation of antiepileptic drugs following successful epilepsy surgery: a survey of Canadian epileptologists**
Tellez-Zenteno JF, Jette N, Burneo JG, Hernandez-Ronquillo L, Nguyen DK, Elizabeth D, Javidan M, Wiebe S (Canada)
- p606 Stress in parents of children with epilepsy before and after epilepsy surgery**
Braams O, Meekes J, Jennekens-Schinkel A, van Nieuwenhuizen O (Netherlands)
- p607 Natural course of medically refractory epilepsies: a retrospective study in patients with epilepsy surgery**
Dobesberger J, Rohrachner A, Höfler J, Unterberger I, Walsler G, Kuchukhidze G, Granbichler C, Ortler M, Trinka E (Austria)
- p608 Implications of surgery for refractory epilepsy in clinical and psychiatric outcomes**
Lobato FG, de Araujo Filho GM, Mazetto L, Martinez M, Caboclo LOS, Yacubian EMT, Centeno RS (Brazil)
- p609 To assess the children operated for drug resistant epilepsy from a large tertiary care centre in India**
Chandra S, Dagar A, Chaudhary K, Chauhan A, Bal C, Garg A, Sarkar C, Gaikwad S, Diwedi R, Madakasira PV, Gulati S, Paul V, Prasad K, Mohapatra AK, Singh M, Tripathi M (India)
- p610 Multi-modality investigation techniques in paediatric epilepsy surgery: a case review**
St. Pier KA, Pressler R, Harkness W, Chakraborty A, Cross H (United Kingdom)
- p611 Anti-epileptic drug reduction and seizure recurrence after epilepsy surgery**
Reynolds LF, Bell GS, de Tisi J, Duncan JS (United Kingdom)



13:00-14:30 Poster Session: Epilepsy surgery III

Poster Area (Botticelli Room)

p612 Is amygdalo-hippocampectomy as effective as standardized temporal lobectomy in “pure” mesial temporal lobe epilepsy with hippocampal sclerosis?

Wendling A-S¹, Staack AM¹, Julia S¹, Bilic S¹, Wisniewski I¹, Valenti M-P², Zentner J¹, Kehrli P², Chassagnon S², Davanture C², Hirsch E², Steinhoff BJ¹ (1Germany, 2France)

p613 What happens after seizure recurrence on antiepileptic drug withdrawal following successful anterior temporal lobectomy?

Jeyaraj KM, Rathore C, Dash GK, Radhakrishnan K (India)

p614 Amigdalo-hippocampotomy: surgical technique and results

Gonçalves-Ferreira A, Rainha-Campos A, Carvalho H, Morgado C, Bentes C, Peralta R, Pimentel J (Portugal)

p615 Impact of pre-surgical psychiatric disorders on the post-surgical clinical outcome in patients with refractory temporal lobe epilepsy and mesial temporal sclerosis submitted to surgical treatment

Centeno RS, Gomes FL, Mazetto L, Marinho MM, Carrete HJ, Filho GMA, Caboclo LOSF, Yacubian EMT (Brazil)

p616 Surgical treatment for drug-resistant temporal lobe epilepsy in neurophysiologic peculiarities aspect of early and late epileptogenesis

Kasumov V, Stepanova T, Kasumov R, Bersnev V, Kravtsova S, Sebelev K (Russian Federation)

p617 Temporal lobe epilepsy surgery outcome predictors

Baz S, Thubaiti I, Al Yamani S, Al Dhalaan H, Al Otaibi F, Al Semari A (Saudi Arabia)

p618 Correlation of interictal spikes, ictal onset pattern, propagation time and postoperative discharges with outcome in persons undergoing epilepsy surgery

Tripathi M, Aggarwal V, Singh P, Goel M, Garg A, Bal C, Gaikwad S, Sarkar C, Madakasira P, Singh M, Prasad K, Chandra S (India)

p619 Hypermotor seizures in temporal lobe epilepsy patients

Marusic P, Elisak M, Krijtova H, Tomasek M, Mohapl M, Zamecnik J (Czech Republic)

p620 Seizure outcome and pathological correlation in drug-resistant temporal lobe epilepsy surgically treated

Rubboli G, Giulioni M, Volpi L, Martinoni M, Riguzzi P, Marucci G, Marliani AF, Battaglia S, Bisulli F, Tinuper P, Calbucci F, Michelucci R (Italy)

p621 Successful temporomedial resection without removing the homolateral lesion in patients with double pathology: illustrative case reports

Rásonyi G, Jakus R, Erőss L, Szűcs A, Fabó D, Maglóczki Z, Kelemen A (Hungary)

p622 Post-traumatic pharmacoresistant temporal lobe epilepsy associated with cortical dysplasia and Dentate Gyrus neurospheres proliferation: case report

Martinoni M, Giulioni M, Rubboli G, Marucci G, Paradisi M, Calzà L, Pozzati E (Italy)



p623 Radio-anatomical localization of the foramen ovale electrode in children with temporal lobe epilepsy

Dorfmüller G, Rodrigo S, Fohlen M, Ferrand-Sorbets S, Blustajn J, Taussig D, Bulteau C, Delalande O (France)

p624 Choice of adequate surgical strategy in treatment of temporal lobe epilepsy

Kostiuk K, Tsybaliuk V, Medvedev Y, Popov A, Zynkevich Y, Dichko S, Kanajkyn O (Ukraine)

p625 Temporomandibular joint disorders in surgical MTLE patients: a prospective evaluation between pre and post operative status

Costa AL, Yasuda CL, de Oliveira E, Tedeschi H, Cendes F (Brazil)



13:00-14:30 Poster Session: Epilepsy surgery IV

Poster Area (Botticelli Room)

- p626 Outcome following resective surgery and its determinants in drug resistant posterior cortex epilepsy (PCE)**
Wattamwar PR, Shivakumar R, Radhakrishnan A, Sarma S, Radhakrishnan K (India)
- p627 Individually tailored epilepsy surgery in strictly extra-temporal localisation: outcome predictors in a population of 37 cases with epilepsy onset under 12 years**
Ljawa A, Francione S, Tassi L, LoRusso G, Cossu M, Mai R, Fontana E, DallaBernardina B (Italy)
- p628 Medically-intractable parietal lobe epilepsy: experience from a large comprehensive Canadian epilepsy program**
Burneo JG, Steven DA, McLachlan RS, Parrent A (Canada)
- p629 Reoperation for failed epilepsy surgery**
Mareckova J, Prochazka T, Vojtech Z, Kalina M, Dbaly V, Sroubek J (Czech Republic)
- p630 Surgical treatment of the patients with rasmussen's encephalitis - 20 cases**
Luan G, Guan Y (China)
- p631 Surgical outcome and prognostic factors of frontal lobe epilepsy surgery**
Alsemani AM, Althubaiti I, Alotaibi F, Aldalaan H, Al-Yamani S, Baz S (Saudi Arabia)
- p632 Parietal lobe epilepsy: great imitator among focal epilepsies**
Ristic AJ^{1,2}, Alexopoulos A², So N², Wong C^{2,3}, Najm I² (1Serbia, 2United States, 3Australia)
- p633 Outcome of extra temporal epilepsy surgery and hemispherectomy after evaluation with a non-invasive protocol**
Panigrahi M, Jayalakshmi S, Puspahata S, Rao S (India)
- p634 Predictors of seizure outcome following resective surgery for drug resistant epilepsy associated with focal gliosis**
Dash GK, Rathore C, Jeyaraj KM, Radhakrishnan K (India)
- p635 Postoperative long-term outcome in 203 patients with focal cortical dysplasia**
Fausser S, Essang C, Bast T, Schubert S, Steinhoff BJ, Strobl K, Zentner J, Schulze-Bonhage A (Germany)
- p636 Treatment with everolimus reduces seizure activity and alters white matter microarchitecture in patients with tuberous sclerosis complex (TSC)**
Franz DN, Care MM, Holland-Bouley K, Agricola K, Tudor C, Mangeshkar P, Weber-Byars A, Sahnoud T, Tillema J, Krueger DA (United States)
- p637 Supplementary motor area surgical series of patients presenting with lesional/non lesional intractable epilepsy**
Alonso Vanegas MA, Buentello-Garcia RM, Castillo-Montoya C, Senties-Madrid H, San Juan-Orta D, Brust-Mascher E, Rubio-Donnadieu F (Mexico)


13:00-14:30 Poster Session: Epilepsy surgery V
Poster Area (Botticelli Room)

p638 Intraoperative ultrasound elastography is superior to MRI at identifying epileptogenic areas
Chakraborty A, Uff C, Harkness W (United Kingdom)

p639 Can Wada test predict verbal memory outcome after anterior temporal lobectomy in patients with mesial temporal lobe epilepsy?
Nishimoto T, Iida K, Kagawa K, Kiura Y, Hashizume A, Hanaya R, Arita K, Kurisu K (Japan)

p640 Task specific stereo-EEG changes during pre-surgical neuropsychological evaluation of patients with focal pharmacoresistant epilepsy
Pastori C, Francione S, Gnatkovsky V, Pelle F, de Curtis M (Italy)

p641 Surface based individual asymmetry with statistical parameter mapping (SPM) analysis to 18-F-FDG PET metabolic abnormalities in epilepsy surgery patients
Kwon HE, Kim JJ, Park HJ, Kang HC, Kim HD, Kwon H (Korea, Republic of)

p642 Multiple subpial transection for epileptogenic foci associated with language area detected by electrical cortical stimulation
Hoshida T, Kawata K, Hirabayashi H, Tamura K, Nakase H (Japan)

p643 Material-specific memory outcomes after surgery for intractable temporal lobe epilepsy
Giummarra J, Bowden SC, Cook M, Murphy M (Australia)

p644 Postoperative neuropsychological evaluation in patients with temporal lobe epilepsy in Argentina
Oddo S, Solis P, Consalvo D, Seoane E, D'Alessio L, Medel N, Kochen S (Argentina)

p645 Provocative memory test for amygdalohippocampectomy using depth electrodes implanted in the entorhinal area
Tani N, Kishima H, Ali M, Oshino S, Hosomi K, Hui Ming K, Maruo T, Saitoh Y, Hirata M, Kato A, Kazui H, Yoshida T, Yoshimine T (Japan)

p646 Verbal memory decline related to temporal lobe resection for epilepsy is less frequent 10 than 2 years postoperatively
Malmgren K, Samuelsson H, Engman E, Andersson Roswall L (Sweden)



13:00-14:30 Poster Session: Epilepsy surgery VI

Poster Area (Botticelli Room)

p647 Reliability of equivalent current dipole cluster on magnetoencephalography: presurgical evaluation for intractable epilepsy

Kagawa K, Iida K, Hashizume A, Nishimoto T, Kiura Y, Hanaya R, Sugiyama K, Arita K, Kurisu K (Japan)

p648 Integrating magnetic-source and functional imaging for neuronavigation of electrode implantation and resection of focal cortical dysplasia in patients with intractable epilepsy

Iida K, Kagawa K, Nishimoto T, Hashizume A, Kiura Y, Hanaya R, Arita K, Kurisu K (Japan)

p649 Intracranial EEG signal processing: a pilot study

Jahodova A¹, Krsek P¹, Marusič P¹, Jezdik P¹, Janca R¹, Cmejla R¹, Kudr M¹, Jiruska P², Komarek V¹ (1Czech Republic, 2United Kingdom)

p650 Reconstructing the optic tract prior to an anterior temporal lobe resection using fMRI-seeded DTI tractography

Ossenblok P¹, Tax C¹, Colon A¹, Jacobs C², Duits R¹, Wagner L¹, ter Haar Romeny B¹, Vilanova A¹ (1Netherlands, 2Germany)

p651 Disappearance of epileptic discharges and seizures with cryoprobe in rat brains

Tokiwa T, Grigorievich ZL, Fujioka H, Inoue T, Fujii M, Ishizuka S, Owada Y, Suzuki M, Yamakawa T (Japan)

p652 Focus detection in intractable neocortical epilepsy using magnetoencephalography

Murakami H, Masuda H, Shirozu H, Kakita A, Takahashi H, Kameyama S (Japan)

p653 Minimally-invasive ECoG recording using the novel subdural electrodes manipulated by a shape memory alloy guidewire

Yamakawa T, Yamakawa T, Inoue T, Aou S, Ishizuka S, Fujii M, Suzuki M (Japan)

p654 Application of intraoperative CT angiography for implantation of SEEG electrodes in intractable partial epilepsy patients

Mirzayan MJ^{1,2}, von Roden M², Najm IM², Alexopoulos A², Bulacio J², Schneider F², Bingaman W², Gonzalez-Martinez J² (1Germany, 2United States)

p655 Synchrotron-generated interlaced microbeams as an antiepileptic therapy: proof of concept in a rodent genetic model

Pouyatos B¹, Serduc R¹, Chipaux M¹, Chabrol T¹, Braüer-Krisch E¹, Nemoz C¹, David O¹, Bernard H¹, Mathieu H¹, Guillemain I¹, Deransart C¹, Laissue JA², Estève F¹, Charpier S¹, Depaulis A¹ (1France, 2Switzerland)

p656 Identifying seizure onset zone and epileptic networks with the dynamic imaging of coherent sources

Elschoff L, Muthuraman M, Wiegand G, Raethjen J, Stephani U, Siniatchkin M (Germany)

p657 Navigation guided less invasive selective amigdalohippocampectomy via inferior temporal gyrus

Kishima H, Oshino S, Hirata M, Tani N, Hosomi K, Maruo T, Saitoh Y, Kato A, Yoshimine T (Japan)

p658 Utility of FDG-PET co-registration with 3 Tesla MRI in presurgical evaluation of children with focal cortical dysplasia

Pérez Jiménez Á, Alvarez-Linera J, Maldonado A, García-Fernández M, Villarejo F (Spain)

p659 Simultaneous dense array EEG and intracranial ECoG: interictal spike detection and localization in temporal lobe epilepsy

Yamazaki M¹, Fujimoto A¹, Tucker DM², Yamamoto T¹ (1Japan, 2United States)


13:00-14:30 Poster Session: Epilepsy surgery VII
Poster Area (Botticelli Room)

- p660 Intraoperative neurophysiological responses in epileptic patients submitted to hippocampal and thalamic deep brain stimulation**
Cukiert A, Burattini J, Lima A, Cukiert C, Baise C, Argentoni-Baldochi M, Forster C, Mello V (Brazil)
- p661 Microlesional effect after DBS electrode insertion in patients with refractory epilepsy: "honeymoon" period**
Cukiert C, Cukiert A, Burattini J, Lima A, Argentoni-Baldochi M, Baise C, Forster C, Mello V (Brazil)
- p662 Habitual seizures induced by DBS in a patient with refractory epilepsy: case report**
Baise C, Cukiert A, Burattini JA, Lima A, Cukiert C, Forster C, Argentoni-Baldochi M, Mello V (Brazil)
- p663 Vagal nerve stimulation for drug-resistant epilepsy: the difficult task to assess the results**
Colicchio G, Conforti G, Fuggetta MF, Lucantoni C, Papacci F, Meglio M (Italy)
- p664 Right-sided VNS therapy: simple and effective option**
Rainha-Campos A, Gonçalves-Ferreira A, Pimentel J (Portugal)
- p665 Extraventricular approach to the anterior nucleus of thalamus for epilepsy treatment**
Rainha-Campos A, Herculano-Carvalho M, Pimentel J, Gonçalves-Ferreira A (Portugal)
- p666 Vagus nerve stimulation for epilepsy: quality of life and patients' satisfaction**
Al Otaibi F, Baz S, Thubaiti I, Abujaber A, Al semari A (Saudi Arabia)
- p667 Deep brain stimulation of the anterior nucleus of the thalamus for refractive epilepsy: experience in the first two patients**
França S, Ribeiro J, Gago M, Carvalho M, Pires I, Linhares P, Costa J, Vaz R, Garret C (Portugal)
- p668 Combined application of electrocorticogram and electrical cortical stimulation in parietal epilepsy surgery**
Wang Z (China)
- p669 Epilepsy surgery in children with tuberous sclerosis, epileptic spasms and multiple seizure foci**
Mohamed A, Freeman JL, Bailey CA, Maixner WJ, Harvey AS (Australia)



13:00-14:30 Poster Session: Paediatric epileptology X Poster Area (Botticelli Room)

- p670 Efficacy and safety of add-on lacosamide in children with refractory epilepsy**
García-Peñas J-J, Ruiz-Falcó ML, Arteaga R, Gutiérrez-Solana LG, Duat A, Herranz JL (Spain)
- p671 Antiepileptic treatment of symptomatic focal forms of epilepsy in children with congenital cerebral malformations**
Milovanova Q (Russian Federation)
- p672 Clinical and electroencephalographic characteristic of patients with panayiotopoulos syndrome**
Jovanovic M¹, Jovic Jakubi B^{1,2}, Tosic T¹, Ilic Tasic S¹, Stankovic Jankovic D¹ (1Serbia, 2Kuwait)
- p673 Parental concerns about using buccal midazolam for prolonged seizures**
Malphrus AD (United States)
- p674 Can carbamazepine induced hyponatremia in epileptic children?**
Sano F, Kanemura H, Yamashiro D, Ohyama T, Sugita K, Aihara M (Japan)
- p675 Dynamic model changes of three times interictal SPECT of epilepsy patients with long-term control with AEDs and its clinical significance (63 cases)**
Wang W, Song W-J, Dang X-L (China)
- p676 Outcome predictors in children with different types of epilepsy partialis continua: the Belgrade cohort study**
Kravljjanac R, Djuric M, Jovic N, Pekmezovic T (Serbia)
- p677 Steroid pulse therapy as an effective treatment for refractory epilepsy in children with glutamate receptor (GluR) antibodies**
Yasumoto S, Ihara Y, Fujita T, Tomonoh Y, Ninomiya S, Nakamura N, Ideguchi H, Inoue T, Takahashi Y, Hirose S (Japan)
- p678 Efficacy of corticosteroids in the management of refractory non convulsive status epilepticus (NCSE) in children**
Fernando S, Dharmaratne KS, Gamage R (Sri Lanka)
- p679 Insulin-dependent diabetes mellitus and epilepsy: a study of three cases**
Gniatkowska Nowakowska A, Gniatkowska I (Poland)
- p680 Two open-label, single-arm, multi-center, safety, tolerability and pharmacokinetic studies of intravenous levetiracetam in children (>1 month to 16 years old) with epilepsy**
Weinstock A¹, Ruiz M², Gerard D³, Toublanc N³, Stockis A³, Dilley D¹, Schiemann J¹ (1United States, 2Mexico, 3Belgium)
- p681 Adjunctive therapy of rufinamide in lennox-gastaut syndrome**
Kim SH, Eun SH, Kang HC, Lee JS, Kim HD (Korea, Republic of)


13:00-14:30 Poster Session: Paediatric epileptology XI Poster Area (Botticelli Room)

- p682 Intelligence and verbal learning after hemispheric disconnection in children with epilepsy**
Bulteau C, Leunen D, Golouboff N, Fohlen M, Dorfmüller G, Delalande O, Jambaque I (France)
- p683 Functional connectivity in children with focal epilepsy**
van Diessen E, Stam CJ, Braun KPJ, van Nieuwenhuizen O, Jansen FE (Netherlands)
- p684 Disconnection as an alternative to partial or complete leboctomies**
Clarke D, Nussbaum N, Titus J, Lee M (United States)
- p685 Interictal electroclinical patterns in cortical dysplasia: study of 6 cases with schizencephaly**
Reyes P, Torres C, Ríos L, Witting S, Troncoso M (Chile)
- p686 Internalizing disorders and psychosocial functioning in the context of successful epilepsy surgery in children: implications for a comprehensive approach and a global perspective of treatment**
Liava A (Italy)
- p687 Cognitive outcome of temporal lobe resection in childhood with temporal lobe epilepsy**
Lee J, Kim JY, Kim HS, Nam SH, Lee M, Chang MS, Kim YK (Korea, Republic of)
- p688 Long-term evaluation of efficacy of vagus nerve stimulation (VNS) and on-demand magnet use in children and adolescents with epilepsy**
Majkowska-Zwolińska B, Zwoliński P, Roszkowski M (Poland)
- p689 Temporal epilepsy presenting as panic attacks: a successful epilepsy case**
Luis C, Calado E, Dias AI, Leal A (Portugal)
- p690 Epilepsy and malformations of cortical development**
Teleanu RI, Epure D, Teleanu DM, Vasile D, Sandu M (Romania)
- p691 Occult cerebral vascular malformations — causes of epilepsy before and after surgery**
Teleanu RI, Sandu M, Teleanu DM, Epure D, Vasile D (Romania)
- p692 Engel class outcome in children after implantation of the vagus nerve stimulator: an international experience**
Marti CE, Libenson MH (United States)



13:00-14:30 Poster Session: Paediatric epileptology XII Poster Area (Botticelli Room)

- p693 Neuroimaging findings and outcome of epilepsy in children with tuberous sclerosis**
Woo Y-J, Park S-M, Lee Y-J, Kim Y-O, Lee K-S (Korea, Republic of)
- p694 Profile of seizure precipitants in children with epilepsy: experience from a developing country**
Ray M, Sah JP, Singhi P (India)
- p695 Nocturnal hypermotor seizures in children with mucopolysaccharidosis: is nocturnal frontal epilepsy?**
Volzone A, Randazzo G, Costantini C, Casanova V, Bonanni P (Italy)
- p696 Clinical features and outcome of epilepsy in patients with hemiparetic cerebral palsy**
Ignjatovic P, Jovic N (Serbia)
- p697 Pattern sensitivity in patients affected by Dravet syndrome: use of blue lens**
Brogna C, Battaglia DI, Lettori D, Leo G, Del Re M, Dravet C (Italy)
- p698 Recurrence of childhood absence epilepsy as pyknolespy in adolescence**
Yozawitz EG, Scantlebury MH, Robinson J, Jehle RS, Moshé SL (United States)
- p699 Focal seizure semiology in the first three years of life**
Calligaris S, Morales M, Aberastury M, Silva W, Giagante B, Maxit C, Agosta G (Argentina)
- p700 Computerised video analysis and quantification of limb movements in automation of seizure detection in children**
Chan D, Lu H, Eng H-L, Mandal B, Ng Y-L (Singapore)
- p701 Prognostic value of combined use of electroencephalogram and neuro-imaging in infants with hypoxic-ischemic encephalopathy**
Cosic-Cerovac N, Jovic N (Serbia)
- p702 The diagnostic value of synchronous tilt-table test and video-EEG monitoring in sudden loss of consciousness and tonus**
Gökben S, Yılmaz S, Serdaroğlu G, Levent E, Akçay A, Tekgül H, Özyürek R (Turkey)
- p703 Detection systems and algorithms for motor seizures in paediatric patients with epilepsy**
Van de Vel A, Cuppens K, Bonroy B, Milosevic M, Krols R, Gijsemans L, Vervisch J, Lagae L, Van Huffel S, Vanrumste B, Ceulemans B (Belgium)
- p705 Ictal Apnoea in Infancy**
Cassidy DA, Courtney J, Tirupathi S (United Kingdom)


13:00-14:30 Poster Session: Paediatric epileptology XII Poster Area (Botticelli Room)

- p706 Dravet syndrome in Sweden: a survey of an epileptic syndrome**
Rosander C, Hallböök T (Sweden)
- p707 Infantile spasms (IS) in patient with down syndrome (DS): variable short-term response to the treatment**
Massaro MEL, Bongiorno L, Ferrea M, Hernández L, Villanueva M (Argentina)
- p708 A novel mutation in the ATP7A gene in a Korean patient with Menkes disease**
Lee R, Kim YH (Korea, Republic of)
- p709 Doose syndrome: natural history of a group of patients**
Damásio J, Ribeiro A, Chorão R, Santos M (Portugal)
- p710 Clinical variability in the expression of SCN1A gene**
Morillo P, Toledano M, Buenache R, Álvarez JA, Pedrera A, Lorenzo G (Spain)
- p711 Malignant migrating partial seizures in infancy (MMPSI): a follow-up study**
Delignieres A, Nabbout R (France)
- p712 Lennox-Gastaut syndrome, a variant in clinical and electrographical features among Saudi population**
Alhameed M (Saudi Arabia)
- p713 Benign familiar neonatal seizures: a three generations family**
Novak V, Kuncikova M, Kovarova M, Podhoranyova Z (Czech Republic)
- p714 Optimized individual AED protocols in patients with Dravet syndrome using electronic documentation with EpiVista®**
Boor R, Doege C, Dreiwes C, von Spiczak S, Stephani U (Germany)
- p715 Perioral myoclonia with absence status: a rare syndrome**
Batra A, Gupta M, Khwaja GA, Chowdhury D, Patidar Y (India)
- p716 Malignant migrating partial seizures in infancy or coppola-dulac syndrome**
Kholin A (Russian Federation)
- p717 Severe myoclonic epilepsy in infancy: first functional MRI results**
Moehring J, von Spiczak S, Galka A, Moeller F, Boor R, Jansen O, Stephani U, Siniatchkin M (Germany)
- p718 The long-term evolution and outcome of Landau-Kleffner syndrome in children in a tertiary referral epilepsy center**
Geerts Y, Goudswaard J, Drost A (Netherlands)



13:00-14:30 Poster Session: Paediatric epileptology XIV Poster Area (Botticelli Room)

- p719 Impact of infantile spasms on cognition: a multi-centre randomized controlled trial of flunarizine as add-on therapy**
Sauerwein HC, Bitton JY (Canada)
- p720 Levetiracetam monotherapy in children and adolescence with epilepsy in Korea**
Kim WS, Sim GY (Korea, Republic of)
- p721 Dissociative disorder secondary to absence seizures in a child resolved through association with valproic acid and ethosuximide**
Cacudi M, Paloscia C, De Rinaldis M, Gennaro LA, Losito L, Cefalo F, Trabacca A (Italy)
- p722 Single oral dose of levetiracetam as a fast, effective and safe treatment for photosensitive epilepsy in children**
Rios-Pohl L, Solari-Bardi F, Varela-Estrada X, Campos -Puebla M, Lobos-Donoso C, Olate-Rosello L (Chile)
- p723 The electroclinical features and treatment of myoclonic-aticonic epilepsy**
Zhang Y-H, Deng J, Liu X-Y, Yang Z-X, Qin J, Wu X-R (China)
- p724 Epileptic encephalopathy without suppression burst with a deletion of MUNC18 gene: a long term response of infantile spasms to Zonisamide**
Chemaly N, Cormier Daire V, Bach N, Nabbout R (France)
- p725 Electroclinical pattern in children affected by cardiofaciocutaneous syndrome with germline mutation in BRAF**
Veltri S, Gambardella ML, Battaglia DI, Lettori D, Perrino F, Alfieri P, Leoni C, Leo G, Dassi P, Dravet C, Zampino G, Mariotti P (Italy)
- p726 Treatment and prognosis of the severest early infantile epileptic encephalopathies: can the patients be prevented to be bedridden?**
Sugai K, Nakagawa E, Komaki H, Saito Y, Sasaki M, Takahashi A, Kaido T, Kaneko Y, Otsuki T (Japan)
- p727 Treatment of children with resistant epilepsy**
Devilat-Barros JM, Gomez V, Buron V, Carrasco X (Chile)
- p728 Antiepileptic treatment of symptomatic focal forms of epilepsy in children with schizencephaly**
Chernysheva NV, Milovanova OA, Pykov MI, Kalinina LV (Russian Federation)
- p729 Anticonvulsive treatment peculiarities in patients with Angelman's syndrome**
Pykov M, Milovanova O, Kalinina L, Chernysheva N (Russian Federation)


13:00-14:30 Poster Session: Neuropathology
Poster Area (Botticelli Room)
p730 In utero knock-down of the epilepsy/speech related protein *Srpx2* causes altered development of the rat brain cortex

Cillario J, Bruneau N, Salmi M, Buhler E, Zimmer C, Massacrier A, Watrin F, Cloarec R, Cardoso C, Durbec P, Muscatelli-Bossy F, Represa A, Szepetowski P (France)

p731 Different pathophysiology of focal cortical dysplasia IIA and IIB: specific neocortical-layer marker expression

Sakakibara T, Saito T, Otsuki T, Takahashi A, Kaneko Y, Kaido T, Saito Y, Nakagawa E, Sugai K, Sasaki M, Goto Y-I, Itoh M (Japan)

p732 Cytoarchitectural abnormalities of the dentate gyrus in refractory medial temporal lobe epilepsy

Silva AV, Silva LRP, Bando SY, Alegro MC, Amaro Jr E, Castro LHM, Hung-Tzu W, Moreira-Filho CA (Brazil)

p733 Morphometric parameters and clinical data in temporal lobe epilepsy associated with hippocampal sclerosis: a comparative study

Pimentel-Silva LR, Bando SY, Alegro MC, Amaro Jr E, Castro LHM, Hung-Tzu W, Moreira-Filho CA, Silva AV (Brazil)

p734 Neuropathologic study of resected brain tissue from patients with infantile spasms who received corpus callosotomy and subsequent surgery

Toda K, Baba H, Ono T (Japan)

p735 Is hemimegalencephaly a fetal tauopathy?

Flores-Sarnat L¹, Sarnat HB¹, Crino PB², Hader W¹, Bello-Espinosa L¹ (1Canada, 2United States)

p736 Neurofibrillary tangle pathology and braak staging in chronic epilepsy: a post mortem study

Thom M, Narkiewicz M, Martinian L, Phadke R, Thompson P, Koeppe M, Caboclo L, Claudia C, Sanjay S (United Kingdom)

p737 Mitochondrial ultrastructural alterations of endothelium in infantile mitochondrial cytopathies: muscle biopsy and implications for epilepsy

Sarnat HB, Flores-Sarnat L, Khan A (Canada)



13:00-14:30 Poster Session: Neuropsychology/psychiatry III Poster Area (Botticelli Room)

- p738 Cognitive and affective functions in adjunctive therapy with lacosamide**
Graf W, Kurzbuch K, Kerling F, Pauli E, Kasper BS, Stefan H (Germany)
- p739 A critical review of clinical trials investigating the effects of antiepileptic drugs on cognition in epileptic children**
La Noce A (Italy)
- p740 Working memory binding in epilepsy patients who underwent unilateral medial temporal lobectomy**
Hendriks MPH, Bouman Z, van Geldorp B, Aldenkamp AP, Kessels RPC (Netherlands)
- p741 Longitudinal study of postoperative changes in emotional recognition and social cognition in temporal lobe epilepsy patients**
Kotaskova J, Marusic P, Kajukova B, Javurkova A (Czech Republic)
- p742 A multicenter comparative trial of zonisamide and topiramate as monotherapy in epilepsy patients: safety for cognitive function**
Kim JE, Lee JJ, Lee SD, Lee SJ, Park SP (Korea, Republic of)
- p743 Memory for morphed faces after temporal lobectomy in children**
Meekes J, Braams O, Jennekens-Schinkel A, van Nieuwenhuizen O (Netherlands)
- p744 Quality of life outcome across years after anterior temporal lobectomy for drug resistant temporal lobe epilepsy**
Alexander A, Radhakrishnan A, Varma R, Radhakrishnan K (India)
- p745 Effects of eslicarbazepine on cognition in patients with focal epilepsy**
Buschmann F, Metternich B, Wagner K, Schulze-Bonhage A (Germany)
- p746 Exploring cognitive functions during insular stimulation by means of intracerebral electrodes in patients with drug-resistant epilepsy**
Cascardo B, Pelle F, Scarpa P, Piroddi C, Bottini G (Italy)
- p747 Impact on autobiographical memory of unilateral temporal resection for control of intractable epilepsy**
Voltzenlogel V, Despres O, Hirsch E, Vignal J-P, Manning L (France)
- p748 Memory performance after amygdalohippocampal deep brain stimulation in patients with medically refractory temporal lobe epilepsy**
Miatton M, Van Roost D, Thiery E, Carrette E, Van Dycke A, Meurs A, Vonck K, Boon P (Belgium)
- p749 Neuropsychological study in children with symptomatic Parieto-occipital epilepsy treated by surgery**
Losito EM, Battaglia D, Chieffo D, Lettori D, Leo G, Ranalli D, Tamburrini G, Caldarelli M, Di Rocco C, Guzzetta F (Italy)
- p750 Dose-dependent gabapentin-induced sexual dysfunction**
Kaufman KR, Struck P (United States)


13:00-14:30 Poster Session: Neuropsychology/psychiatry IV Poster Area (Botticelli Room)

- p751 Neuropsychological assessment in children with rolandic epilepsy**
Neri ML, Guimarães CA, Oliveira EPM, Medeiros LL, Guerreiro MM (Brazil)
- p752 Attention difficulties in children with absence epilepsy referred to a tertiary clinic**
Stendevad P (Denmark)
- p753 Cognitive and adaptive findings in paediatric epilepsy**
Cappelletti S, Gentile S, Fusco L, Specchio N, Di Ciommo V, Caviglia S, Secco D, Capuzzo F, Vigevano F (Italy)
- p754 Epileptiform activity, related to autistic disorders**
Zenkov L (Russian Federation)
- p755 The Penelope syndrome (1): memory consolidation in children with sleep-induced epileptiform activity (ESES)**
Bjørnæs H¹, Heminghyt E¹, Brager-Larsen L¹, Larsson PG¹, Bakke KA¹, Eriksson A-S² (1Norway, 2Sweden)
- p756 Neuropsychological assessment of executive functions in children and adolescents with frontal lobe epilepsy**
Verche E, Cairós M, Marrero-Abrante R, Hernández S (Spain)
- p757 Childhood epilepsy: identifying the neuropsychological profile and speech intervention outcomes in a rare case of Landau Kleffner syndrome- from diagnosis to five year follow up**
Scholes A, Fleming M, Harrison B (Australia)
- p758 Right temporal lobe epilepsy and social cognition in adolescents**
Andelman F, Kazenelbogen L, Kramer U, Schweiger A, Fried I (Israel)
- p759 Correlation between language impairment and locomotion problems in children with Rolandic epilepsy**
Overvliet G, Aldenkamp A, Klinkenberg S, Nicolai J, Vles J, Besseling R, Backes W, Hofman P, Hendriksen J (Netherlands)
- p760 Identifying anxiety disorders in children with epilepsy**
Jones JE, Fujikawa M, Blocher J, Almane D, Jackson D, Seidenberg M, Hermann BP (United States)
- p761 Pseudoseizures monitoring in paediatric population**
Rodriguez Clavijo BD, Vasquez R (Colombia)
- p762 Does cognitive functioning influence on epilepsy occurrence in children diagnosed with ADHD by the time of ADHD assessment**
Einarsdottir S, Lorange M, Socanski D (Norway)
- p763 Rolandic spikes and Benign epilepsy with centrotemporal spikes (BECTS) in children diagnosed with attention deficit/hyperactivity disorder (ADHD)**
Socanski D, Herigstad A (Norway)
- p764 Certain peculiarities of physiological functioning in children while benign epileptiform discharges of childhood are being formed**
Zaytsev DE, Titov NA, Lutin DV, Eletszkova LV (Russian Federation)



13:00-14:30 Poster Session: Neuropsychology/psychiatry V Poster Area (Botticelli Room)

- p765 Biological factors in epilepsy causing intelligence deficit**
González Pal S, Fabelo Roche R, González Delgado E, Iglesias Moré S (Cuba)
- p766 Auditory and visual naming in patients with lateralized refractory epilepsy: initial experience at Ghent University Hospital**
De Vogelaere F, Miatton M, Meurs A, Vonck K, Boon P (Belgium)
- p767 Neuropsychological impairment in patients with early onset nocturnal frontal lobe epilepsy**
Mostacci B, Bianchi F, Poda R, Bisulli F, Provini F, Oppi F, Naldi I, Licchetta L, Posar A, Stipa C, Gallassi R, Tinuper P (Italy)
- p768 Neuropsychological characteristics of Georgian-speaking persons with epilepsy of different etiology**
Tchintcharauli T, Mamukadze S, Gagoshidze T, Kasradze S, Kvernadze D, Karaulashvili A (Georgia)
- p769 Spectrum of ictal aphasia in temporal lobe epilepsy**
Trebouchon A, Mcgonigal A, Gavaret M, Carron R, Chauvel P, Bartolomei F (France)
- p770 Influence of clinical and demographic variables on short-term visual memory in patients with epilepsy**
Gagoshidze T, Mikiashvili T, Kasradze S (Georgia)
- p771 Cognitive deficits after a first unprovoked seizure: preliminary results**
Rühle N, Schley A, Pohley I, Benecke R, Rösche J (Germany)
- p772 PLEDs on EEG during unilateral spatial neglect: a case study**
Ito Y, Motooka H, Yasumoto S, Ishida S, Uchimura N (Japan)
- p773 Exploring the dimensionality of digit span**
Petrauskas VM, Bowden S, Bardenhagen FJ, Meade C, Simpson L (Australia)
- p774 Neuropsychological testing in generalized vs frontal epilepsies**
Burriel L, Carrasco S, Gudín M, Dominguez Bertalo J, Alvarez MJ, Vaamonde J (Spain)



13:00-14:30

Poster Session: Social issues / nursing I

Poster Area (Botticelli Room)

p775 Quality of life in epilepsy subjects and their care givers — a study of 82 subjects

Mehndiratta MM, Alam A, Pandey S (India)

p776 Epilepsy in the elderly: the impact of epilepsy on daily living, fears and overall quality of life

May TW, Pfaefflin M, Brandt C, Fueratsch N, Kerling F, Schmitz B, Wandschneider B, Kretz R, Runge U, Geithner J, Karakizikis H, Rosenow F, Stefan H (Germany)

p777 The impact of seizure control and adverse events of antiepileptic drugs on quality of life in patients with newly diagnosed epilepsy: a 1-year observational study

Lim H-W, Park S-P (Korea, Republic of)

p778 Employment outcomes after resective surgery in Korean patients with temporal lobe epilepsy

Cho Y-J, Lee BI, Chang JW, Park S, Chang JH, Lee MK, Ko ES, Heo K (Korea, Republic of)

p779 Managing epilepsy well: self-management needs assessment

Fraser RT, Johnson EK, Miller JW, Temkin N, Ciechanowski P, Chaytor N, Caylor L, Barber J (United States)

p780 The impact of epilepsy on the quality of life of the adult population in Ireland

Cunningham D (Ireland)



13:00-14:30 Poster Session: Social issues / nursing II Poster Area (Botticelli Room)

- p781 The attitudes and public awareness towards epilepsy in Georgia**
Okujava N¹, Gzirishvili N¹, Kasradze S¹, Lomidze G¹, Toidze O¹, de Boer HM², Dua T³, Sander JW⁴
(¹Georgia, ²Netherlands, ³Switzerland, ⁴United Kingdom)
- p782 Clinical and socio-cultural aspects of epilepsy in Sierra Leonean Africans**
Lisk R¹, Moses F², Jalloh A², Mansaray T²
(¹United Kingdom, ²Sierra Leone)
- p783 Is attitude towards epilepsy changing?**
Haldar A, Ganguly M, Chakraborty D (India)
- p784 A survey of public awareness, attitudes towards and understanding of epilepsy in Bulgaria**
Derelieva L, Djalev L, Sabeva V (Bulgaria)
- p785 Factors influencing medication persistence among patients with convulsive epilepsy in rural areas of west China: A prospective study**
Zhang Q, Liu L, Zhou D, Li H, Zhu C (China)
- p786 What happens in your brain when you see an epileptic seizure?**
Fernandes PT, Silva EL, Castellano G, Li LM (Brazil)
- p787 Together we are stronger — collaboration between IBE and ILAE local chapters in arising awareness about epilepsies**
Tervonen S, Lindström K, Kälviäinen R (Finland)
- p788 Email publication “Epilepsy Disaster” during the first 2 weeks of the catastrophic earthquake and tsunami in the Tohoku district, Japan**
Nakasato N, Jin K, Iwasaki M, Tominaga T (Japan)
- p789 Tumor: a graphic novel representation of glioblastoma multiforme and multiple seizures types**
Branco Germiniani FM (Brazil)


13:00-14:30 Poster Session: Social issues / nursing III Poster Area (Botticelli Room)

- p790 An investigation into the place of music in the field of epileptic art**
Stoker GW (United Kingdom)
- p791 Epilepsy and the olympics**
Spensley TS (United Kingdom)
- p792 Death and resurrection: the paradigm of epilepsy in Christian painting**
Mann MW (France)
- p793 Hand over hand: images of athletes and people with epilepsy**
Morris-Coole C, Shorvon S, Smith P (United Kingdom)
- p794 Changes in knowledge of epilepsy and attitudes toward people with epilepsy in adolescents in Croatia**
Sruk A, Ivaković A, Zobić I, Bielen I (Croatia)
- p795 Epilepsy and the school environment**
Daub-Sychra A, Malmberg L-E (United Kingdom)
- p796 The managing epilepsy well (MEW) network**
Dilorio C, Fraser R (United States)
- p797 Hippocratic corpus: on the sacred disease**
Krommyda M, Tsiptsios D, Deretzi G, Rudolf J, Kyriazopoulou E, Tsiptsios I (Greece)
- p798 Why are epileptic people stigmatized, rejected from schools and consequently deprived of decent education while Special Educational Needs students are accepted? Are cognitive problems easier to accommodate in schools than epilepsy seizures?**
Al Assi N (Lebanon)



13:00-14:30 Poster Session: Drug Therapy V

Poster Area (Botticelli Room)

p799 Efficacy and safety of perampanel as adjunctive therapy in adolescents with refractory partial-onset seizures: analysis of a randomized, double-blind, placebo-controlled phase III study

Villanueva V¹, Rozentals G², Yang H³, Squillacote D³, Zhu J³, Laurenza A³ (1Spain, 2Latvia, 3United States)

p800 Efficacy and tolerability of lacosamide as add-on therapy in patients with treatment-resistant epilepsy. Preliminary experience at a tertiary centre in Cyprus

Kkolou E, Flourentzou A, Malikkidou A, Papacostas SS (Cyprus)

p801 Efficacy and tolerability of zonisamida in outpatient clinical practice

Bertol Alegre V, Mauri Llerda JA, Sánchez Marín B, Tejero Juste C, Santos Lasaosa S, Capablo Liesa JL (Spain)

p802 A clinical study method used to evaluate the efficacy and safety of novel antiepileptic drug eslicarbazepine acetate in epileptic children with partial-onset seizures

Pinto R, Mota F, Moreira J, Nunes T, Soares-da-Silva P (Portugal)

p803 Efficacy and tolerability of add-on lacosamide in patients with childhood onset pharmacoresistant focal epilepsy

Moavero R, Specchio N, Capuano A, Vigeveno F, Curatolo P, Cusmai R (Italy)

p804 Efficacy and tolerability of lacosamide in add-on in children and young adult affected by drug-resistant focal epilepsy

Lettori D, Brogna C, Contaldo I, Rossi V, Gambardella ML, Leo G, Ranalli D, Mittica A, Battaglia DI (Italy)

p805 Effectiveness and tolerability of rufinamide in children and young adults with LGS: preliminary data in Korea

Lee EH, Yum M-S, Choi H-W, Chung S, Ko T-S (Korea, Republic of)

p806 Evaluation of efficacy, tolerability and adverse effects of the anti-epileptic drug levetiracetam in children and young adults

Goldberg-Stern H, Feldman L (Israel)

p807 Efficacy of add-on Rufinamide in children and young adults with drug-resistant focal epilepsy

Cusmai R, Capuano A, D'Aniello A, Di Pasquale F, Specchio N, Vigeveno F, Moavero R, Curatolo P, Coppola G (Italy)

p808 Efficacy, tolerability and quality of life in add-on treatment of Zonisamide in adults patients with epilepsy

Donati F, Kraemer G, Seek M, Moramarco F, Huebschen M (Switzerland)

p809 Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in epilepsy patients

Kim DW, Lee SK (Korea, Republic of)


13:00-14:30 Poster Session: Drug Therapy VI
Poster Area (Botticelli Room)

- p810 A multicenter trial of oxcarbazepine oral suspension monotherapy in children with partial epilepsy**
Eun S-H, Kim HD, Chung HJ, Kang H-C, Lee JS, Kim JS, You SJ, Moon HK, Lee Y-M, Kim DW, Suh ES, Kim J-Y, Lee J-Y, Eun B-L (Korea, Republic of)
- p811 Rufinamide add-on therapy in refractory generalized epilepsy in children**
Kim KJ, Kim SH, Chae JH, Hwang YS (Korea, Republic of)
- p812 Clinical experience of rufinamide in children with severe epilepsy**
Dahlin MG, Ohman I (Sweden)
- p813 Challenges in treatment of child pharmacoresistant epilepsy**
Teleanu RI, Epure D, Sandu M, Vasile D (Romania)
- p814 The incidence, features and risk predictors of antiepileptic drugs-induced cutaneous adverse drug reactions in Chinese population**
He N, Min F-L, Shi Y-W, Guo J, Liu X-R, Liao W-P (China)
- p815 A validated chiral liquid-chromatography tandem mass-spectrometry (LC-MS/MS) method for the separation and quantification of eslicarbazepine acetate and its metabolites in human plasma**
Fernandes-Lopes C, Loureiro AI, Bonifacio MJ, Wright LC, Soares-da-Silva P (Portugal)
- p816 Compliance to antiepileptic drugs in Egyptian epileptics**
Shafik MMH (Egypt)
- p817 Add-on lacosamide in brain tumor-related epilepsy; preliminary report: efficacy and tolerability**
Maschio M, Dinapoli L, Mingoia M, Sperati F, Pace A, Pompili A, Carapella CM, Vidiri A, Muti P (Italy)
- p818 The long-term efficacy and safety of levetiracetam in the tertiary epilepsy center**
Lee SK, Chu K, Moon HJ, Kang BS (Korea, Republic of)
- p819 Effects of levetiracetam as monotherapy on interictal abnormalities and background activity in adult focal epilepsy**
Prosperetti C^{1,2}, Romigi A¹, Pisani LR¹, Abbafati M¹, Marchi A¹, Izzi F¹, Marciani MG¹, Placidi F¹ (¹Italy, ²Switzerland)
- p820 Five years in the treatment of status epilepticus with intravenous levetiracetam**
Eue S, Grumbt M, Latsch A, Irimie A, Macieik-Zuj G, Müller M, Schulze A, Sepsí O (Germany)
- p821 Population pharmacokinetics of perampanel, a selective, non-competitive AMPA receptor antagonist, in patients with refractory partial-onset seizures participating in a randomized, double-blind, placebo-controlled phase III study**
Hussein Z¹, Critchley D¹, Ferry J², Laurenza A² (¹United Kingdom, ²United States)



13:00-14:30 Poster Session: Drug Therapy VII

Poster Area (Botticelli Room)

p822 The cognitive and language abilities of children exposed in utero to levetiracetam and sodium valproate: three-four years of age
Shallcross R, Bromley R, Irwin B, Morrow J, Baker G (United Kingdom)

p823 Academic achievement of Australian children prenatally exposed to antiepileptic drugs
Nadebaum C¹, Anderson V¹, Vajda F¹, Reutens D¹, Barton S¹, Wood A^{1,2}
(¹Australia, ²United Kingdom)

p824 Pregabalin kinetics in the neonatal period, and during lactation
Öhman I, de Flon P, Tomson T (Sweden)

p825 Second generation of antiepileptic drugs (AEDs) data from the Australian pregnancy register (APR)
Vajda F, Graham J, Roten A, Lander C, O'Brien T, Eadie M (Australia)

p826 Effect of topiramate and carbamazepine on sexual dysfunction in women with epilepsy
Ilic A (Serbia)

p827 Drug-induced metabolic acidosis: comparison induced of Topiramate and Zonisamide
Ishihara N, Natsume J, Yamamoto H, Yokoi S, Negoro T, Watanabe K (Japan)

p828 Cardiac safety and rates of sudden unexplained death in patients with epilepsy treated with retigabine (ezogabine)
Brickel N¹, Hall ST², DeRossett SE²
(¹United Kingdom, ²United States)

p829 Cognitive adverse events under topiramate in patients with epilepsy and intellectual disability — first results
Brandt C, Lahr D, Linneweber I, May TW (Germany)

p830 Temporal changes in plasma taurine level in patients with infantile spasms taking vigabatrin
Shimono KK, Azuma J, Ikeda T, Iwatani Y, Kimura SO, Tominaga K, Okinaga T, Taniike M, Nagai T, Ozono K (Japan)

p831 Long-term cognitive effects of treatment carbamazepine and valproate
IJff DM, Aldenkamp AP (Netherlands)

p832 An integrated data analysis from three placebo-controlled clinical studies on over-read electrocardiograms of epileptic patients treated with eslicarbazepine acetate: are there any effects on cardiac impulse transmission?
Gil-Nagel A¹, Lopes-Lima J², Ben-Menachem E³, Halasz P⁴, Versavel M⁵, Tripp K⁵, Gama H², Soares-da-Silva P²
(¹Spain, ²Portugal, ³Sweden, ⁴Hungary, ⁵United States)

p833 Effect of lamotrigine on motility and cervical mucus penetration of human sperm cells
Boxer M, Band G, Madgar I, Blatt I (Israel)


13:00-14:30 Poster Session: Drug Therapy VIII
Poster Area (Botticelli Room)

- p834 Effects of sodium valproate on neutrophils' oxidative metabolism and oxidant status in children with idiopathic epilepsy**
Zhang Y, Zhang M, Wang X, Yu Y, Jin P, Wang Y (China)
- p835 Effectiveness of lamotrigine in epilepsy patients: a single-center study**
Asano S, Takanashi S, Murakami H, Tanaka J, Fujii N, Ogawa A, Shinohara T, Watanabe T, Naito Y, Ueno T, Furuya K, Nakagomi T (Japan)
- p836 Adjunctive lacosamide for partial-onset seizures: preliminary outcomes from an epilepsy clinic**
Kelly K, Stephen LJ, Parker P, Brodie MJ (United Kingdom)
- p837 Randomized, double-blind, placebo-controlled phase III study of perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial-onset seizures: efficacy by seizure type**
*Krauss G¹, Wang X-F², Haldre S³, Yang H¹, Squillacote D¹, Zhu J¹, Laurenza A¹
 (¹United States, ²China, ³Estonia)*
- p838 Phase III evaluation of perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: effects on seizure freedom and other exploratory efficacy endpoints**
*Steinhoff BJ¹, French J², Kwan P³, Yang H², Squillacote D², Zhu J², Laurenza A²
 (¹Germany, ²United States, ³China)*
- p839 Seizure freedom on more than one antiepileptic drug**
Stephen LJ, Forsyth M, Kelly K, Brodie MJ (United Kingdom)
- p840 Efficacy of therapeutic changes in patients on antiepileptic polytherapy**
Hernando V, Huertas N, Diez A, Juarez N (Spain)
- p841 Sodium valproate treating epilepsy in rural communities in China: an efficacy and safety assessment**
Wang W, Wu J, Li S, Ru X, Zheng J, Zhu S (China)
- p842 Multi-centre service evaluation of lacosamide**
Colbeck KL, Kemp S, Goulding P, Geldard J, Wright E (United Kingdom)
- p843 Economic evaluation of adjunctive eslicarbazepine acetate in patients with refractory partial-onset seizures**
*Philips Z¹, Cope S¹, Maclaine G², Raper S²
 (¹Netherlands, ²United Kingdom)*
- p844 Effectiveness of Convulex in the treatment of neonatal seizures in children with congenital herpes-cytomegalovirus infection**
Myrzaliyeva B (Kazakhstan)
- p845 Treatment of infantile spasms with vigabatrin as the first drug**
Djuric M, Kravljanc R, Vucetic B, Kovacevic G (Serbia)



13:00-14:30 Poster Session: Drug Therapy IX

Poster Area (Botticelli Room)

p846 Effect of levetiracetam on pilocarpine- and cobalt-homocysteine- induced status rats
Park S, Kim J (Korea, Republic of)

p847 Effects of commonly-used antiepileptic drugs in the MTLE mouse: a model of mesial temporal lobe epilepsy to explore new treatments for drug-resistant epilepsies?
Bressand K, Deransart C, Delotterie D, Bouyssières C, Dumont C, Roche Y, Langlois M, Roucard C, Depaulis A (France)

p848 The metabolic profile of patients with epilepsy treated with eslicarbazepine acetate: integrated analyses of plasma lipid and glucose parameters, and distribution of related adverse events in placebo-controlled phase III clinical studies
Lopes-Lima J, Almeida L, Mota F, Nunes T, Soares-da-Silva P (Portugal)

p849 Effects of eslicarbazepine acetate in the amygdala kindling model of temporal lobe epilepsy
Soerensen J¹, Pekcec A¹, Potschka H¹, Soares-da-Silva P² (1Germany, 2Portugal)

p850 Effects of eslicarbazepine acetate and its metabolites in the corneal kindling mice model of epilepsy
Pekcec A¹, Potschka H¹, Soares-da-Silva P² (1Germany, 2Portugal)

p851 Inhibitory effects of eslicarbazepine acetate and its metabolites against neuronal voltage-gated sodium channels
Hebeisen S¹, Brady K¹, Konrad D¹, Soares-da-Silva P² (1Switzerland, 2Portugal)

p852 Effects of eslicarbazepine, R-licarbazepine and carbamazepine on NMDA and AMPA receptor-mediated currents
Bulling A¹, Hebeisen S¹, Konrad D¹, Soares-da-Silva P² (1Switzerland, 2Portugal)

p853 Eslicarbazepine and R-licarbazepine do not have effects on ion transmission through alpha1, alpha2, alpha3 and alpha5 GABA channels
Bonifacio MJ¹, Bulling A², Hebeisen S², Konrad D², Soares-da-Silva P¹ (1Portugal, 2Switzerland)

p854 The effects of eslicarbazepine, R-licarbazepine and carbamazepine on ion transmission through Kv7.2 channels
Soares-da-Silva P¹, Bulling A², Hebeisen S², Konrad D² (1Portugal, 2Switzerland)

p855 Effects of topiramate on body weight and serum levels of insulin and leptin in young rats fed a high fat diet
Lee IG, Cho KS, Kwon OJ, Kim YH (Korea, Republic of)

p856 Effects of valproate and topiramate on pancreatitis in rats
Cansu A¹, Turkyilmaz S¹, Çelik K¹, Gurgun SG¹, Vanızörkural B², Erçin C¹, Alhan E¹ (1Turkey, 2Turkmenistan)

p857 Interaction of the antiepileptic drug ilepicimide with Na⁺ channels in mice hippocampal neurons
Zeng Y, Liao W (China)

p858 The effects of eslicarbazepine, R-licarbazepine, oxcarbazepine and carbamazepine on ion transmission through Cav3.2 channels
Brady K¹, Hebeisen S¹, Konrad D¹, Soares-da-Silva P² (1Switzerland, 2Portugal)


13:00-14:30 Poster Session: Late submissions
Poster Area (Botticelli Room)

- p860 Sudden unexpected death in epilepsy (SUDEP): paediatric cases**
Besag F, Ackers R, Nashef L, Hughes E, Wong IC (United Kingdom)
- p861 The predictors of seizure in cerebral venous sinus thrombosis and its prognostic significance**
Kalita J, Misra UK, Chandra S, Kumar B, Bansal V (India)
- p862 Comparative study of Carbamazepine and Levetiracetam on bone mineral status in elderly patients with epilepsy**
Srivastava T, Jain R (India)
- p863 The relationship between sleep and epilepsy in infancy and childhood**
Atkins MD, Berquist-Hansen M, Nikanorova M, Hjalgrim H (Denmark)
- p864 Novel mutations in the GLRA1 gene associated with an apparently sporadic case of hyperekplexia**
Ballaban-Gil K, Jehle RS (United States)
- p865 Levetiracetam versus lorazepam in status epilepticus: a randomized open labeled pilot study**
Misra UK, Kalita J, Maurya PK (India)
- p866 Retrospective analysis of major congenital malformations (MCMs) and oral clefts (OC) associated with in utero topiramate exposure**
Pack A, Meador K, Bhattachuria A (United States)
- p867 Electric modulation of ongoing pharmacoresistent focal motor seizures by Subthalamic nucleus in a primate model**
Prabhu S, Piallat B, Michallat S, David O, Chabardès S (France)

- p870 Preliminary results from the CATZ Study: a phase III, double-blind, randomised, placebo-controlled trial to assess the efficacy and safety of adjunctive zonisamide in paediatric patients with partial-onset seizures**
Rosati A, Pellacani P, Falchi M, Guerrini R (Italy)
- p871 Respiratory rate and carbon dioxide tension in children with febrile convulsions and febrile status epilepticus**
Man RXG, Beausang O, Flavin B, Pappachan J, Kirkham F (United Kingdom)
- p872 Iron deficiency and febrile seizures in children**
Beausang O, Man R, Flavin B, Kirkham F (United Kingdom)
- p873 Effect of Carbapenem on Plasma Valproic Acid Concentration**
Denpong Patanasethanont, Aporanee Chaiyakum, Siriluk Jaisue, Somsak Tiamkao, Integrated Epilepsy Research Group (Thailand)
- p874 Perception of epilepsy: A survey from patients with epilepsy in Northeastern Thailand**
Somsak Tiamkao, Jiamjit Saengsuwan, Suwanna Boonyaleeapan 1, Jitpinan Srijakkot, Kittisak Sawanyawisuth, Integrated Epilepsy Research group, Integrated Epilepsy Research Group (Thailand)

**LIST OF SPEAKERS**

Name	Session Type	Date	Time	Room	Chair/Speaker
Acevedo C (Chile)	Platform session	29-Aug	14:30	Hall 5	Speaker
Acevedo C (Chile)	Plenary session	1-Sep	9:00	Hall 4	Chair
Acevedo C (Chile)	Plenary session	1-Sep	9:00	Hall 4	Speaker
Akpalu A (Ghana)	Parallel session	31-Aug	11:30	Hall 5	Speaker
Alarcon (United Kingdom)	Teaching session	29-Aug	7:30	Hall 6	Speaker
Amos A (Malawi)	Platform session	30-Aug	14:00	Hall 3	Speaker
Aronica E (Netherlands)	Special symposium	29-Aug	16:30	Hall 1	Speaker
Aronica E (Netherlands)	Parallel session	31-Aug	11:30	Hall 4	Chair
Aronica E (Netherlands)	Parallel session	31-Aug	11:30	Hall 4	Speaker
Arzimanoglou A (France)	Platform session	29-Aug	14:30	Hall 2	Chair
Arzimanoglou A (France)	Parallel session	31-Aug	11:30	Hall 2	Speaker
Avaliani N (Sweden)	Platform session	29-Aug	14:30	Hall 4	Speaker
Avanzini G (Italy)	Satellite symposium	28-Aug	17:30	Hall 1	Chair
Avanzini G (Italy)	Parallel session	31-Aug	11:30	Hall 6	Chair
Avanzini G (Italy)	Parallel session	31-Aug	11:30	Hall 6	Speaker
Avanzini G (Italy)	Parallel session	1-Sep	11:30	Hall 5	Speaker
Axelrod S (United States)	Presidential symposium	29-Aug	9:00	Hall 1	Speaker
Aziz H (Pakistan)	Platform session	29-Aug	14:30	Hall 5	Speaker
Bala K (India)	Platform session	30-Aug	14:00	Hall 3	Speaker
Ballaban Gil K (United States)	Plenary session	31-Aug	9:00	Hall 2	Speaker
Bando SY (Brazil)	Platform session	29-Aug	14:30	Hall 4	Speaker
Baraban S (United States)	Parallel session	30-Aug	11:30	Hall 3	Speaker
Barbosa PH (Brazil)	Platform session	30-Aug	14:00	Hall 4	Speaker
Barkovich AJ (United States)	Platform session	29-Aug	11:30	Hall 2	Speaker
Barragán E (Mexico)	Plenary session	31-Aug	9:00	Hall 2	Chair
Barragán E (Mexico)	Plenary session	31-Aug	9:00	Hall 2	Speaker
Bartolomei F (France)	Plenary session	30-Aug	9:00	Hall 2	Speaker
Bassetti C (Switzerland)	Video session	31-Aug	7:30	Hall 3	Speaker
Bateman LM (United States)	Platform session	29-Aug	14:30	Hall 3	Speaker
Baulac M (France)	Platform session	30-Aug	14:00	Hall 2	Chair
Baulac M (France)	Platform session	30-Aug	14:00	Hall 2	Speaker
Baulac M (France)	Post presidential symposium	31-Aug	11:30	Hall 1	Speaker
Baulac S (France)	Parallel session	29-Aug	11:30	Hall 3	Speaker
Beghi E (Italy)	Plenary session	30-Aug	9:00	Hall 1	Chair
Beghi E (Italy)	Plenary session	30-Aug	9:00	Hall 1	Speaker
Beghi E (Italy)	Satellite symposium	30-Aug	18:00	Hall 1	Chair
Bentivoglio M (Italy)	Parallel session	31-Aug	11:30	Hall 5	Speaker
Berg A (United States)	Plenary session	1-Sep	9:00	Hall 3	Chair
Berg A (United States)	Plenary session	1-Sep	9:00	Hall 3	Speaker
Bergen D (United States)	Parallel session	29-Aug	11:30	Hall 6	Chair
Bergen D (United States)	Parallel session	29-Aug	11:30	Hall 6	Speaker
Berkovic S (Australia)	Teaching session	30-Aug	7:30	Hall 4	Chair
Berkovic S (Australia)	Teaching session	30-Aug	7:30	Hall 4	Speaker
Berkovic S (Australia)	Platform session	31-Aug	14:30	Hall 2	Chair
Berkovic S (Australia)	Plenary session	1-Sep	9:00	Hall 3	Speaker
Bertram E (United States)	Neurobiology workshop	28-Aug	12:30	Hall 6	Chair
Bertram E (United States)	Case oriented learning series	30-Aug	7:30	Hall 6	Chair
Bertram E (United States)	Case oriented learning series	30-Aug	7:30	Hall 6	Speaker
Bharucha N (India)	Parallel session	30-Aug	11:30	Hall 4	Speaker
Bialer M (Israel)	Plenary session	31-Aug	9:00	Hall 1	Speaker
Bialer M (Israel)	Parallel session	31-Aug	11:30	Hall 3	Chair
Bianchi A (Italy)	Platform session	31-Aug	14:30	Hall 2	Chair
Bien C (Germany)	Teaching session	1-Sep	11:30	Hall 4	Chair
Bien C (Germany)	Teaching session	1-Sep	11:30	Hall 4	Speaker
Blümcke I (Germany)	Parallel session	29-Aug	11:30	Hall 2	Chair
Blümcke I (Germany)	Parallel session	29-Aug	11:30	Hall 2	Speaker
Blumenfeld H (United States)	Plenary session	30-Aug	9:00	Hall 2	Chair
Blumenfeld H (United States)	Plenary session	30-Aug	9:00	Hall 2	Speaker
Bogacz A (Uruguay)	Parallel session	30-Aug	11:30	Hall 6	Chair
Bogacz A (Uruguay)	Parallel session	30-Aug	11:30	Hall 6	Speaker
Bonini F (France)	Platform session	31-Aug	14:30	Hall 3	Speaker



Name	Session Type	Date	Time	Room	Chair/Speaker
Boon P (Belgium)	Satellite symposium	28-Aug	15:30	Hall 2	Chair
Boon P (Belgium)	Satellite symposium	28-Aug	15:30	Hall 2	Speaker
Boon P (Belgium)	Satellite symposium	28-Aug	15:30	Hall 2	Speaker
Brazdil M (Czech Republic)	Platform session	30-Aug	14:00	Hall 4	Speaker
Brodie M (United Kingdom)	Platform session	30-Aug	14:00	Hall 2	Speaker
Brodie M (United Kingdom)	Satellite symposium	30-Aug	16:00	Hall 1	Speaker
Bromley RL (United Kingdom)	Platform session	30-Aug	14:00	Hall 2	Speaker
Bruno E (Italy)	Platform session	30-Aug	14:00	Hall 3	Speaker
Bungei WK (Kenya)	Post presidential symposium	29-Aug	11:30	Hall 1	Speaker
Burgess R (United States)	Satellite symposium	30-Aug	8:00	Hall 2	Chair
Burgess R (United States)	Satellite symposium	30-Aug	8:00	Hall 2	Speaker
Camfield P (Canada)	Satellite symposium	31-Aug	16:30	Hall 3	Speaker
Campos M (Chile)	"How to" series	29-Aug	7:30	Hall 4	Speaker
Capovilla G (Italy)	Video session	29-Aug	7:30	Hall 3	Chair
Capovilla G (Italy)	Video session	29-Aug	7:30	Hall 3	Speaker
Capovilla G (Italy)	Parallel session	30-Aug	11:30	Hall 2	Chair
Capovilla G (Italy)	Parallel session	30-Aug	11:30	Hall 2	Speaker
Capovilla G (Italy)	Plenary session	1-Sep	9:00	Hall 3	Chair
Capovilla G (Italy)	Plenary session	1-Sep	9:00	Hall 3	Speaker
Caraballo R (Argentina)	Video session	29-Aug	7:30	Hall 3	Speaker
Carmant L (Canada)	Platform session	29-Aug	14:30	Hall 5	Speaker
Cavalheiro E (Brazil)	Post presidential symposium	29-Aug	11:30	Hall 1	Speaker
Cendes F (Brazil)	Teaching session	1-Sep	11:30	Hall 3	Speaker
Cenus M (Switzerland)	Platform session	29-Aug	14:30	Hall 3	Speaker
Ceulemans B (Belgium)	Platform session	30-Aug	14:00	Hall 2	Speaker
Chabardes S (France)	Satellite symposium	28-Aug	15:30	Hall 5	Speaker
Chambliss J (Australia)	Parallel session	29-Aug	11:30	Hall 5	Speaker
Chauvel P (France)	Claudio Munari workshop 2011	28-Aug	14:00	Hall 1	Chair
Chipaux M (France)	Platform session	29-Aug	14:30	Hall 4	Speaker
Choi J (Korea, Republic of)	Platform session	31-Aug	14:30	Hall 2	Speaker
Chung JM (United States)	Platform session	31-Aug	14:30	Hall 3	Speaker
Cilio MR (Italy)	Video session	1-Sep	7:30	Hall 4	Speaker
Cole R (Australia)	IBE Workshop	28-Aug	12:30	Hall 2	Speaker
Coppola A (Italy)	Platform session	31-Aug	14:30	Hall 4	Speaker
Covanis A (Greece)	Video session	31-Aug	7:30	Hall 3	Chair
Covanis A (Greece)	Video session	31-Aug	7:30	Hall 3	Speaker
Craiu D (Romania)	Plenary session	31-Aug	9:00	Hall 2	Chair
Craiu D (Romania)	Plenary session	31-Aug	9:00	Hall 2	Speaker
Craiu D (Romania)	Case oriented learning series	1-Sep	7:30	Hall 6	Speaker
Cramer J (United States)	Satellite symposium	30-Aug	16:00	Hall 1	Chair
Cross H (United Kingdom)	Post presidential symposium	29-Aug	11:30	Hall 1	Chair
Cross H (United Kingdom)	Post presidential symposium	29-Aug	11:30	Hall 1	Speaker
Cross H (United Kingdom)	"How to" series	1-Sep	7:30	Hall 3	Chair
Cross H (United Kingdom)	"How to" series	1-Sep	7:30	Hall 3	Speaker
Cukiert A (Brazil)	Satellite symposium	28-Aug	15:30	Hall 5	Chair
Cukiert A (Brazil)	Satellite symposium	28-Aug	15:30	Hall 5	Speaker
Curatolo P (Italy)	Satellite symposium	31-Aug	16:30	Hall 4	Speaker
Dalla Bernardina B (Italy)	Claudio Munari workshop 2011	28-Aug	12:15	Hall 1	Speaker
De Boer H (Netherlands)	IBE Workshop	28-Aug	12:30	Hall 2	Chair
De Curtis M (Italy)	Plenary session	1-Sep	9:00	Hall 3	Speaker
De Curtis M (Italy)	Parallel session	1-Sep	11:30	Hall 5	Chair
De Jonghe P (Belgium)	Teaching session	30-Aug	7:30	Hall 4	Speaker
De Tiège X (Belgium)	Satellite symposium	30-Aug	8:00	Hall 2	Speaker
De Weerd A (Netherlands)	Case oriented learning series	31-Aug	7:30	Hall 4	Speaker
Delalande O (France)	"How to" series	1-Sep	7:30	Hall 3	Speaker
Depaulis A (France)	Satellite symposium	28-Aug	17:30	Hall 1	Speaker
Ding D (China)	Parallel session	30-Aug	11:30	Hall 5	Speaker
Dravet C (France)	Satellite symposium	31-Aug	16:30	Hall 3	Chair
Dressler A (Austria)	Platform session	29-Aug	14:30	Hall 2	Speaker
D'Souza WJ (Australia)	Platform session	29-Aug	14:30	Hall 3	Speaker
Dua T (Switzerland)	Post presidential symposium	31-Aug	11:30	Hall 1	Chair
Duncan J (United Kingdom)	Plenary session	1-Sep	9:00	Hall 3	Speaker
Duncan J (United Kingdom)	Teaching session	1-Sep	11:30	Hall 3	Chair
Duncan J (United Kingdom)	Teaching session	1-Sep	11:30	Hall 3	Speaker
Dupont S (France)	Satellite symposium	30-Aug	16:00	Hall 1	Speaker



Name	Session Type	Date	Time	Room	Chair/Speaker
Eisermann M (France)	Platform session	31-Aug	14:30	Hall 4	Speaker
Engel Jr. J (United States)	Parallel session	30-Aug	11:30	Hall 6	Chair
Engel Jr. J (United States)	Parallel session	30-Aug	11:30	Hall 6	Speaker
Falk Pedersen J (Norway)	IBE Workshop	28-Aug	12:30	Hall 2	Speaker
Fejerman N (Argentina)	Video session	29-Aug	7:30	Hall 3	Chair
Finucane A (United States)	IBE Workshop	28-Aug	12:30	Hall 2	Speaker
Francione S (Italy)	Claudio Munari workshop 2011	28-Aug	14:00	Hall 1	Chair
French J (United States)	Platform session	30-Aug	14:00	Hall 2	Speaker
French J (United States)	Parallel session	31-Aug	11:30	Hall 3	Speaker
Friedmann A (Israel)	Plenary session	1-Sep	9:00	Hall 4	Speaker
Fujii M (Japan)	Platform session	31-Aug	14:30	Hall 3	Speaker
Fusco L (Italy)	Claudio Munari workshop 2011	28-Aug	12:15	Hall 1	Speaker
Gaillard WD (United States)	Platform session	29-Aug	14:30	Hall 2	Speaker
Galanopoulou A (United States)	Parallel session	30-Aug	11:30	Hall 2	Speaker
Galanopoulou A (United States)	Satellite symposium	31-Aug	16:30	Hall 4	Chair
Galanopoulou A (United States)	Satellite symposium	31-Aug	16:30	Hall 4	Speaker
Gardella E (Italy)	Video session	30-Aug	7:30	Hall 3	Speaker
Gilliam F (United States)	Satellite symposium	30-Aug	16:00	Hall 1	Speaker
Gilliam F (United States)	Plenary session	31-Aug	9:00	Hall 1	Speaker
Gil-Nagel A (Spain)	Video session	30-Aug	7:30	Hall 3	Speaker
Gil-Nagel A (Spain)	Satellite symposium	30-Aug	16:00	Hall 1	Speaker
Glynn M (Ireland)	Presidential symposium	29-Aug	9:00	Hall 1	Chair
Glynn M (Ireland)	Parallel session	30-Aug	11:30	Hall 5	Chair
Glynn M (Ireland)	Parallel session	30-Aug	11:30	Hall 5	Speaker
Goldman A (United States)	Parallel session	30-Aug	11:30	Hall 1	Speaker
Goodwin M (United Kingdom)	Satellite symposium	30-Aug	16:00	Hall 1	Speaker
Gotman J (Canada)	Plenary session	30-Aug	9:00	Hall 2	Speaker
Gotman J (Canada)	Platform session	30-Aug	14:00	Hall 4	Chair
Gotman J (Canada)	Teaching session	1-Sep	11:30	Hall 3	Speaker
Granbichler CA (Austria)	Platform session	29-Aug	14:30	Hall 3	Speaker
Greenberg D (United States)	Satellite symposium	28-Aug	17:30	Hall 1	Speaker
Gröhn O (Finland)	Neurobiology workshop	28-Aug	12:30	Hall 6	Speaker
Gross-Tsur V (Israel)	Parallel session	31-Aug	11:30	Hall 2	Speaker
Guerrini R (Italy)	Parallel session	29-Aug	11:30	Hall 2	Speaker
Guerrini R (Italy)	Parallel session	31-Aug	11:30	Hall 2	Chair
Guerrini R (Italy)	Satellite symposium	31-Aug	16:30	Hall 3	Chair
Halasz P (Hungary)	Platform session	30-Aug	14:00	Hall 2	Speaker
Hanna J (United Kingdom)	Parallel session	30-Aug	11:30	Hall 1	Speaker
Hesdorffer D (United States)	Post presidential symposium	31-Aug	11:30	Hall 1	Chair
Heywood J (United States)	Satellite symposium	29-Aug	18:00	Hall 1	Speaker
Hirsch E (France)	Platform session	31-Aug	14:30	Hall 4	Chair
Hirsch E (France)	Plenary session	1-Sep	9:00	Hall 3	Speaker
Hjalgrim H (Denmark)	Platform session	31-Aug	14:30	Hall 2	Speaker
Holmes M (United States)	Satellite symposium	31-Aug	7:30	Hall 5	Speaker
Holthausen H (Germany)	Claudio Munari workshop 2011	28-Aug	12:15	Hall 1	Speaker
Hsin YL (Taiwan)	Platform session	30-Aug	14:00	Hall 4	Speaker
Inoue Y (Japan)	Parallel session	29-Aug	11:30	Hall 3	Chair
Inoue Y (Japan)	Parallel session	29-Aug	11:30	Hall 3	Speaker
Jansen L (United States)	Special symposium	29-Aug	16:30	Hall 1	Speaker
Jayakar P (United States)	Case oriented learning series	29-Aug	7:30	Hall 2	Chair
Jayakar P (United States)	Case oriented learning series	29-Aug	7:30	Hall 2	Speaker
Jensen F (United States)	Post presidential symposium	31-Aug	11:30	Hall 1	Speaker
Jette N (Canada)	Platform session	30-Aug	14:00	Hall 3	Speaker
Johannessen S (Norway)	Teaching session	1-Sep	11:30	Hall 6	Speaker
Józwiak S (Poland)	Satellite symposium	31-Aug	16:30	Hall 4	Speaker
Kahane P (France)	Claudio Munari workshop 2011	28-Aug	12:15	Hall 1	Chair
Kahane P (France)	Claudio Munari workshop 2011	28-Aug	14:00	Hall 1	Speaker
Kahane P (France)	"How to" series	30-Aug	7:30	Hall 5	Speaker
Kakooza A (Uganda)	Platform session	29-Aug	14:30	Hall 2	Chair
Kälviäinen R (Finland)	Parallel session	30-Aug	11:30	Hall 4	Speaker
Kaneko S (Japan)	Platform session	29-Aug	14:30	Hall 5	Chair
Kanner A (United States)	Parallel session	29-Aug	11:30	Hall 4	Chair
Kanner A (United States)	Parallel session	29-Aug	11:30	Hall 4	Speaker
Kanner A (United States)	"How to" series	31-Aug	7:30	Hall 2	Speaker
Kapur J (United States)	Teaching session	1-Sep	7:30	Hall 5	Speaker



Name	Session Type	Date	Time	Room	Chair/Speaker
Keikelame M (South Africa)	Parallel session	30-Aug	11:30	Hall 6	Speaker
Kelemen A (Hungary)	Case oriented learning series	31-Aug	7:30	Hall 4	Speaker
Kinoshita M (Japan)	Platform session	29-Aug	14:30	Hall 3	Speaker
Köhling R (Germany)	Parallel session	31-Aug	11:30	Hall 4	Chair
Köhling R (Germany)	Parallel session	31-Aug	11:30	Hall 4	Speaker
Kokaia M (Sweden)	Parallel session	30-Aug	11:30	Hall 3	Speaker
Koutroumanides M (United Kingdom)	Case oriented learning series	1-Sep	7:30	Hall 6	Speaker
Krämer G (Switzerland)	Plenary session	1-Sep	9:00	Hall 4	Speaker
Krueger D (United States)	Platform session	30-Aug	14:00	Hall 2	Speaker
Kwan P (Hong Kong)	Satellite symposium	29-Aug	18:00	Hall 1	Speaker
Kwan P (Hong Kong)	Plenary session	31-Aug	9:00	Hall 1	Chair
Kwan P (Hong Kong)	Plenary session	31-Aug	9:00	Hall 1	Speaker
Lagae L (Belgium)	Case oriented learning series	1-Sep	7:30	Hall 6	Chair
Lagae L (Belgium)	Case oriented learning series	1-Sep	7:30	Hall 6	Speaker
Lai S (Taiwan)	Parallel session	30-Aug	11:30	Hall 6	Speaker
Lai S (Taiwan)	Platform session	30-Aug	14:00	Hall 3	Chair
Lamberts RJ (Netherlands)	Platform session	29-Aug	14:30	Hall 3	Speaker
Lambrecht K (United States)	Satellite symposium	28-Aug	15:30	Hall 5	Speaker
Laureys S (Belgium)	Plenary session	30-Aug	9:00	Hall 2	Speaker
Leach J (United Kingdom)	Presidential symposium	29-Aug	9:00	Hall 1	Speaker
Lee S-A (Korea, Republic of)	Platform session	30-Aug	14:00	Hall 3	Speaker
Lee Y-J (Korea, Republic of)	Platform session	29-Aug	14:30	Hall 2	Speaker
Lerche H (Germany)	Satellite symposium	28-Aug	17:30	Hall 1	Speaker
Lerche H (Germany)	Satellite symposium	30-Aug	18:00	Hall 1	Speaker
Lerche H (Germany)	Platform session	31-Aug	14:30	Hall 4	Chair
Li S (China)	Post presidential symposium	29-Aug	11:30	Hall 1	Chair
Li S (China)	Post presidential symposium	31-Aug	11:30	Hall 1	Speaker
Liao W (China)	Parallel session	29-Aug	11:30	Hall 3	Speaker
Lim S (Singapore)	Case oriented learning series	30-Aug	7:30	Hall 6	Speaker
Lo Russo G (Italy)	Claudio Munari workshop 2011	28-Aug	14:00	Hall 1	Speaker
Lo Russo G (Italy)	"How to" series	30-Aug	7:30	Hall 5	Chair
Lo Russo G (Italy)	"How to" series	30-Aug	7:30	Hall 5	Speaker
Löscher W (Germany)	Parallel session	31-Aug	11:30	Hall 3	Chair
Löscher W (Germany)	Parallel session	31-Aug	11:30	Hall 3	Speaker
Lowenstein D (United States)	Parallel session	30-Aug	11:30	Hall 4	Speaker
Luders H (United States)	Claudio Munari workshop 2011	28-Aug	14:00	Hall 1	Speaker
Manganotti P (Italy)	Satellite symposium	31-Aug	7:30	Hall 5	Chair
Mantegazza M (Italy)	Parallel session	31-Aug	11:30	Hall 6	Speaker
Mathern G (United States)	Plenary session	30-Aug	9:00	Hall 1	Chair
Mathern G (United States)	Plenary session	30-Aug	9:00	Hall 1	Speaker
Mathern G (United States)	"How to" series	1-Sep	7:30	Hall 3	Speaker
Mazetto L (Brazil)	Platform session	31-Aug	14:30	Hall 3	Speaker
Mbuba CK (Kenya)	Platform session	30-Aug	14:00	Hall 3	Speaker
McGinnity C (United Kingdom)	Platform session	31-Aug	14:30	Hall 3	Speaker
Mesa T (Chile)	Parallel session	30-Aug	11:30	Hall 5	Speaker
Michelucci R (Italy)	Parallel session	29-Aug	11:30	Hall 3	Chair
Michelucci R (Italy)	Parallel session	29-Aug	11:30	Hall 3	Speaker
Mifsud J (Malta)	Teaching session	31-Aug	7:30	Hall 6	Chair
Mifsud J (Malta)	Teaching session	31-Aug	7:30	Hall 6	Speaker
Mifsud J (Malta)	Parallel session	31-Aug	11:30	Hall 6	Chair
Milh M (France)	Platform session	31-Aug	14:30	Hall 2	Speaker
Min L (Brazil)	Post presidential symposium	31-Aug	11:30	Hall 1	Speaker
Mitchell G (Ireland)	IBE Workshop	28-Aug	12:30	Hall 2	Speaker
Morita ME (Brazil)	Platform session	31-Aug	14:30	Hall 4	Speaker
Moshé SL (United States)	Presidential symposium	29-Aug	9:00	Hall 1	Chair
Mula M (Italy)	Parallel session	29-Aug	11:30	Hall 4	Chair
Mula M (Italy)	Parallel session	29-Aug	11:30	Hall 4	Speaker
Murphy P (Ireland)	IBE Workshop	28-Aug	12:30	Hall 2	Speaker
Muzik O (United States)	Platform session	30-Aug	14:00	Hall 4	Speaker
Nabbout R (France)	Satellite symposium	31-Aug	16:30	Hall 3	Speaker
Nakasato N (Japan)	Platform session	29-Aug	14:30	Hall 5	Speaker
Nehlig A (France)	Neurobiology workshop	28-Aug	12:30	Hall 6	Chair
Nehlig A (France)	Plenary session	31-Aug	9:00	Hall 2	Speaker
Newton C (Kenya)	Parallel session	31-Aug	11:30	Hall 5	Speaker
Ngo Bum E (Cameroon)	Parallel session	31-Aug	11:30	Hall 5	Speaker



Name	Session Type	Date	Time	Room	Chair/Speaker
Nitta N (Japan)	Platform session	29-Aug	14:30	Hall 4	Speaker
Nobili L (Italy)	Case oriented learning series	31-Aug	7:30	Hall 4	Chair
Nobili L (Italy)	Case oriented learning series	31-Aug	7:30	Hall 4	Speaker
Noebels J (United States)	Neurobiology workshop	28-Aug	13:45	Hall 6	Chair
Noebels J (United States)	Presidential symposium	29-Aug	9:00	Hall 1	Speaker
Núñez Orozco L (Mexico)	Parallel session	29-Aug	11:30	Hall 4	Speaker
O'Brien T (Australia)	Post presidential symposium	29-Aug	11:30	Hall 1	Speaker
O'Brien T (Australia)	Teaching session	1-Sep	7:30	Hall 5	Chair
O'Brien T (Australia)	Teaching session	1-Sep	7:30	Hall 5	Speaker
Okumura A (Japan)	Video session	1-Sep	7:30	Hall 4	Speaker
Onat F (Turkey)	Platform session	29-Aug	14:30	Hall 4	Chair
Osorio I (United States)	Satellite symposium	28-Aug	15:30	Hall 2	Speaker
Otsuki T (Japan)	Plenary session	30-Aug	9:00	Hall 1	Speaker
Overvliet GM (Netherlands)	Platform session	29-Aug	14:30	Hall 2	Speaker
Özkara Ç (Turkey)	"How to" series	30-Aug	7:30	Hall 5	Speaker
Palma E (Italy)	Platform session	29-Aug	14:30	Hall 4	Speaker
Patel M (United States)	Neurobiology workshop	28-Aug	12:30	Hall 6	Speaker
Pedley T (United States)	Special symposium	29-Aug	16:30	Hall 1	Chair
Pellock J (United States)	Teaching session	1-Sep	11:30	Hall 6	Chair
Pellock J (United States)	Teaching session	1-Sep	11:30	Hall 6	Speaker
Petrelli C (Italy)	Platform session	29-Aug	14:30	Hall 2	Speaker
Picard F (Switzerland)	Plenary session	30-Aug	9:00	Hall 2	Chair
Pillai A (India)	Parallel session	29-Aug	11:30	Hall 6	Speaker
Pillay N (Canada)	Platform session	31-Aug	14:30	Hall 3	Speaker
Pitkänen A (Finland)	Plenary session	30-Aug	9:00	Hall 1	Speaker
Pitkänen A (Finland)	Teaching session	1-Sep	7:30	Hall 5	Speaker
Plouin P (France)	Case oriented learning series	29-Aug	7:30	Hall 2	Speaker
Plouin P (France)	Parallel session	31-Aug	11:30	Hall 2	Chair
Plouin P (France)	Video session	1-Sep	7:30	Hall 4	Chair
Plouin P (France)	Video session	1-Sep	7:30	Hall 4	Speaker
Poduri A (United States)	Platform session	31-Aug	14:30	Hall 2	Speaker
Potschka H (Germany)	Plenary session	31-Aug	9:00	Hall 1	Chair
Potschka H (Germany)	Plenary session	31-Aug	9:00	Hall 1	Speaker
Preux PM (France)	Parallel session	31-Aug	11:30	Hall 5	Chair
Rathore C (India)	Platform session	30-Aug	14:00	Hall 4	Speaker
Ravizza T (Italy)	Parallel session	30-Aug	11:30	Hall 3	Speaker
Represa A (France)	Parallel session	31-Aug	11:30	Hall 6	Speaker
Rho J (United States)	Neurobiology workshop	28-Aug	12:30	Hall 6	Speaker
Rubboli G (Italy)	Case oriented learning series	30-Aug	7:30	Hall 6	Speaker
Rubboli G (Italy)	Platform session	30-Aug	14:00	Hall 4	Chair
Ryvlin P (France)	Satellite symposium	29-Aug	18:00	Hall 1	Chair
Ryvlin P (France)	Parallel session	30-Aug	11:30	Hall 1	Speaker
Ryvlin P (France)	Satellite symposium	30-Aug	18:00	Hall 1	Speaker
Sanchez-Carpintero R (Spain)	Platform session	29-Aug	14:30	Hall 2	Speaker
Sander L (United Kingdom)	Presidential symposium	29-Aug	9:00	Hall 1	Speaker
Sander L (United Kingdom)	Parallel session	30-Aug	11:30	Hall 1	Chair
Sander T (Germany)	Parallel session	31-Aug	11:30	Hall 6	Speaker
Satish Chandra P (India)	Parallel session	29-Aug	11:30	Hall 4	Speaker
Satish Chandra P (India)	"How to" series	31-Aug	7:30	Hall 2	Speaker
Sattaluri SJ (India)	Platform session	31-Aug	14:30	Hall 4	Speaker
Saxena V (India)	Teaching session	31-Aug	7:30	Hall 6	Speaker
Schachter S (United States)	Parallel session	29-Aug	11:30	Hall 5	Speaker
Scheffer I (Australia)	Teaching session	30-Aug	7:30	Hall 4	Speaker
Scheffer I (Australia)	Satellite symposium	31-Aug	16:30	Hall 3	Speaker
Scheffer I (Australia)	Plenary session	1-Sep	9:00	Hall 3	Speaker
Scheffer I (Australia)	Plenary session	1-Sep	9:00	Hall 3	Speaker
Schmidt B (Germany)	Parallel session	31-Aug	11:30	Hall 3	Speaker
Schulze-Bonhage A (Germany)	Satellite symposium	28-Aug	15:30	Hall 2	Speaker
Secco M (Canada)	Teaching session	31-Aug	7:30	Hall 6	Speaker
Seeck M (Switzerland)	Satellite symposium	31-Aug	7:30	Hall 5	Speaker
Shinnar S (United States)	Presidential symposium	29-Aug	9:00	Hall 1	Speaker
Shorvon S (United Kingdom)	Parallel session	30-Aug	11:30	Hall 4	Chair
Shorvon S (United Kingdom)	Plenary session	1-Sep	9:00	Hall 4	Chair
Shorvon S (United Kingdom)	Plenary session	1-Sep	9:00	Hall 4	Speaker
Sills G (United Kingdom)	Satellite symposium	30-Aug	18:00	Hall 1	Speaker



Name	Session Type	Date	Time	Room	Chair/Speaker
Simonato M (Italy)	Platform session	29-Aug	14:30	Hall 4	Chair
Simonato M (Italy)	Parallel session	30-Aug	11:30	Hall 3	Speaker
Siniatchkin M (Germany)	Parallel session	1-Sep	11:30	Hall 5	Speaker
Sisodiya S (United Kingdom)	Plenary session	1-Sep	9:00	Hall 3	Speaker
Skjei K (United States)	Platform session	31-Aug	14:30	Hall 2	Speaker
Smith M (Canada)	Plenary session	30-Aug	9:00	Hall 1	Speaker
Sontheimer H (United States)	Parallel session	31-Aug	11:30	Hall 4	Speaker
Specchio N (Italy)	Platform session	31-Aug	14:30	Hall 4	Speaker
Spreafico R (Italy)	Parallel session	29-Aug	11:30	Hall 2	Chair
Spreafico R (Italy)	Parallel session	29-Aug	11:30	Hall 2	Speaker
Stefan H (Germany)	"How to" series	29-Aug	7:30	Hall 4	Speaker
Steinhoff B (Germany)	Teaching session	29-Aug	7:30	Hall 6	Chair
Steinhoff B (Germany)	Teaching session	29-Aug	7:30	Hall 6	Speaker
Steinhoff B (Germany)	Platform session	31-Aug	14:30	Hall 3	Chair
Stypulkowski P (United States)	Satellite symposium	28-Aug	15:30	Hall 5	Speaker
Tan CT (Malaysia)	"How to" series	31-Aug	7:30	Hall 2	Chair
Tan CT (Malaysia)	"How to" series	31-Aug	7:30	Hall 2	Speaker
Tanaka T (Japan)	Platform session	31-Aug	14:30	Hall 3	Chair
Tassinari CA (Italy)	Video session	31-Aug	7:30	Hall 3	Speaker
Tinuper P (Italy)	Satellite symposium	28-Aug	15:30	Hall 2	Chair
Tinuper P (Italy)	Satellite symposium	28-Aug	15:30	Hall 2	Speaker
Tinuper P (Italy)	Case oriented learning series	29-Aug	7:30	Hall 2	Speaker
Tomson T (Sweden)	Parallel session	30-Aug	11:30	Hall 1	Speaker
Tomson T (Sweden)	Teaching session	1-Sep	11:30	Hall 6	Speaker
Trinka E (Austria)	Video session	30-Aug	7:30	Hall 3	Chair
Trinka E (Austria)	Video session	30-Aug	7:30	Hall 3	Speaker
Trinka E (Austria)	Parallel session	30-Aug	11:30	Hall 4	Chair
Trinka E (Austria)	Parallel session	30-Aug	11:30	Hall 4	Speaker
Tuchman R (United States)	Parallel session	31-Aug	11:30	Hall 2	Speaker
Tulio Medina M (Honduras)	Parallel session	29-Aug	11:30	Hall 6	Speaker
Tulio Medina M (Honduras)	Platform session	30-Aug	14:00	Hall 3	Chair
Tuxhorn I (United States)	Claudio Munari workshop 2011	28-Aug	14:00	Hall 1	Speaker
Tyvaert L (France)	Parallel session	1-Sep	11:30	Hall 5	Speaker
Van Bogaert P (Belgium)	Parallel session	30-Aug	11:30	Hall 2	Speaker
Van Emde Boas W (Netherlands)	"How to" series	29-Aug	7:30	Hall 4	Chair
Van Emde Boas W (Netherlands)	"How to" series	29-Aug	7:30	Hall 4	Speaker
Vecht CJ (Netherlands)	Parallel session	31-Aug	11:30	Hall 4	Speaker
Vezzani A (Italy)	Parallel session	30-Aug	11:30	Hall 3	Chair
Vezzani A (Italy)	Teaching session	1-Sep	11:30	Hall 4	Speaker
Vigevano F (Italy)	Parallel session	30-Aug	11:30	Hall 2	Chair
Vigevano F (Italy)	Parallel session	30-Aug	11:30	Hall 2	Speaker
Vincent A (United Kingdom)	Teaching session	1-Sep	11:30	Hall 4	Speaker
Vogrin SL (Australia)	Platform session	30-Aug	14:00	Hall 4	Speaker
Vonck K (Belgium)	Teaching session	29-Aug	7:30	Hall 6	Speaker
Watanabe M (Japan)	Parallel session	30-Aug	11:30	Hall 1	Chair
Weckhuysen S (Belgium)	Platform session	31-Aug	14:30	Hall 2	Speaker
Werhahn K (Germany)	Satellite symposium	29-Aug	18:00	Hall 1	Speaker
White HS (United States)	Parallel session	30-Aug	11:30	Hall 3	Chair
White HS (United States)	Parallel session	31-Aug	11:30	Hall 3	Speaker
Wiebe S (Canada)	Platform session	29-Aug	14:30	Hall 5	Chair
Wiebe S (Canada)	Plenary session	1-Sep	9:00	Hall 3	Speaker
Wirrell EC (United States)	Platform session	31-Aug	14:30	Hall 4	Speaker
Wolf P (Denmark)	Parallel session	29-Aug	11:30	Hall 5	Chair
Wolf P (Denmark)	Parallel session	29-Aug	11:30	Hall 5	Speaker
Wykes RC (United Kingdom)	Platform session	29-Aug	14:30	Hall 4	Speaker
Yamamoto T (Japan)	Satellite symposium	31-Aug	7:30	Hall 5	Speaker
Yang T (China)	Parallel session	1-Sep	11:30	Hall 5	Speaker
Zimba A (Zambia)	Parallel session	30-Aug	11:30	Hall 5	Speaker
Zimba A (Zambia)	Parallel session	31-Aug	11:30	Hall 5	Chair
Zuberi S (United Kingdom)	Video session	29-Aug	7:30	Hall 3	Speaker



EXHIBITORS LIST


EXHIBITION OPENING HOURS

Monday 29 th August	09.00 - 17.00
Tuesday 30 th August	09.00 - 17.00
Wednesday 31 st August	09.00 - 17.00
Thursday 1 st September	09.00 - 12.00

Exhibitor	Stand no.
Ad-Tech Medical	20
Biocodex	10
Blackrock	7
Cadwell	12
CareFusion	34
Compumedics Ltd.	33
Cyberonics	25
Dixi Medical	9
EB Neuro SpA	11
Eisai Europe Ltd.	31
Electrical Geodesics, Inc.	18
Elekta	14/15/16
Elsevier	8
EURAP	27
GlaxoSmithKline	30
Grass-Technologies	3
Integra	19
International Bureau for Epilepsy	24/28
International League Against Epilepsy	24/28
John Libbey Eurotext	13
Medtronic	26
Micromed	7
Neurotech S.A.	1/2
Nihon Kohden Europe	17
Novartis Oncology	32
Special Products Ltd	35
The Anita Kaufman Foundation	
UCB Pharma SA	29
ViroPharma	5/6
Wiley-Blackwell	4
Wisepress Bookshop	21/22/23



EXHIBITION FLOOR PLAN





LONDON 2012

10th European Congress on Epileptology
September 30th - October 4th



10th European Congress on Epileptology
LONDON ILAE-CEA
The year of the Olympics and the European Epileptology Congress
September 30th - October 4th 2012

30th INTERNATIONAL EPILEPSY CONGRESS MONTREAL 2013



23rd – 27th June 2013





PRESCRIBING INFORMATION

Zonegran® (zonisamide) Please refer to the SPC before prescribing. **Presentation:** Hard capsules: 25 mg, 50 mg, 100 mg zonisamide. **Indication:** Adjunctive therapy in adult patients with partial seizures, with or without secondary generalisation. **Dose and administration: Adults:** Starting dose is 50 mg in two divided doses. After one week, increase to 100 mg daily. Then increase at one weekly intervals in 100mg increments. Can be taken once or twice daily after titration. In renal or hepatic impairment and patients not receiving CYP3A4-inducing agents consider two weekly intervals. Withdraw gradually. **Elderly and patients with renal or hepatic impairment:** Caution. Not recommended in severe hepatic impairment. **Children and adolescents under 18 years:** Not recommended. **Contra-Indications:** Hypersensitivity to zonisamide, sulphonamide or any excipient. **Pregnancy:** Do not use during pregnancy unless potential benefits justify the risks. Women of childbearing potential must use contraception during treatment and for one month after discontinuation. **Lactation:** Excreted into breast milk. Either discontinue Zonegran or stop breast-feeding. **Warnings and Precautions:** Serious rashes occur, including cases of Stevens-Johnson syndrome. Contains a sulphonamide group which is associated with serious immune based adverse reactions. Closely supervise and consider discontinuation in patients with unexplained rash. Cases of agranulocytosis, thrombocytopenia, leukopenia, aplastic anaemia, pancytopenia and leucocytosis have been reported. Monitor for signs of suicidal ideation and behaviours and consider appropriate treatment. Use with caution in patients with risk factors for nephrolithiasis, including prior stone formation, family history of nephrolithiasis and hypercalcaemia. Evaluate and monitor serum bicarbonate levels in patients who are at risk of metabolic acidosis. If metabolic acidosis develops and persists, consider reducing the dose, discontinuing or alkali treatment. Use with caution in patients treated with carbonic anhydrase inhibitors, e.g. topiramate. Decreased sweating, elevated body temperature and heat stroke have been reported. Patients should maintain hydration and avoid excessive temperatures. Monitor pancreatic lipase and amylase levels in patients taking Zonegran who develop clinical signs and symptoms of pancreatitis, consider discontinuation. In cases of severe muscle pain/weakness with or without fever, assess markers of muscle

damage and consider discontinuation. Zonegran 100 mg capsules contain E110. Caution in patients less than 40 kg. In patients with weight loss consider dietary supplement, increased food intake or discontinuation. **Drug Interactions:** No clinically relevant pharmacokinetic effects on carbamazepine, lamotrigine, phenytoin, sodium valproate, oral contraceptives (ethinylestradiol or norethisterone). Insufficient data with carbonic anhydrase inhibitors, e.g. topiramate. Zonegran was not affected by lamotrigine or CYP3A4 inhibitors. Caution with drugs which are P-gp substrates. Avoid concomitant administration with drugs causing urolithiasis. Zonisamide is metabolised partly by CYP3A4, N-acetyl-transferases and conjugation with glucuronic acid; therefore caution with substances that can induce or inhibit these enzymes. **Side effects:** Most common adverse reactions in controlled adjunctive-therapy studies were somnolence, dizziness and anorexia. Refer to SPC for all side effects. Very common effects ($\geq 1/10$): anorexia, agitation, irritability, confusional state, depression, ataxia, dizziness, memory impairment, somnolence, diplopia, decreased bicarbonate. Common effects ($\geq 1/100$, $< 1/10$): echymosis, hypersensitivity, affect lability, anxiety, insomnia, psychotic disorder, bradyphrenia, disturbance in attention, nystagmus, paraesthesia, speech disorder, tremor, abdominal pain, constipation, diarrhoea, dyspepsia, nausea, rash, nephrolithiasis, fatigue, influenza-like illness, pyrexia, weight decreased. Serious effects: pneumonia, suicidal attempt, convulsion, cholecystitis, calculus urinary. Isolated cases of Sudden Unexplained Death in Epilepsy Patients (SUDEP). Post-marketing data suggests patients aged ≥ 65 years report a higher frequency of Stevens-Johnson syndrome and Drug Induced Hypersensitivity syndrome. **Legal Category:** POM **Basic UK NHS cost:** Zonegran 25 mg: packs of 14 £8.82, Zonegran 50 mg: packs of 56 £47.04, Zonegran 100 mg: packs of 56 £62.72. **Irish price to wholesaler:** Zonegran 25 mg: packs of 14 €9.20, Zonegran 50 mg: packs of 56 €48.78, Zonegran 100 mg: packs of 56 €65.18. **Marketing authorisation numbers:** Zonegran 25 mg 14 capsules: EU/1/04/307/001, Zonegran 50 mg 56 capsules: EU/1/04/307/003, Zonegran 100 mg 56 capsules: EU/1/04/307/004. **Marketing authorisation holder:** Eisai Ltd. **Further Information from/Marketed by:** Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN. **Date of preparation:** Jan 2011

Adverse events should be reported. Reporting forms and Information can be found at www.yellowcard.gov.uk. Adverse events should also be reported to Eisai Ltd on 0208 600 1400/0845 676 1400 or Lmedinfo@eisai.net

zonegran® 
zonisamide
Beyond efficacy

Date of Preparation: June 2011
ZON-UK2390



Zonegran is indicated as adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.

Prescribing information can be found overleaf.

Date of Preparation: June 2011
ZON-UK2390

▼ **zonegran**[®] 
zonisamide
Beyond efficacy